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Abstract
This thesis describes our characterization of a specific tetraspanin domain: the large
extracellular loop (LEL). Tetraspanins are involved in cellular migration, adhesion, and
metastasis, sperm-egg fusion, and viral infectivity. The large extracellular loop domain is
the major extracellular domain of tetraspanins and the binding of a monoclonal antibody
against the tetraspanin CD9 serves to inhibit fertilization, consistent with the CD9-null
mouse model. The first area of focus in this thesis is the characterization of the murine
CD9-LEL domain. We present a methodology to express and purify the mCD9-LEL to
homogeneity. Biophysical characterization of the mCD9-LEL protein reveals that it is an
autonomously folding, a-helical dimer. Mutagenesis over much of the mCD9-LEL
protein reveals that it is composed of two subdomains: a dimerization subdomain and a
variable subdomain proposed to mediate heterotypic interactions. These results suggest
both a means for exploring endogenous tetraspanins functions and a mechanism by which
tetraspanins may oligomerize. Surprisingly, we were not able to detect oligomerization
of the intact CD9 molecule, in discordance with our biophysical data on the mCD9-LEL.
In the latter part of this thesis, we expand our methodology to purify and characterize
three different tetraspanins-LELs, the hCD9-LEL, the hCD63-LEL, and the hCD8 1-LEL.
These tetraspanins-LELs all exhibit similar characteristics to the mCD9-LEL, consistent
with a published crystal structure of the hCD81-LEL. Lastly, we demonstrate the ability
of our tetraspanin-LEL proteins to bind integrins, to inhibit sperm-egg fusion, and to
inhibit hepatitis C viral infectivity. Taken as a whole, these studies present novel,
biophysically validated tetraspanins-LELs that lend insight into endogenous tetraspanins
functions.
Thesis Co-Supervisor: Peter S. Kim
Title: Professor of Biology
Thesis Co-Supervisor: Richard 0. Hynes
Title: Professor of Biology
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Introduction.
Tetraspanins are cell surface membrane proteins comprising a family of over
twenty-five genes sharing a characteristic membrane topology. Tetraspanins have been
identified in both vertebrates and invertebrates, suggesting the early evolutionary
development of these proteins (Levy and Shoham 2005). Furthermore, tetraspanins have
been implicated in a wide range of functions involving the immune and nervous systems,
development, cancer progression (Hemler 2003), and infectious diseases. These
functions have been identified through function-inhibitin anti-tetraspanin antibodies,
modulation of tetraspanin expression levels, recombinant, soluble mimics of tetraspanins,
and genetics.. However, the molecular mechanisms by which tetraspanins mediate these
effects are unknown. Strong sequence and structural conservation among all tetraspanins
suggest the existence of a generalized tetraspanin function. This function, which we
propose is to regulate affinity and/or avidity at the cell surface, is propagated through
protein-protein interactions specific to each biological system. In the body of this thesis,
we describe our attempts to probe the role of tetraspanin large extracellular loops, the
major extracellular domain of tetraspanins. Towards these ends, we have developed
novel reagents that enhance our understanding of both the role of CD9 in sperm-egg
fiusion in particular and tetraspanin functions in general. This introduction serves to
introduce tetraspanins and their multitude of effects, with specific emphasis on
biochemical studies of tetraspanins and their roles in membrane fusion. Ultimately, this
thesis strives towards enabling us to understand how tetraspanins function at the cell
membrane.
The Tetraspanin Family
The first sequence characterization of a tetraspanin protein, CD63, was identified
in the late 1980s as an antigen associated with melanoma tumor progression (Hotta, Ross
et al. 1988). Subsequently, sequence identification of another tetraspanin, CD81, as the
target of an anti-proliferative antibody by Shoshana Levy's group in 1990 established
tetraspanins as a family of conserved proteins (Oren, Takahashi et al. 1990).
Tetraspanins have been identified in fungi (but not yeast), sponges, schistosomes,
Caenorhabditis elegans, Drosophila melanogaster, zebrafish, and all mammals. With the
x
advent of whole-genome sequencing, 28 human (Figure 1. B), 37 Drosophila (Todres,
Nardi et al. 2000), and 20 C. elegans tetraspanins (Moribe, Yochem et al. 2004) have
been identified. All mammalian cells, except for erythrocytes, express tetraspanins and it
has been estimated that 20 individual tetraspanins are expressed in the immune system
(Levy and Shoham 2005).
Tetraspanins are small, ranging between 250 and 350 amino acids in length
(Figure 1. A). SDS-PAGE analysis reveals that many tetraspanins (although not CD9 or
CD81) are heavily glycosylated, resulting in the addition of 20-50 kDas of additional
molecular weight (Boucheix and Rubinstein 2001). As their name suggests, tetraspanins
are a family of proteins that have four transmembrane domains. Conserved, polar amino
acid residues exist in each of the transmembrane domains (Figure 1. 1A)(Stipp,
Kolesnikova et al. 2003), resulting in hypotheses suggesting that tetraspanins may
oligomerize to form channels (Horejsi and Vlcek 1991). However, no experimental
evidence has supported these suggestions and this role for tetraspanins has been
discounted. At this time, it is not clear what role conserved residues in the
transmembrane regions serve.
Tetraspanin proteins share a common membrane topology, having intracellular
amino- and carboxyl-termini and four transmembrane segments delimiting two
extracellular loops of unequal size (Figure 1.2A). Transmembrane segments one and two
delimit a short extracellular loop (-20 amino acids) and transmembrane segments three
and four delimit a large extracellular loop (-80 to 140 amino acids). Lastly, an
absolutely conserved cysteine motif, CCG, and two other conserved cysteine residues in
the large extracellular loops define the tetraspanin family. It is worth noting that not all
four transmembrane containing proteins (L6, MM3, PERP, claudins) contain these
signature motifs and likely have different functions from tetraspanins.
Sequence Conservation Of the Tetraspanin Large Extracellular Loop
When we started working on tetraspanins, a number of functions had already been
assigned to them, most commonly in the haematopoietic and hemostasis systems
(Hemler 2001). As with the cloning of CD63 and CD81, a number of monoclonal
antibodies recognize tetraspanins and induce dramatic cellular changes (Boucheix and
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Rubinstein 2001). The tetraspanin CD9 was first cloned as the antigen of an antibody
which inhibits cell motility (Miyake, Koyama et al. 1991). To date, all function-
inhibiting anti-tetraspanin antibodies bind to the tetraspanin large extracellular loop
(Stipp, Kolesnikova et al. 2003), suggesting the critical importance of this domain to
tetraspanin function.
Tetraspanin large extracellular loops (LELs) vary between 70 and 120 amino acids
in length. Overall, there is quite low homology (5-40%) between tetraspanin-LELs, with
an average pairwise homology of 15% (Seigneuret, Delaguillaumie et al. 2001). As
tetraspanin-LELs vary greatly in length, alignment of this region results in significant
gaps. Even with low sequence homology, there are sufficient conserved residues to allow
LELs to be aligned with one another (Figure 1.2A). Tetraspanins almost all contain
either four, six, or eight cysteines which are presumed to oxidize to form intramolecular
disulfide bonds. In the case of outlying tetraspanin family members such as RDS and
ROM, there is an additional cysteine which may participate in an intermolecular covalent
bond (Loewen and Molday 2000).
The tetraspanin large extracellular loops (LELs) have a conserved cysteine residue
pattern, including a tri-amino-acid sequence of cysteine-cysteine-glycine (CCG).
Strikingly, the distance between transmembrane segment three and this CCG motif,
which is always the most N-terminal of LEL cysteines, is conserved at approximately 40
amino acids. Secondary structural analysis of these forty amino acids predicts that they
form two a-helices in all tetraspanins. Furthermore, the last cysteine residue in all
tetraspanin-LELs is positionally conserved at approximately ten amino-acids N-terminal
to transmembrane segment four. These ten amino acids are also predicted to form an ca-
helix (Seigneuret, Delaguillaumie et al. 2001). Predicted solvent accessibility of these
two segments, the most N-terminal and C-terminal portions of the LEL, revealed a
hydrophobic periodicity in a roughly 3-4 residue pattern, also suggestive of the helical
nature of these regions (Seigneuret, Delaguillaumie et al. 2001). These regions are not
predicted to form coiled-coils (Wolf, Kim et al. 1997) (C.C.L., data not shown).
The two described a-helical segments bracket a variable region. This region
contains the CCG motif that is a defining characteristic of tetraspanins (Figure 1.2A. All
tetraspanins contain four or more cysteines in this region and the position of these
l0
cysteine residues has allowed the classification of tetraspanins into 3 groups containing
four, six, or eight cysteines (Seigneuret, Delaguillaumie et al. 2001). Among tetraspanin
orthologues, which contain approximately 70% identity, this region contains the majority
of amino-acid substitutions (Hemler 2001). Studies mapping epitopes of function-
inhibiting anti-tetraspanin antibodies (including one described in this thesis) have all
identified this region as particularly antigenic. Furthermore, functional studies of
tetraspanin-LELs have suggested that this variable region is important in sperm-egg
fusion and the binding of tetraspanins to integrins (Zhu, Miller et al. 2002). Only
recently, through biophysical analysis of recombinant tetraspanin-LELs and the solution
of a crystal structure of the human CD81-LEL (Figure 1.2B) (Kitadokoro, Bordo et al.
2001), has the role of sequence conservation in tetraspanin-LEL oligomerization been
revealed. In fact, historically, the series of sequence analyses described in this section
were conducted after this tetraspanin-LEL structure was solved.
Structural Studies of the hCD81-LEL
In 2001, the Bolognesi group solved the structure of the human CD81-LEL, a
tetraspanin-LEL containing four cysteines (Figure 1.2B) (Kitadokoro, Bordo et al. 2001).
Ultimately, the Bolognesi group found that the hCD8 1-LEL protein crystallized into two
similar, but non-identical forms: a monoclinic form solved as pdb ID: 1G8Q and a
hexagonal form solved as pdb ID: IIV5 (Kitadokoro, Ponassi et al. 2002). Both of these
structures had two molecules in the crystallographic asymmetric unit and formed similar,
superimposable structures (Figure 1.3A), although the crystal contacts were dramatically
different. In fact, the second structure (IIV5) was solved through molecular replacement
with the first structure (1G8Q).
The CD81-LEL molecule consisted of five ct-helices, consistent with secondary
structure predictions of the protein sequence. There were two ct-helices N-terminal of the
variable region (designated helix A and B), two cc-helices formed by the variable region
(designated helix C and D), and a single ct-helix C-terminal of the variable region
(designated helix E). The N- and C-termini fall in close proximity to one another and
extend to transmembrane segments three and four respectively (Kitadokoro, Bordo et al.
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2001). Two disulfide bridges stretch in opposite directions from the conserved CCG
motif and serve to stabilize the structure (Figure 1.2B).
Surprisingly, the CD81-LEL structure was solved with two molecules in the
crystallographic asymmetric unit. These two molecules assemble around a local two-fold
axis in an anti-parallel fashion. A large hydrophobic region of approximately 1000 A2
mediates CD81-LEL dimerization and no water molecules were observed at the dimer
interface. Each monomer adopts a similar tertiary structure of five helical regions as
described and helices A, B, and E all contribute to form the hydrophobic dimerization
interface. These three helices have been called a "stalk" or dimerization subdomain and
are predicted to be conserved among all tetraspanin homologues (Figure 1.2A and Figure
1.2B).
The remaining two helices, helices C and D, constitute a head subdomain and
present a second, smaller, low polarity region. As noted previously, this variable region
of approximately 30 amino acids is where function-blocking antibody epitopes have been
localized (Figure 1.2A and B). The antiparallel nature of CD81-LEL dimer serves to
present the head subdomains at apposing ends of the molecules (Figure 1.2B), with a
distance of approximately 30 A between the two small hydrophobic patches (Kitadokoro,
Bordo et al. 2001).
Both CD81-LEL structures contain a similar dimerization sub-domain mediated
through helices A, B, and E. However, the head sub-domain is slightly altered between
the two structures with helices C and D presented at different angles respective to one
another. The disparities in the head sub-domain are most likely due to dramatically
different crystal packing contacts (Kitadokoro, Ponassi et al. 2002). Analysis of average
mass-weighted fluctuation of all atoms in each molecule suggests that under
physiological conditions, the hCD81-LEL quarternary structure is plausible, with some
flexibility in the head sub-domain (Neugebauer, Klein et al. 2004). This molecular
dynamics study of both hCD81-LEL crystal structures also suggests that the latter crystal
structure (1IV5) is more accurate (Neugebauer, Klein et al. 2004). As the first,
monoclinic 18Q, CD81-LEL structure was solved concurrent with our biophysical
analysis of the mCD9-LEL protein; we refer to this structure of the CD81-LEL
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exclusively in the body of this thesis. Close analysis of both isoforms of the hCD81-LEL
structures suggests that the structures are interchangeable for our level of analysis.
Spurred on by crystallographic studies of the hCD81-LEL, several groups
(including our studies in Chapter 3) have modeled other tetraspanin-LEL domains, both
in isolation and with the transmembrane domains, onto the hCD81-LEL structure.
Conjead et. al. used the hCD81-LEL crystal structure, homology alignments, and
secondary structure predictions to predict the disulfide connectivites of tetraspanin-LELs
(Figure 1.3C) (Seigneuret, Delaguillaumie et al. 2001). They present a compelling body
of evidence for structural conservation among all tetraspanin dimerization subdomains
mediated by the conserved helices A, B, and E. They further classified all tetraspanin-
LELs into three classes based upon signature patterns of cysteine residues in the variable
subdomain (Figure 1.3C). The variable subdomain is not predicted to be structurally
conserved among tetraspanin-LELs (Seigneuret, Delaguillaumie et al. 2001).
In an ambitious study, Bienstock and Barrett attempted to model the
transmembrane-intact CD82 molecule (Bienstock and Barrett 2001). The tetraspanin
CD82, also called Kai 1, has been functionally identified as a metastasis suppressor
(Dong, Lamb et al. 1995), although its mechanism of action is unclear. Bienstock and
Barrett modeled each domain of the CD82 molecule individually and then combined each
domain to form the intact molecule (Figure 1.3B). To model the transmembrane regions
of CD82, an alignment of tetraspanin transmembrane proteins was created. Helical
hydrophobic moments were calculated to predict the orientation of each transmembrane
region with respect to one another. Molecular models of the short intracellular segments,
the short extracellular loop, and large extracellular loop, were constructed, assembled,
and energy minimization and molecular dynamics simulations of the intact molecule
were performed (Bienstock and Barrett 2001). As expected, the hCD82-LEL model
adopts a global fold similar to the hCD81-LEL (Figure 1.3B). However, there are many
caveats to this model.
All of the tetraspanin-LEL models described (including ours) have been modeled
onto a monomeric CD81-LEL molecule. As described above, the CD81-LEL contains a
desolvated, 1000 A2, hydrophobic region that lies at the interface between each monomer
(Kitadokoro, Bordo et al. 2001). Deconvoluting the dimer and computationally exposing
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this region to solvent serves to artificially minimize the dimerization interface (Bienstock
and Barrett 2001) (Seigneuret, Delaguillaumie et al. 2001). As a result, these models
most likely (1do not accurately represent intersubunit contacts between tetraspanin
homodimers.
Furthermore, the model of the hCD82 molecule does not take into account the
effects of glycosylation on the hCD82 molecule. Although all tetraspanins have a
predicted molecular weight of between 22 and 30 kDa, CD82 is observed to be especially
glycosylated (Boucheix and Rubinstein 2001). SDS-PAGE analysis of CD82 reveals
bands ranging from 50 to 80 kDas, suggesting that glycosylation may double or triple the
molecular weight of CD82. No studies on tetraspanin glycosylation have been reported
and currently, it is not clear what are the functions of sugar residues.
Most importantly, sequence, structural, and our biophysical studies strongly
suggest an intrinsic, dimeric nature to all tetraspanin-LELs. Barrett's model of the whole
CD82 molecule displays the CD82-LEL as projecting in a perpendicular manner to the
cellular membrane (Figurel.3C) (Bienstock and Barrett 2001). Extrapolating from the
antiparallel CD81-LEL dimer, only a CD82 trans dimer, or a dimer traversing two
apposing lipid bilayers, would seem plausible and serve to cap the large, hydrophobic
dimerization interface. It is plausible that the angle between helix A and transmembrane
3 (presented as -180 ° in this figure) is highly flexible and that the CD82-LEL lies in a
more planar fashion to the lipid bilayer. This model would allow the formation of a cis
tetraspanin dimer, or a dimer existing on the same lipid bilayer. Although currently no
trans tetraspanin/tetraspanin interactions have been observed, the antiparallel nature of
the CD81-LEL dimer is plausible either in cis or in trans.
The fiunctional relevance of tetraspanin-LEL-mediated oligomerization remains a
contentious issue in the field. A common misgiving lies in reconciling the orientation of
the CD81-LEL antiparallel dimer with its endogenous, adjacent, transmembrane domains
(Levy and Shoham 2005). The hCD81-LEL structure does not rule out the formation of a
cis antiparallel tetraspanin dimer (in the same lipid bilayer). As in many crystal
structures, several amino acid residues at the distal N- and C-termini of the hCD81-LEL
protein were disordered in the crystal structure. Given the -helical nature of residues
proximal to these termini, the addition of each helical amino acid to the (o-helix would
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twist the orientation of the adjacent transmembrane domains 100° (Branden and Tooze
1999). This helical nature of both N- and C-termini allow almost any orientation of the
tetraspanin transmembrane segments three and four relative to the dimeric structure, as
long as they are in close proximity to the N- and C- termini. To date, these issues have
not been resolved and misgivings about the biological relevance of the hCD81-LEL
structure have not been laid to rest.
In summary, crystallization of the CD8 1-LEL has identified two subdomains: a
dimerization region and a variable region whose organization is predicted to be conserved
among all tetraspanin-LELs. The CD81-LEL structure matches predicted secondary
structural elements of tetraspanins. Furthermore, previously identified functional
residues and antigenic regions were surface-exposed and clustered to the variable region.
By these criteria, the CD81-LEL meets the benchmark of all crystal structures: "does this
structure make sense?" Although many homology models of tetraspanin-LELs based
upon the CD8 1-LEL structure have been constructed, they are not completely accurate.
As a result, it would be highly desirable to determine atomic level structures for a number
of other tetraspanin-LELs. In lieu of these detailed structural studies, biophysical
characterizations of tetraspanin-LELs in solution are clearly necessary.
Recombinant Tetraspanin-LELs
Both anti-tetraspanin antibody and mutagenesis studies have underscored the
importance of tetraspanin-LELs. As a result, tetraspanin-LELs have been expressed,
purified, and studied in a variety of ways. For the crystallization studies described above,
the human CD81-LEL was expressed as a fusion sandwiched between the IgG binding
domain of Staphylococcus Aureus Protein A, which was subsequently removed, and a
hexahistidine tag, which was not ordered in the crystal structure (Kitadokoro, Bordo et al.
2001). The Grandi group, which collaborated on the CD81-LEL structure, has also
successfully expressed the CD81-LEL as both a thioredoxin fusion (Pileri, Uematsu et al.
1998) and also as a glutathione-S-transferase (GST) fusion (Petracca, Falugi et al. 2000).
Removal of the GST tag resulted in a single CD81-LEL species as assessed by reverse-
phase HPLC, which was shown to inhibit Hepatitis C viral entry (Petracca, Falugi et al.
2000). Inhibition of hepatitis C viral fusion was also shown with a GST-CD81-LEL
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fusion protein constructed by the Monk group, albeit with decreased efficacy (Flint,
Maidens et al. 1999).
The GST fusion system has been used by the Monk group to express the CD9-
IEL (Higginbottom, Takahashi et al. 2003), the CD81-LEL (Flint, Maidens et al. 1999),
and the CD63-LEL (personal communication). This GST-fused CD9-LEL has been
shown to inhibit lymphocyte transendothelial migration by the Sanchez-Madrid group
(Barreiro, Yanez-Mo et al. 2005). The Primakoff group has also used a GST-CD9-LEL
fusion to inhibit sperm-egg fusion (Zhu, Miller et al. 2002) (see Chapter 7 and
Appendix). On the other hand, the Mekada group has shown a pro-fusogenic effect on
macrophage fusion with both GST-fused CD9-LEL and CD81-LEL (Takeda, Tachibana
et al. 2003).
The Levy group has expressed the CD81-LEL as fusions with Fc, GST, or
maltose-binding protein fusion (MBP) (Maecker, Todd et al. 2000; Nakajima, Cocquerel
et al. 2005). By surface plasmon resonance, they measured the binding kinetics of both
GCST-fused and MBP-fused CD81-LEL constructs to soluble, recombinant hepatitis C
glycoproteins. Analysis of the oligomeric states of these two fusion proteins by both gel
filtration and sedimentation equilibrium yielded surprising results (Nakajima, Cocquerel
et al. 2005). Both assays revealed that the GST-CD81-LEL protein was dimeric and the
MBP-CD81-LEL protein was monomeric. As the GST protein is dimeric and the MBP
protein is monomeric, their data suggest that the CD81-LEL fusion partner is monomeric.
These results are antithetical both to our understanding of tetraspanin-LELs as a family
and to results presented in Chapter 6 of this thesis, suggesting that more detailed
biophysical analysis of fusion GST and MBP fusion proteins is required. No other
detailed biophysical analysis of tetraspanin-LELs has been published. Lastly, when these
tetraspanin-LEL proteins were used as antigens to generate polyclonal antibodies, the
resulting antibodies were never immunoreactive to the intact CD9 molecule, also
suggestive that the fusion proteins may be misfolded, even after repeated trials (Shoshana
Levy, personal communication).
Almost all soluble, recombinant, tetraspanin-LEL-mediated inhibitions of
function match the effects observed when anti-tetraspanin antibodies are added.
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Nevertheless, soluble, recombinant tetraspanin-LELs are an important and increasingly
utilized tool to probe endogenous tetraspanin functions.
In this thesis, we describe our own studies with soluble, recombinant tetraspanins
(Figure 1. 1B). Complementary to the studies described above, we show that it is
unnecessary to fuse tetraspanin-LELs to a large carrier protein to achieve high protein
expression. By utilizing a short, C-terminal hexahistidine tag and the nickel and reverse-
phase chromatographic systems these fusions make tractable, we are readily able to
express and purify to conformational homogeneity the CD9-LEL, the CD81-LEL, and the
CD63-LEL (see Chapter 6). These conformationally pure proteins exhibit significantly
greater potency of inhibition (except for the study of the CD81-LEL (Petracca, Falugi et
al. 2000) in all assays tested to date (see Chapter 7 and 9). Given the nearly ubiquitous
binding nature of tetraspanins (described below), the importance of pure, validated
reagents is increasingly appreciated. The reagents described in this thesis are rapidly
becoming the touchstone of tetraspanin-LEL biology.
More importantly, the lack of a large fusion partner allows detailed biophysical
characterization of tetraspanin-LELs which may lend insight into their functional
mechanisms. Concurrently with the crystal structure of the CD81-LEL described above
(Kitadokoro, Bordo et al. 2001), our biophysical analysis of the murine CD9-LEL
revealed that it is an autonomously folding, ca-helical dimer. Our empirical estimate of
secondary structure content matched secondary structure predictions of the CD9-LEL and
we observed that proper disulfide-connectivites were critical for achieving cc-helical
content. Sedimentation equilibrium analysis also revealed that the murine CD9-LEL is a
stable dimer (Chapter 2). Our extension of these analytical techniques to the CD81-LEL
and the CD63-LEL proteins revealed that these proteins are also autonomously folding cx-
helical dimers (Chapter 7).
The development of a rapid, biochemical and biophysical methodology to
express, purify, and analyze tetraspanin-LELs allowed us to identify the determinants of
the folding stability of the murine CD9-LEL. Mutational analysis based upon a structural
homology model of the mCD9-LEL (Chapter 3) confirmed the presence of two
subdomains: a dimerization subdomain and an antigenic, variable region in solution
(Chapter 4). Furthermore, we show that the variable region of the mCD9-LEL is discrete
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from the dimerization subdomain and hypothesize that function-inhibiting anti-
tetraspanin antibodies have no effect on mCD9-LEL-mediated homooligomerization
(Chapter 4). These results, combined with the structural studies of the CD81-LEL and
inhibition of tetrapanin functions by soluble tetraspanin-LELs (Chapter 7), reinforce the
importance of tetraspanin-LELs to endogenous tetraspanin functions. Although the
significance of tetraspanin-LELs is undisputed, their precise contribution to endogenous
tetraspanin functions is still unclear.
Heterotypic Tetraspanin Interactions
Many classes of proteins have been hypothesized to complex with tetraspanins
(Figure 1.4) (Boucheix and Rubinstein 2001). These interactions vary highly in their
composition., strength of their interaction, and the stoichiometry of complex formation
(Hemler 2003). For simplicity, we have codified these interactions by their components.
We refer to tetraspanin/non-tetraspanin interactions as heterotypic interactions and
tetraspanin/tetraspanin interactions as homotypic interactions. Furthermore,
oligomerization of individual tetraspanins is described as homooligomerization.
Heterotypic interactions have been further classified by the detergent sensitivity of
macromolecular complex formation. In most instances, it is necessary to use mild
detergent conditions, such as Brij 96, Brij97, or CHAPS before these complexes can be
immunoprecipitated (Charrin, Manie et al. 2003).
Detergent solubilization is often an essential step to isolate transmembrane
proteins. However, any experiment that requires the addition of detergent is fraught with
the possibility of artifacts. Detergent solubilization of membranes often results in
incomplete membrane protein isolation, leaving large patches of the native lipid bilayer
that can be visualized by electron microscopy. Furthermore, detergent treatment often
brings about fusion of disparate portions of the membrane, fusing fragments into
continuous sheets (Mayor and Maxfield 1995). It is essential to be careful with the
interpretation of detergent-solubilized protein complexes (Chamberlain 2004). It is only
necessary to look to the lipid raft or detergent-resistant microdomain field to realize how
contentious detergent solubilization of membrane proteins may be (Simons and Vaz
2004).
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To overcome these controversies, we will focus this introduction on only robust
tetraspanin heterotypic interactions which have been shown to interact in either TX-100
or digitonin and characterized as primary interactions. By restricting this introduction to
robust tetraspanin interactions (Hemler 2003), we do not focus on the vast majority of
weaker, and possibly artifactual, tetraspanin complexes. Although we do not wish to
discount the validity of these complexes, we deem them to be controversial. Under weak
detergent conditions, tetraspanins associate both with one another (homotypic
interactions) and with numerous non-tetraspanin proteins (Rubinstein, Le Naour et al.
1996), raising the likelihood of large, indirect macromolecular interactions and possibly
artifactual results. Severely restricting the focus of this introduction in this manner also
eliminates any direct involvement of tetraspanins in mediating signals across the cellular
membrane. Tetraspanins have been shown to mediate FAK (Berditchevski and
Odintsova 1999) and PI4-kinase-dependent signalling pathways (Yauch and Hemler
2000) and protein kinase C (Zhang, Bontrager et al. 2001); however, it is unclear whether
these effects are direct or mediated through intermediaries. The large number of
identified binding partners to tetraspanins under mild detergent conditions is confusing, at
best.
A limited number of primary, robust, heterotypic tetraspanin complexes have
been observed. The most striking primary tetraspanin complexes are with uroplakins,
distant relatives to canonical tetraspanins. These tetraspanins, uroplakin la and uroplakin
lb, associate heterotypically with uroplakin II and uroplakin III (Wu, Medina et al.
1995). These proteins are expressed exclusively on the bladder epithelium and have been
suggested to play a role in uropathogenic E. coli infection (Wu, Sun et al. 1996; Mulvey,
Lopez-Boado et al. 1998). Uroplakins are expressed at such high concentrations that they
form hexagonal, two-dimensional lattices that can be visualized and resolved using Cryo-
EM techniques (Min, Zhou et al. 2003). Presently, these techniques are not at sufficient
resolution to model the predicted dimerization and variable subdomains of the uroplakin-
LEL.
On the surface of B-lymphocytes, CD81 has been shown to associate in a
complex with CD19, CD21, and Leu-13 (Levy, Todd et al. 1998) (Horvath, Serru et al.
1998). Monoclonal antibodies against CD81, CD19, CD21 and Leu-13 share similar
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effects on B-cell co-stimulation, proliferation, and homotypic aggregation, suggesting
that this complex is functionally relevant (Cherukuri, Shoham et al. 2004). Targeted
deletion of CD81 in a mouse model also reduces all components of this complex, making
it difficult to assign individual functions to each member of the complex (Shoham,
Rajapaksa et al. 2003). A large number of weak, heterotypic interactions in the immune
system have been identified and are extensively reviewed elsewhere (Levy and Shoham
2005).
A third, robust complex, between the tetraspanin CD9 and the precursor of
heparin-binding epidermal growth factor (Nakamura, Mitamura et al. 2000), which is also
the diphtheria toxin receptor, has been observed (Iwamoto, Higashiyama et al. 1994).
Overexpression of CD9 serves to increase diphtheria toxin binding. The tetraspanins
CD9 and CD81 have also been shown to interact with the immunoglobulin superfamily
members EWI-2 (also called PGRL) (Stipp, Kolesnikova et al. 2001) (Charrin, Le Naour
et al. 2003) and EWI-F (also called CD9P-1 or FPRP) (Stipp, Orlicky et al. 2001). This
interaction is TX-100 resistant and of high stoichiometry (Charrin, Le Naour et al. 2001).
To date, the functions of these proteins and the biological relevance of their association
with CD9 and CD81 is unknown.
Lastly, tetraspanins have been shown to associate with integrins (Figure 1.5),
consistent with observed roles for tetraspanins in cellular motility and metastasis
(Boucheix, Duc et al. 2001) (Berditchevski 2001).
Tetraspanins and Integrins
Integrins are obligate cell-surface heterodimers that mediate cellular adhesion to
the extracellular matrix and play major roles in immune functions, leukocyte traffic, and
human disease (Hynes 2002). Each integrin subunit is a class 1 transmembrane domain
and their N-terminal regions are in close association to form a head domain consisting of
a beta-propeller (in the ca subunit) (Springer 1997) and a Rossman fold (in the 13 subunit)
(Takagi and Springer 2002). Carboxy-terminal to the head domain are elongated legs
leading to the transmembrane domains and cytoplasmic tails. Integrins have the ability to
change conformation (affinity) (Takagi, Petre et al. 2002), cluster (avidity) (Li, Babu et
al. 2001) (Luo, Springer et al. 2004), and to bind the cytoskeleton (anchoring) (van der
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Flier and Sonnenberg 2001). A recent crystal structure of the av133 extracellular domain
raised the prospect of global conformational changes in this domain to mediate integrin
affinity (Xiong, Stehle et al. 2001). A series of molecular design (Luo, Springer et al.
2003) and electron micrographic (Takagi, Petre et al. 2002) studies revealed that integrins
undergo both global and local (in the head domain) conformational changes, reinforcing
the notion that regulation of integrin affinity is complex (Takagi and Springer 2002).
Artificially, integrin affinity can be modulated by cations (EDTA decreases, Mn++
increases), monoclonal antibodies (to both increase and decrease), and peptidomimetics
of integrin ligands (cyclic RGD peptides). Biologically, integrin affinity can be
modulated by binding to natural ligands (outside-in signaling) or separation of the
cytoplasmic tails (inside-out signaling) both resulting in the separation of integrin
transmembrane and stalk domains and affinity upregulation (Hynes 2002).
Recently, it was shown that integrin transmembrane domains may play a role in
both modulating integrin affinity and avidity (Li, Mitra et al. 2003). Individual a integrin
and 13 integrin transmembrane domains were shown to spontaneously homooligomerize.
It is enticing to envision an extended lateral network of ca/f integrin heterodimers
coupled with ca/ia and 3/13 oligomeric transmembrane domains, although avidity
regulation by integrin transmembrane domains remains controversial (Luo, Carman et al.
2005). Biologically, the ability of integrins to cluster into large, extended, high-avidity
complexes has been observed for some time (Hynes 2002). It is plausible that
tetraspanins may participiate in integrin affinity regulation, avidity regulation, or both
through binding either extracellularly or within the lipid bilayer.
Although fairly ubiquitous binding between tetraspanins and integrins have been
observed (Figure 1.5), only a small subset of these heterotypic interactions have been
documented under stringent detergent conditions. Of these, the best-characterized
interaction is between the tetraspanin CD151 and integrin t331 (Yanez-Mo, Alfranca et
al. 1998; Stipp and Hemler 2000). Through chimeric molecule and mutagenesis
experiments, it was shown that this interaction requires the CD151-LEL and stalk domain
of the oc3 integrin subunit and it is presumed that this is the heterotypic interaction
domain (Yauch, Kazarov et al. 2000; Berditchevski, Gilbert et al. 2001). Domain
swapping between the ct3 (CD151-binding permissive) and o5 (CD151-binding non-
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permissive) of their respective transmembrane and cytoplasmic domains did not
disrupt the robust CD151/a3151 association (Yauch, Kazarov et al. 2000).
When detergent stringency is lowered, a wide array of tetraspanin/integrin
interactions is observed (Charrin, Manie et al. 2003). As observed pairwise interactions
are a subset of expressed, potential tetraspanin/integrin interactions, these observed
interactions have been classified as low-affinity, specific interactions (Berditchevski,
Zutter et al. 1996). Again, due to widespread co-immunoprecipitation of tetraspanins
under these conditions, it is difficult to assess if these interactions are specific or
artifactual. The ability to cross-link pairwise detergent-solubilized tetraspanin/integrin
complexes, although technically distinct from immunoprecipitation experiments, is
subject to the same detergent-induced experimental caveats described above.
Tetraspanin/integrin association under mild detergent conditions is not affected by
changes in integrin conformation. The addition of divalent cations, function-blocking,
and function-inducing anti-integrin antibodies had no effect on tetraspanin/integrin
interactions (Mannion, Berditchevski et al. 1996) (Longhurst, White et al. 1999).
Ligand-binding also had no effect on the association of tetraspanins and integrins under
mild detergent conditions (Yanez-Mo, Tejedor et al. 2001).
In the studies described in this thesis, we circumvent potential problems of
detergent-induced lipid domain fusion by testing pairwise interaction of soluble
tetraspanin-LELs with a panel of integrins (see Chapter 8). Contrary to the published
literature, we observed a strong influence of cations on tetraspanin/integrin interactions,
but could not decipher a specific pair-wise binding pattern (see Chapter 8). To reconcile
the disparity between our own and published data, we speculate that mild detergent
conditions may have dual effects. Mild detergent may serve both to disrupt low-affinity
extracellular-mediated tetraspanin/integrin interactions (which we observe in Chapter 8)
and also serve to constitutively bring tetraspanins and integrins together, thus obscuring
preferential, conformation-dependent interactions. As a result, observed, constitutive
tetraspanin/integrin interactions under mild detergent conditions would obscure the
integrin-conformational dependence of these interactions. Strong detergents may serve to
completely disrupt these low-affinity tetraspanin/integrin interactions.
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In summary, this hypothesis suggests that lateral association on the cellular
membrane is necessary to form a high avidity tetraspanin/integrin complex. Formation of
this complex (which may be mediated by both transmembrane regions and tetraspanin
palmitoylation) brings the extracellular tetraspanin and integrin domains into close
proximity and allows tetraspanin-LEL regulation of extracellular integrin activation.
Indeed, the ability of anti-tetraspanin antibodies and tetraspanin expression levels to
induce integrin-mediated signaling (Zhang, Bontrager et al. 2001), adhesion
(Lammerding, Kazarov et al. 2003), and cellular motility (Sugiura and Berditchevski
1999) strongly suggests the influence of tetraspanins (and tetraspanin-LELs in particular)
on integrin-related cellular functions. This hypothesis, which postulates that both
tetraspanin transmembrane regions and dimeric tetraspanin-LELs are necessary for
heterotypic tetraspanin interactions, is consistent with the notion of both the tetraspanin
web and transmembrane-enriched microdomains (discussed below). Furthermore, this
hypothesis is consistent with our biophysical observations that the tetraspanin-LEL form
two functional domains: a large hydrophobic interface that mediates homodimerization
and a much smaller hydrophobic interface that mediates heterotypic interactions (Chapter
4).
Homotypic Tetraspanin/tetraspanin Interactions
As described previously, our biophysical analysis of multiple tetraspanin-LELs
and the structure of the hCD8 1-LEL strongly suggested a conserved role for tetraspanin-
LELs to mediate tetraspanin dimer formation. These observations raised two attractive
possibilities: tetraspanin-LELs may mediate homo- and/or hetero-dimerization. The
combinatorial assembly of homo- and hetero- oligomers is a common phenomenon in
biology that serves to increase the number of potential interactions in an exponential
fashion (Newman and Keating 2003) (Klemm, Schreiber et al. 1998). For example,
homodimerization of the known mammalian tetraspanin genes would result in 28
homotypic tetraspanin interactions that would in turn bind to 28 heterotypic partners. If
tetraspanin heterodimers were to exist, the potential number of homotypic tetraspanin
complexes rises dramatically to 282, or 784, potential tetraspanin complexes. These
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complexes, in turn, could interact heterotypically to bind any number of non-tetraspanin
partners.
In the limited number of pair-wise tetraspanin-LELs tested, potential
heterooligomers were not observed (Chapter 6). Even more discouragingly, we did not
observe homooligomerization of intact CD9 molecules under strong detergent conditions,
although we did observe homooligomerization under weak detergent conditions (Chapter
5). The requisite use of detergents when working with the intact CD9 molecule
precluded an accurate estimate of the CD9 oligomerization state. Although surprising to
us, the inability to observe homooligomerization under strong detergent conditions was
neither surprising to the tetraspanin field nor inconsistent with the published results
described above. Although we did not observe robust detergent resistance of tetraspanin-
LEL-mediated homooligomerization, it is quite possible that the presence of other
tetraspanin domains serves to abrogate tetraspanin-LEL mediated oligomerization
(discussed fuirther in Chapter 5).
On the other hand, a large number of homotypic, tetraspanin/tetraspanin,
oligomers have been observed in mild, but not strong, detergent conditions (Rubinstein,
Le Naour et al. 1996). The ubiquitous nature of tetraspanin interactions under mild
detergent, and the observation that antibodies against different tetraspanin may induce
similar effects, has resulted in the proposal of a tetraspanin web on the cell surface
(Rubinstein, Poindessous-Jazat et al. 1997). This model, that extracellular tetraspanin-
LELs mediate heterotypic interactions and tetraspanin hydrophobic domains (both
transmembrane domains and palmitoylation) mediate homotypic tetraspanin interactions.
Inhibition endogenous tetraspanin palmitoylation may serve to impair homotypic
tetraspanin interactions (Berditchevski, Odintsova et al. 2002; Charrin, Manie et al. 2002;
Yang, Claas et al. 2002). Again, it is difficult to interpret these results. The presence or
absence of hydrophobic palmitate groups may influence the non-specific recruitment of
individual tetraspanins into detergent solubilized complexes. Given the large number of
observed interactions under mild detergent conditions, it is impossible to decipher direct
and indirect tetraspanin interactions.
To further complicate matters, ubiquitous observations of tetraspanin
palmitoylation (Yang, Kovalenko et al. 2004) has led to the proposal that they may
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constitute a new form of rafts on the cellular membrane. However, detergent
solubilization of tetraspanins reveals that they only partially exhibit traditional raft-like
characteristics (Cherukuri, Shoham et al. 2004) (Claas, Stipp et al. 2000). As these
results are more ambiguous (and indirect) than the contentious characterization of lipid-
rafts (Simons and Vaz 2004), it is difficult to fully ascertain the biological relevance of
these experiments. We feel that without further, rigorous characterization, the current
hypotheses of the tetraspanin web and tetraspanin-enriched microdomains, which are
core concepts in the tetraspanin field, will remain unresolved. Detailed analysis of
homotypic and heterotypic tetraspanin oligomerization will most likely require more
detailed biophysical methods, such as fluorescence resonance energy transfer (FRET) and
fluorescence recovery after photobleaching (FRAP) of purified, reconstituted tetraspanins
and their mutants.
Lastly, we note that our hypothesis: mild-detergent solubilization of lipid bilayers
serving to artificially coalesce disparate tetraspanin complexes into a single, large
complex (Chamberlain 2004), is sufficient to explain both the ubiquitous interactions
seen in the tetraspanin literature and the notion of a tetraspanin web and lipid-raft-like
tetraspanin-enriched microdomains.
Our characterization of tetraspanin-LELs, and their ability to disrupt endogenous
tetraspanin functions on the cell surface, suggest that tetraspanin-LEL mediated
oligomerization is biologically relevant. The most fascinating of these inhibition studies
is for the mCD9-LEL to inhibit the role of CD9 in sperm-egg fusion (Stein, Primakoff et
al. 2004). This unique function of CD9, which until recently was the only gene shown to
be necessary for sperm-egg fusion, was the result of various genetic studies on
tetraspanins.
Genetic Studies of Tetraspanins
Tetraspanin-null organisms have been generated in a number of model organisms
by targeted deletion of genes, siRNA, and mutagenesis screening. In the nematode C.
elegans, all twenty predicted tetraspanin molecules have been sequentially targeted with
small interfereing RNAs with no significant consequences. Only one, tsp-15, has been
shown to have a defect in epithelial cell integrity, leading to blistering of the hypodermis
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(Moribe, Yochem et al. 2004). The Drosophila tetraspanin, latebloomer, had a delay in
synaptic contacts at the neuromuscular junction (Kopczynski, Davis et al. 1996).
However, latebloomer is not essential for embryo viability. Genetic deletion of nine (out
of 37 predicted) drosophila tetraspanins had no effect on the Drosophila lifecycle
(Fradkin, Kamphorst et al. 2002). Recently, deletion of another non-essential Drosophila
tetrapanin, sunglasses, results in light-induced retinal degeneration (Xu, Lee et al. 2004).
Human genetics has identified a number of tetraspanin-deficiency related
diseases. Similar to the drosophila sunglasses deletion mutant, mutation of
peripherin/RDS in humans leads to several retinal diseases (Kohl, Giddings et al. 1998).
Although phenotypically similar, RDS and Drosophila sunglasses (which is most related
to CD63) are, not orthologues. A series of missense mutation in the RDS large
extracellular loop, as well as deletion mutants, result in the onset of retinopathies, In
mouse model systems, targeted deletion of RDS (Sanyal, De Ruiter et al. 1980) or its
closest homologue, ROM (Clarke, Goldberg et al. 2000), lead to abnormal photoreceptor
morphogenesis. Lastly, the tetraspanin, TM4SF2, is associated with mental retardation in
humans (Zemni, Bienvenu et al. 2000). Either truncation of the protein or a single
missense mutation, P172H (which lies in the large extracellular loop), is sufficient for
onset of the phenotype.
A number of tetraspanin-null mice have been generated which result in mild
immune defects (Figure 1. lB). Deletion of CD37 results in slight defects of B-cell
humoral responses and B-and T-cell interactions (Knobeloch, Wright et al. 2000).
Targeted deletion of the CD81 gene also resulted in a slight reduction of B-cell humoral
responses but: had no effect on T lymphocyte development (as expected from antibody
inhibition experiments) (Maecker and Levy 1997; Miyazaki, Muller et al. 1997;
Tsitsikov, Gutierrez-Ramos et al. 1997). On the other hand, deletion of the tetraspanin
Tssc6 resulted in normal B cell development but a slight elevation in T cell receptor-
dependent proliferation (Tarrant, Groom et al. 2002). CD151-deleted mice also exhibit
an increase in T-cell mediated hyperproliferation (Wright, Geary et al. 2004).
Furthermore, CD151 deletion results in hemostasis problems, including prolonged
bleeding times, due to defects in mild defects in caIIb3 integrin signaling (Lau, Wee et
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al. 2004). Targeted deletions of the tetraspanins, CD37, CD81, CD151, and Tssc6 in
mouse models were viable and fertile (Hemler 2001).
In the central nervous system, deletion of either CD9 or CD81 results in mice that
have enlarged brains due to increased numbers of glia and astrocytes (Geisert, Williams
et al. 2002). Neuronal binding to CD81 on astrocytes inhibits astrocyte proliferation
(Kelic, Levy et al. 2001). As a result, deletion of CD81 results in astrocytic
hyperproliferation. Puzzlingly, in vitro experiments show that antibodies against CD81
serve to suppress astrocyte proliferation, suggesting a case where antibody binding to a
tetraspanin is the reverse of the null-phenotype (Geisert, Yang et al. 1996; Dijkstra,
Geisert et al. 2001). In the central nervous system, CD9 has also been shown to be
essential for proper paranodal maintenance and staltory conductance in the axon
(Ishibashi, Ding et al. 2004).
Unexpectedly, the only dramatic tetraspanin-null phenotype was due to deletion
of the CD9 gene. The CD9 molecule has proposed roles in cellular migration
(Scherberich, Giannone et al. 2002), adhesion (Rubinstein, Le Naour et al. 1994),
metastasis (Ikeyama, Koyama et al. 1993). It has been shown to bind both 31 integrins
and the platelet integrin cIIbf33 under mild detergent conditions (Longhurst, White et al.
1999). Targeted deletion of the CD9 gene did not result in dramatic effects in any of
these systems. On the other hand, CD9, which is expressed on the oocyte, was shown to
be essential for fertilization (Kaji, Oda et al. 2000; Le Naour, Rubinstein et al. 2000;
Miyado, Yamada et al. 2000). CD9 is expressed on oocytes (Kaji, Oda et al. 2000) and
CD9-null oocytes bind normally, but can not fuse with sperm (Le Naour, Rubinstein et al.
2000). Bypassing the sperm-egg fusion event using intracytoplasmic sperm injection
resulted in normal onset of development (Miyado, Yamada et al. 2000). The CD9-null
phenotype is mimicked by the exogenous addition of an antibody against CD9 (Chen,
Tung et al. 1999; Miller, Georges-Labouesse et al. 2000).
Given the dramatic effects induced by the addition of antibodies against
tetraspanins, the mild phenotypes described above were surprising. Except for the case
of astrocytic hyperproliferation, deletion of a tetraspanin gene mimics the binding of
antibodies to the tetraspanin-LEL, albeit with a milder effect. Perhaps in the case of null-
mice, these non-deleted tetraspanins may serve to compensate for one another through
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the formation of novel tetraspanin complexes. Only in specific biological systems, such
as fertilization, is compensation insufficient to make up for the loss. We further
hypothesize that antibody addition serves to rapidly disrupt cell-surface tetraspanin
macromolecular complexes mediated by the tetraspanin-LEL. This effect is rapid and
eclipses the rate of de novo complex formation, which results in the near wild-type
phenotypes observed in tetraspanin-null mice.
Viral Membrane Fusogens
Only one gene, CD9, has been shown to be essential for sperm-egg fusion
(another gene, izumo, was just recently shown to be essential (Inoue, Ikawa et al. 2005)).
Since the invention of the microscope, sperm and egg cells have been the focus of intense
biological interest. The regulated fusion of these two cells restores diploidy and marks
the beginning of a new embryo. Functionally, this fascinating biological event is most
analogous to viral-cell fusion and this functional similarity served as the basis for our
interest into this field.
Virions are inert particles with a wide range of sizes and shapes (Fields 2001).
Like spermatozoa, virions are terminally differentiated and do not have the ability to self-
replicate without external assistance. Virions encapsulate genomic material (either DNA
or RNA), contain structural proteins (and possibly polymerases), and a set coat proteins
that mediate virion entry (Eckert and Kim 2001). Like the sperm cell, virions need to
recognize that they are in proximity to a potential host cell, bind to it, and release its
genomic material into the cytoplasm of the host cell. In the case of the sperm cell, this
host cell is also a fully differentiated gamete, the egg (Talbot, Shur et al. 2003). Carrying
genetic material from one location to another is the central purpose of both sperm cells
and virions. In fact, both sperm and viruses generate huge numbers of these genetic
packages, many orders of magnitude in excess of what ultimately is needed. In the case
of human fertilization, a typical male ejaculate contains about 100 million sperm, only
about 100 of which reach the upper reproductive tract, and only one of which fuses with
the egg. The dynamics of both virus infectivity and sperm competition is an actively
investigated field of research (Brikhead and Moller 1998; Nowak and May 2000).
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Membrane lipid bilayers are stable structures that do not fuse spontaneously.
Furthermore, cell membranes do not have spontaneous curvature and are fully hydrated
(Tanford 1980). To overcome the barriers to lipid mixing, a wide variety of membrane
fusogens have evolved to catalyze this event, which is central to fertilization, vesicle
trafficking, muscle development, and viral entry (Earp, Delos et al. 2005). The most well
characterized protein catalysts of membrane-fusion are viral fusion proteins.
As obligate intracellular parasites, it is essential for viruses to enter and infect host
cells. This entry event is controlled and catalyzed by large, extracellular viral surface
proteins (fusogens) that have been structurally classified into two groups. Class I fusion
proteins are synthesized as a single protein precursor that is subsequently activated and
cleaved. This proteolytic processing creates a metastable trimeric structure that is
conserved among several classes of virions and forms a "spike" on the surface of the
virion (Figure 1.6) (Eckert and Kim 2001). Activation of these metastable proteins
through either receptor binding or pH changes results in global conformational changes
and the insertion of an amphipathic fusion peptide into the target membrane, creating a
fusion intermediate (Carr and Kim 1993). Subsequent formation of a thermodynamically
stable six-helical bundle, termed a "trimer of hairpins" (Figure 1.6), likely provides the
energy for bringing apposing phospholipids into close proximity and mediating fusion
(Chan, Fass et al. 1997). A similar membrane fusion mechanism, utilizing the formation
of a stable alpha-helical coiled-coil structure to mediate lipid mixing has also been shown
for SNAP/SNARE mediated vesicle fusion (Jahn, Lang et al. 2003).
Structurally, class II fusion proteins are quite dissimilar from the conserved alpha-
helical class I fusion proteins (Earp, Delos et al. 2005). The most studied models of class
II fusion proteins (which include Hepatitis C virus) are the tick-borne encephalitis (TBE)
and Semliki Forest Virus (SFV) virions. Unlike the ca-helices characteristic of class I
fusion proteins, the TBE (Rey, Heinz et al. 1995) and SFV envelope (Lescar, Roussel et
al. 2001) proteins both adopt a predominantly beta-strand structure. The TBE
glycoprotein forms an antiparallel dimer that lies flatly on the viral surface (Figure 1.7).
A putative amphipathic fusion peptide (which inserts into the target membrane) is
internal, unlike class I fusion proteins (Allison, Schalich et al. 2001). Upon activation
under acidic conditions, the homodimer globally rearranges into an elongated homotrimer
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that lies perpendicular to the virion surface (Allison, Schalich et al. 1995; Ferlenghi,
Clarke et al. 2001; Stiasny, Allison et al. 2001; Bressanelli, Stiasny et al. 2004), possibly
allowing the fusion peptide to insert into the target membrane (Figure 1.7). Although no
detailed structural analysis of the hepatitis C viral glycoproteins is available, they have
been proposed to adopt and undergo similar conformational changes as their closely
related flaviviridae family members TBE and SFV (Garry and Dash 2003).
In conclusion, although class I and class II viral fusion proteins are structurally
dissimilar, they share many conserved features. They are synthesized in a metastable
state that upon activation, undergo global oligomerization rearrangements to catalyze
lipid mixing (Chan and Kim 1998). This membrane fusion event, similar to most cell-
cell fusion events is irreversible and unlike vesicle fusion, does not require recycling of
fusion proteins (Sudhof 2004). Extrapolating from known fusogens in these diverse
membrane fusion systems, tetraspanins do not appear to directly catalyze lipid mixing
and fusion. The extracellular domains of tetraspanins are relatively small and few known
trans binding partners are known. The studies described in this thesis indicate that the
CD9-LEL exists as a stable, a-helical dimer and does not adopt multiple conformations
(Chapter 2). Furthermore, inhibition of fertilization by soluble, recombinant mimics of
the CD9-LEL show that the major role of the egg CD9 is to act in cis(Zhu, Miller et al.
2002), on the egg surface, and not to function in trans, with the sperm cell (Chapter 7).
So why is CD9 essential for membrane fusion? First we review other cell-cell fusion
systems.
Cell-Cell Fusion
A number of genetic and biochemical screens have attempted to probe the
molecular mechanisms of membrane fusion. As a- and alpha- type yeast mating involves
membrane apposition and fusion, a screen for yeast fusogens was conducted by the
Walter laboratory. They identified a single protein, Prmpl, which showed normal
membrane apposition and decreased fusion. However, deletion of the prmpl gene
yielded ambiguous results, where membrane fusion was only reduced 50% (Heiman and
Walter 2000). Given the ease and elegance of yeast genetics, it is unclear why this screen
has been unsuccessful to date.
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Recently, the C. elegans protein Eff-1 has been identified as a potential epithelial
fusogen (Mohler, Shemer et al. 2002), although it has no effect on sperm-egg fusion (del
Campo, Opoku-Serebuoh et al. 2005). The Eef-1 protein is a novel type 1
transmembrane protein with no orthologues in other sequenced organisms (Mohler,
Shemer et al. 2002). Similar to canonical membrane fusion proteins (syncytia review),
ectopic expression of Eef-1 in non-fusogenic cell is sufficient to induce cell-cell fusion,
although its mechanism of action is unclear (Shemer, Suissa et al. 2004). Without the
presence of orthologues, it is unlikely that the identification of eef- will lend insight into
mammalian cell-cell fusion. A C. elegans screen for fertilization-incompetent sperm
specific mutations has yielded spermatogenesis and gamete binding defects, but not
fusion defects (L'Hernault, Shakes et al. 1988; Singson, Mercer et al. 1998). A
systematic screen of C. elegans genes using RNAi (Kamath, Fraser et al. 2003) did not
yield a sperm-egg fusogen. However, often RNAi does not work in C. elegans gametes
(L'Hernault, personal communication).
Genetic screens have implicated a variety of genes in the fusion of drosophila
myoblasts to form myotubes (Schnorrer and Dickson 2004). These screens have
identified intracellular small GTPases, GTPase exchange factors (GEFs), and adaptor
proteins as essential genes in myoblast fusion. Furthermore, identification of cell-surface
proteins containing immunoglobulin-domains are thought to function in homotypic
myoblast recognition and adhesion and not to directly mediate fusion. At this time a
myoblast fusogen has not been identified.
Recently, a review has noted the widespread identification of IgG superfamily
proteins playing essential roles in a wide variety of cell-cell fusion events (Chen and
Olson 2005). As a result, they have proposed that ct-helical structures are non-essential
for catalysis of membrane fusion. As described above, although ac-helical coiled-coil
structures are widely used to catalyze membrane fusion, other O-strand glycoproteins
(class II viral fusogens) may also serve to mediate membrane fusion (Earp, Delos et al.
2005). The common mechanism underlying all known membrane fusion events is the
presence of metastable proteins that undergo global, oligomeric, conformational changes.
This specific class of proteins does not include either tetraspanins or the immunoglobulin
superfamily of proteins. Although putative cell-cell fusogens have yet to be identified,
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we are optimistic that in time the mechanisms underlying heterotypic and homotypic cell-
cell membrane fusion events will converge with those already known.
Sperm-Egg Fusion
Like many researchers in the tetraspanin field, our interest in tetraspanins was
sparked in other cell-biological systems. CD9 first came to our attention through work
by Brent Miller in Paul Primakoff's laboratory, who showed that a monoclonal antibody
against CD9, clone KMC8, could specifically inhibit sperm-egg fusion (Miller, Georges-
Labouesse et al. 2000). As CD9 was thought to be complexed with integrin a6p1 on the
egg surface, these results were striking, but fit the paradigm for a central role of egg-
surface integrins interacting with the sperm-surface ADAM family members (Chen, Tung
et al. 1999).
The ADAM family of molecules were first identified as the targets of a
monoclonal antibody, PH-30, that inhibited sperm-egg binding and fusion (Blobel,
Wolfsberg et al. 1992) (Primakoff and Myles 2000). PH-30 was especially striking as its
antigen was spatially restricted to the equatorial region of murine sperm, a subdomain of
the sperm head that had been observed to mediate sperm-egg binding and fusion
(Primakoff and Myles 1983). After a decade of intense research, mouse genetics
revealed that targeted deletion of a PH-30 antigen, ADAM2, had minimal effects on
sperm-egg binding and no effect on sperm-egg fusion (Cho, Bunch et al. 1998).
Subsequently, mouse genetics studies showed that integrins also played a non-essential
role in sperm-egg binding and fusion (He, Brakebusch et al. 2003). Currently, the
molecular mechanism underlying sperm-egg binding is not known.
Concurrently, three groups independently presented mouse genetic experiments
illustrating that CD9 is essential for sperm-egg fusion, with no role in sperm-egg binding
(Kaji, Oda et al. 2000; Le Naour, Rubinstein et al. 2000; Miyado, Yamada et al. 2000).
These results are striking. Sperm-egg fusion was specifically blocked and the phenotype
was 98% penetrant. This surprising role for the tetraspanin CD9 raises several intriguing
questions. Are there other factors that mediate sperm-egg fusion? Furthermore, no other
major effects have been observed with any tetraspanin-null mice to date as it is believed
32
that many tetraspanins may compensate for one another. Why does this not occur at the
egg surface?
The functional nature of the clone KMC8 targeted our fertilization studies to the
extracellular domain of the protein CD9. Our inhibition results with the soluble,
recombinant mCD9-LEL protein further suggest that CD9 functions on the egg surface,
and not as a receptor for sperm. This result suggests againsts experiments to probe the
sperm-surface for a CD9 receptor, which we have contemplated.
A recent finding that CD9 may bind in trans to pregnancy-specific glycoprotein
17 (PSG17) is puzzling (Ellerman, Ha et al. 2003). PSG proteins are members of the
immunoglobulin superfamily, synthesized by the placenta during pregnancy, and secreted
into the maternal circulation. They are hypothesized to play a role in the immune system
and may function in inhibiting maternal rejection of the foetus (Ha, Waterhouse et al.
2005). Consistent with this role, PSG17 has been shown to interact with CD9 on
macrophages (Waterhouse, Ha et al. 2002). It is not certain if PSG17 is present on
mature spermatogonia and their expression pattern does not match that expected for a
protein with a role in sperm-egg fusion. On the other hand, the Primakoff lab showed
binding specificity of PSG17 to the murine CD9-LEL; the introduction of non-fusogenic
permissive mutations abolished the interaction. Interestingly, it was shown that transient
binding of PSG17 (washing out PSG17 prior to gamete mixing) was insufficient to
inhibit sperm-egg fusion (wash-out experiments were not attempted with our mCD9-LEL
protein inhibition), suggesting that the CD9-LEL is not involved in priming the egg for
sperm entry (Ellerman, Ha et al. 2003). These results also suggest that CD9 does not
serve to hold a fusogen in a metastable state.
Although we have identified CD9 as acting in cis on the egg surface, the
molecular mechanisms underlying sperm-egg fusion remain opaque. It is possible that
CD9 functions as a chaperone to assist in the maintenance of an egg fusogen in a
metastable state. However, transient inhibition results with the PSG17 protein suggest
against this. It is also possible that CD9 functions only to provide a high-affinity or high-
avidity scaffold for either a egg-bound membrane fusogen or a receptor to a sperm-bound
fusogen. A role for CD9 in mediating affinity or avidity is consistent with its proposed
roles in other cellular contexts.
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Recently, a gene on the sperm cell, izumo, was also characterized as a necessary
protein to sperm-egg fusion (Inoue, Ikawa et al. 2005). Izumo is the antigen to a sperm-
egg fusion-blocking antibody and is localized to the posterior head of sperm (the
membrane domain where fusion occurs). Targeted deletion of izumo was results in a
specific defect in sperm-egg fusion and bypassing this event with izumo-null
spermatozoa resulted in normal development. Izumo is a small type 1 transmembrane
protein with a single, extracellular, immunoglobulin fold with no predicted homology to
other characterized proteins. Izumo does not directly bind CD9 (Okabe, personal
communication). It is striking that the only two known essential genes for membrane
fusion are small with unknown functions.
Motivated by evidence for the role of CD9 in sperm-egg fusion, we focused our
studies on the CD9-LEL. This approach both targets our approach to the domain
recognized by a fertilization-inhibiting antibody and also circumvents the issues of
detergent solubility problematic for transmembrane proteins. In this thesis, I describe the
purification and characterization of the mCD9-LEL. This methodology is expandable to
some, but not all, tetraspanins-LELs. Using our biophysical characterization of the
mCD9-LEL as a model, we explore both the oligomerization of intact CD9 molecules
and the interactions of tetraspanins-LELs with integrins. Lastly, we demonstrate the
inhibitory activity of our panel of soluble tetraspanins-LELs in a number of biological
contexts, including fertilization and hepatitis C viral infectivity.
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Figure 1.1 Sequence conservation and phylogeny of tetraspanin proteins. A) Conserved amino
acids among 28 known human tetraspanin and 37 Drosophila tetraspanins. The short
extracellular loop (SEL) and large extracellular loop (LEL) are labeled. The non-a-helical
variable region is indicated with a red bar. The predicted, conserved, a-helical lies N- and C-
terminal of this region, extending to transmembrane segment 3 and transmembrane segment 4.
B) Twenty-seven human and one murine tetraspanin sequence were aligned. The murine
sequence is indicated with "**". Shaded genes are mutated tetraspanins in humans or targeted
deletions in mouse. Tetraspanins with a red box are studied in more detail in Chapter 6
(from Martin Hemler, Journal of Cell Biology, 155(7) 1103-1107, 2001)
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Fig 1.3 Homology Analysis of the hCD8 I1-LEL
structure A) Superposition of the monoclinic
1G8Q (green) and hexagonal IIV5 (red) crystal
structures. B) Model of the intact CD82 molecule
using the hCD81-LEL structure as a template.
Helical elements are shown in red. Disulfide bonds
are shown in yellow. C) Predicted disulfide-bond
connectivitiesof tetraspanin-LELs containing two
disulfides bonds (Group 1; top) three disulfide
bonds (Group 2; middle) and four disulfide bonds
(Group 3). Conserved helical structures
comprising the dimerization subdomain are shown
in blue. The variable subdomain is shown in red
and key conserved residues are indicated in green.
(From A) Neugebauer et. al. Bioorg Med Chem Lett
14: 1765-1769 (2004) B) Bienstock and Barrett Mol
Carcin. 32: 139-153 (2001) C) Seigneuret et. al. JBC
267 (43) 40055-40064 (2001))
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Figure 1.4 A table of observed tetraspanin heterotypic interactions circa 1997. Listed are
the tetraspanin family members (left), species, cell type where the interaction was observed
and associated molecules. The list includes tetraspanin binding partners under both robust
and non-robust detergent conditions
(from Maecker et. al. FASEB J. 11 (6) 428-42 (1997).
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Figure 1.5 A table of observed tetraspanin integrin interactions circa 2001. Listed are the
tetraspanin family members (left), integrin heterodimer, cell type where the interaction was
observed and references where the interaction was initially observed. This list includes
tetraspanin binding partners under both robust and non-robust detergent conditions and
illustrated the rapid curation of tetraspanin heterotypic binding partners.
(from Berditchevski J of Cell Sci. 114, 4143-4151 (2001).
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Figure 1.6 A model of HIV (Class I) Membrane Fusion. The native state of the HIV
glycoprotein is depicted on the left. Binding to cellular receptors induces insertion of a
fusion peptide(red) into the host target membrane, forming a pre-hairpin intermediate. This
inhibition is long-lived and susceptible to multiple inhibition. The pre-hairpin intermediate
then collapses to a hairpin structure, where trimeric N peptide coiled coils (gray) form a six
bundle with helical C peptides (blue). This global conformational rearrangement results in
membrane apposition and fusion. Ultimately, both fusion peptide (red)and the
transmembrane segments (purple) in the same membrane.
(from ChanDC and KimPS Cell 93, 681-684 (1998).
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Figure 1.7 A model of TBE (Class II) Membrane Fusion. The primary domain structure of
the TBE glycoprotein is depicted with regions color coordinated to the domain structure
below. Transmembrane segments are in gray towards the C- termini and the internal fusion
peptide is in orange towards the N-termini. A) A cartoon of the native TBE glycoproteins as
planar antiparallel dimers on the left. A cartoon of the final post-fusion TBE glycoproein as
a trimer that sits orthogonal to the lipid bilayer on the right. B) A cartoon of the TBE
glycoprotein hairpin structure with fusion peptides inserted into the target membrane. This
intermediate structure is formed upon receptor activation of the native TBE glycoprotein (A
left) and ultimately resolves into the post-fusion TBE glycoprotein (A right)
(from Bressanelli et.al.EMBO J. 23, 728-738 (2004).
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Chapter 2
Purification and Characterization of the Murine
CD9 Large Extracellular Loop
These experiments were conceived by Christopher C. Liu and Peter S. Kim. All
experiments were carried out by Christopher C. Liu. We thank Michael W. Burgess for
technical assistance with chromatography and David L. Akey for technical assistance
with both biophysical instrumentation and analysis of data. All errors are my own.
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Introduction
Tetraspanins have been implicated in a wide variety of cell biological effects.
Surprisingly, knockout mouse models of several tetraspanin proteins have resulted only
in mild immune phenotypes (Hemler 2001). In contrast, female CD9-null mice are
infertile, and this phenotype was pinpointed to a defect in sperm-egg fusion (Kaji, Oda et
al. 2000; Le Naour, Rubinstein et al. 2000; Miyado, Yamada et al. 2000). Lack of CD9
does not affect either sperm-egg binding or subsequent development of the zygote, when
sperm-egg fusion is artificially bypassed. Exogenous addition of an antibody against
murine CD9, clone KMC8, mimics the CD9-null mutant (Chen, Tung et al. 1999; Miller,
Georges-Labouesse et al. 2000). This antibody specifically inhibits sperm-egg fusion and
has no effect on gamete binding.
Due tlo our interest in cell-cell membrane fusion, we chose to focus our studies on
the murine CD9-large extracellular loop (mCD9-LEL). By focusing on the extracellular
domain of the murine CD9 molecule, we targeted our experiments to the protein domain
recognized by a fertilization-blocking monoclonal antibody(Miller, Georges-Labouesse et
al. 2000). Furthermore, restricting our studies to this domain also circumvented issues of
solubility and aggregation commonly associated with the biophysical characterization of
membrane proteins.
In this chapter, we describe our method to express and purify to conformational
homogeneity a single disulfide-bonded species of the murine CD9-LEL. Furthermore,
we show that this mCD9-LEL species is specifically recognized by the fertilization-
blocking monoclonal antibody KMC8 and biophysical analysis reveals that it is an
autonomously folding cc-helical dimer. Lastly, we present evidence of the critical
importance in the contribution of proper-disulfide bond formation to the stability and
function of this mCD9-LEL species.
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Materials and Methods
Cloning and Expression of the Murine CD9-LEL.
Fresh, primary bone marrow cells were flushed from the long-bones of a BL6
mouse. Total ribonucleic acid (RNA) was prepared from bone marrow cells using the
RNA STAT-60 total RNA purification kit (Tel-Test, Friendswood, TX). Total RNA was
reverse-transcribed using oligo-dT primers with the Superscript Preamplification System
(Gibco BRL, Grand Island, NY). The oligonucleotide primers CL34 and CL35 (Research
Genetics, Huntsville, AL) were designed to amplify the murine CD9-LEL:
CL34 = 5'-CCCGCTAGCACCCACAAGGATGAGGTGATTAAAGAACTGC-3'
CL35, = 5'-(CCCTCGAGGATGTGGAACTTGTTGTTGAAGACCTCAC-3'
PCR was peiformed in a Robocycler (Stratagene, La Jolla, CA) with a 45-65 0 C gradient.
The amplified product was inserted into the NheI-XhoI restriction site of the carboxy-
terminal hexahistidine expression vector pET24a (Novagen, Madison, WI). Proper
plasmid construction was confirmed by DNA sequencing through the open reading frame
and referenced to the NCBI database.
Purification of the Murine CD9-LEL
The resulting plasmid, denoted recmCD9-LEL, was transformed into E. coli
BL21/pLysS competent cells for protein expression. Cells were grown in Luria-Bertani
medium to an optical density of 0.2 at 600 nm. Protein expression was induced with 1
mM isopropyl-beta-D-thiogalactopyranoside, and cells were harvested after 5 hours.
Cells were lysed in a French press and separated into soluble and insoluble
fractions by centrifugation. The insoluble portion was resuspended in 6 M guanidine-
HCI, and subsequently clarified by both centrifugation and filtration. The recombinant
protein was purified by nickel-nitrilotriacetic acid metal-affinity chromatography
(Qiagen, Chatsworth, CA), followed by reverse-phase HPLC (Waters, Milford, MA)
using a Vydac C18 preparative column (Vydac, Hesperia, CA) with a water/acetonitrile
gradient of 0.05%/min in the presence of 0.1% trifluoroacetic acid.
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Protein samples were analyzed by reverse-phase HPLC connected to an LCQ
electrospray mass spectrometer (Finnigan-MAT, San Jose, CA). Proteins were
centrifuged under vacuum to remove the acetonitrile, lyophilized, and resuspended in
PBS (pH 7.4); all protein concentrations were determined by absorbance at 280 nm in 20
mM phosphate-buffered 6M guanidine-HCl (pH 6.5) (Edelhoch 1967).
Western Blot Analysis
Lyophilized samples were resuspended in PBS and analyzed by 18% SDS-PAGE
under non-reducing and reducing conditions and Coomassie Blue staining (Lu, Blacklow
et al. 1995). Gels were transferred onto Hybond-C membrane (Amersham-Pharmacia,
Piscataway, NJ) in 10 mM CAPS/10% MeOH (pH 11.0). Membranes were blocked for 2
hours at room temperature in 4% non-fat dry milk/TBS/0. 1% Tween-20. A monoclonal
antibody against mCD9, clone KMC8 (BD Pharmingen, San Diego, CA), was used as the
primary probe at a 1:1000 dilution. Horseradish peroxidase (HRP)-conjugated goat anti-
rat (BD Pharmingen) at a 1:1000 dilution was used to detect the presence of KMC8. The
membrane was developed using the ECL system (Amersham-Pharmacia) and exposed to
film.
Quantitation of Free Thiols.
Free thiols were quantified using Ellman's Reagent (Pierce, Rockford, IL) as per
the manufacturer's instructions. In brief, resuspended protein was added to a fresh 0.08
mg/ml solution of Ellman's reagent in 100 mM sodium phosphate, pH 8.0. Absorbance
was measured at 412 nm using an extinction coefficient of 14,000.
Circular Dichroism Spectroscopy
Circular dichroism (CD) spectra were measured at 10 tM protein concentration in
PBS buffer with an AVIV 62A DS CD spectrometer (Aviv Associates, Lakewood, NJ) as
described (Wu and Kim 1997). Thermal melts were performed over a temperature range
from 0-80°C in 2°C increments. Protein samples were equilibrated for 90 seconds and
data were acquired over 30 seconds. The midpoint of the thermal unfolding transition
(Tm) reported is the maximum of the first derivative of the thermal melt data.
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Sedimentation Equilibrium Analysis
Sedimentation equilibrium analysis was performed on a Beckman XLA-90
analytical ultracentrifuge (Beckman Instruments, Palo Alto, CA). Samples were dialyzed
overnight against PBS and spun at 20,000 and 30,000 rpm. Protein samples were
analyzed at concentrations of 10, 20, and 50 gM. Data were collected at three
wavelengths per rotor speed after spinning for 24 hours at 25°C. For all speeds and time
points, a second data set was acquired 3 hours after the first. The two data sets were
compared to ensure that the samples were at equilibrium. A single ideal species model
was fit to the data and the partial specific volume was calculated from the residue-
weighted average of the amino acid sequence. Solvent density was calculated from the
solvent composition (Laue, Shah et al. 1992).
Disulfide-Shuffling of the Murine CD9-LEL protein
The murine CD9-LEL was expressed, purified, and eluted from a Ni-NTA
column under denaturing conditions. This protein fraction was diluted 10-fold into PBS
(for a final concentration of .6M guanidine-HCl) containing the specified concentrations
of reduced or oxidized glutathione. The protein solution was shaken at room temperature
for 5 hours, and simulated disulfide shuffling was stopped with the addition of neat
HOAc to a final concentration of 5% (pH 2.0). Each solution was clarified by both
centrifugation and filtration and analyzed by reverse-phase HPLC on a Vydac C18
analytical column. Protein content was monitored at 229 nm.
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Results
Expression and Partial Purification of the Murine CD9-LEL construct.
To study the mCD9-LEL we isolated primary murine bone marrow cells by
flushing the long bones of a mouse. Total RNA was extracted and first-strand cDNA
synthesis was used to create a template pool containing the murine CD9 cDNA. The
oligonucleotides CL34 and CL35 were designed to amplify the mCD9-LEL,
corresponding to murine CD9 residues 110-193 with an NheI and XhoI site inserted 5'
and 3' of the: LEL respectively for subcloning purposes. The large extracellular loop
portion of the CD9 cDNA was successfully amplified and inserted into pET24a, excising
almost the entire multiple-cloning site, and verified by DNA sequencing. The plasmid
was designed to contain a C-terminal hexahistidine tag in frame with the mCD9-LEL
(Figure 2.1A).
The recmCD9-LEL plasmid was transformed into BL21/pLysS cells for protein
expression. Overnight cultures were diluted 1:100 into Luria-Bertani growth medium
and protein expression was induced with mM isopropyl-beta-D-thiogalactopyranoside
when cells were at an optical density of 0.2 at 600nm. It should be noted that no protein
expression was observed when cells were induced at higher optical densities. Post-
induction, E. coli cells continued to grow in near-logarithmic phase, as monitored at
OD600 nm, and induced cells were harvested after 5 hours.
The mCD9-LEL protein was highly expressed and sequestered into inclusion
bodies. The mCD9-LEL protein was solubilized, air-oxidized under denaturing
conditions, and partially purified using metal-ion chromatography (Figure 2. iB). Non-
reducing SDS-PAGE analysis of the nickel-purified mCD9-LEL protein revealed several
higher order oligomers which collapsed to the monomeric form upon addition of 10%
beta-mercaptoethanol prior to loading onto SDS-PAGE (data not shown). This suggests
that nickel-purified higher order oligomers are intermolecular disulfide-bonded variants
of the mCD9--LEL protein.
Isolation and Characterization of Two mCD9-LEL Protein Species
Nickel-purified mCD9-LEL protein was diluted 10-fold into PBS, acidified, and
clarified by both centrifugation and filtration. The sample was loaded onto a reverse-
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phase C18 HPLC and protein content was monitored at 229nm. We observed and
isolated two mCD9-LEL species, designated mP1 and mP2, respectively, which were
chosen for further characterization (Figure 2.2A). Mass spectrometry revealed the
molecular weights of each of mP1 and mP2 to be 10,989.5 +/- 0.3 Da. These data
matched the predicted molecular weight of mCD9-LEL (for the oxidized species) with
the N-terminal methionine residue cleaved, but no further modifications. Using Ellman's
reagent, we detected no free sulfhydryls in either mP1 or mP2 (data not shown).
Western blot analysis revealed that only the mP1 protein was recognized by a
fertilization-blocking monoclonal antibody, clone KMC8 (Figure 2.2B). Residual KMC8
immunoreactivity of the mP2 protein may be due to traces of mP1 in the protein prep.
Reduced mP1 was weakly recognized by KMC8 at the same low levels as reduced mP2,
suggesting that KMC8 recognizes only a single, oxidized isomer of the mCD9-LEL
protein. Sandwich ELISA studies revealed that the C-terminal hexahistidine tag did not
interfere with KMC8 binding (data not shown). These results suggest that the
hexahistidine epitope is discrete from the KMC8 epitope and that the hexahistidine tag
may be utilized to probe KMC8 function (Chapter 7).
Circular Dichroism and Sedimentation Equilibrium Analyses of mCD9-LEL
Protein Species.
The mP1 protein folds into an a-helical structure in PBS as determined by
circular dichroism analysis (Figure 2.3A), with characteristic minima at 208 nm and 222
nm (Chen, Yang et al. 1974). Our measurement of a mean molar ellipticity at 222nm of
approximately -11,000 empirically corresponds to approximately one-third global,
helical content. The mP1 protein undergoes a cooperative, reversible, thermal unfolding
transition, with a Tm value of approximately 58°C. Conversely, circular dichroism
experiments reveal that mP2 does not have a well-folded structure. At 80°C, when mP1 is
thermally denatured, both mP1 and mP2 have the same CD signal at 222 nm (Figure
2.3B). When mP1 was thermally denatured to 1000C and then renatured, it did not regain
native levels o.f a -helicity. As a result, all subsequent thermal denaturation/renaturation
analysis was done to 80°C.
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Sedimentation equilibrium analyses clearly indicate that mP1 is a dimer in
solution (Figure 2.4A). Residuals (deviations) from the predicted molecular dimeric
weight were randomly distributed (Laue, Shah et al. 1992). These data are consistent at
concentrations of 10, 20, and 50 [tM in PBS (pH 7.4). The dimerization state of mP1 was
confirmed by gel filtration chromatography (see Chapter 4). Sedimentation equilibrium
experiments with the mP2 protein reveal that it is a slightly aggregated monomer (Figure
2.4B). The best linear fit for mP2 was estimated at a molecular weight of 1.14 times that
of the monomeric molecular weight. Lastly, there was a high degree of auto-correlation
in the residuals, indicative of a poor fit to a linear molecular weight model (Laue, Shah et
al. 1992). This sedimentation equilibrium result is consistent with the unstructured nature
of mP2.
Disulfide-Shuffling of the mCD9-LEL Protein Variants.
The presence of two variants of the mCD9-LEL (P1 and P2) that had identical
masses, but different chromatographic properties allowed us to hypothesize that these
proteins were disulfide-bonded variants. However, the presence of two adjacent cysteine
residues (Figure 1A) frustrated attempts to map the disulfide-bond connectivities by
tryptic proteolysis followed by mass spectral analysis (data not shown). To explore the
role of cysteine residues in the P1 and P2 variants of the mCD9-LEL protein, we turned
to simulated disulfide-shuffling conditions (Tu and Weissman 2004).
It has been shown that a mix of reduced and oxidized glutathione can simulate the
redox environment of the endoplasmic reticulum (Tu and Weissman 2004). In our
purification scheme, the mCD9-LEL protein is oxidized as it is solubilized by 6M
Guanidine-HCl from the insoluble portion of E. coli cells. This oxidation occurs under
denaturing conditions, which is consistent with the approximately equimolar ratio
between the mCD9-LEL P1 and P2 (Figure 2.2A). We rapidly diluted equivalent
quantities of fully oxidized, denatured mCD9-LEL into non-denaturing conditions
containing various ratios of reduced and oxidized glutathione. In most cases, significant
amounts of protein precipitate formed within several minutes. After 5 hours, we stopped
the redox reaction by lowering the pH and monitored mCD9-LEL P1 and P2 quantities
with an analytical C18 column.
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We observed that the presence of a glutathione mix significantly increased the
yield of both the mCD9-LEL P1 and P2 proteins (Figure 2.5). Under all redox
conditions, there was more mCD9-LEL P1 than mCD9-LEL P2, suggesting that the
mCD9-LEL is the preferred disulfide-bonded state. The ability of a redox reaction to
increase mCD9-LEL P1 yields emphasizes the contribution of a proper disulfide-bond
connectivity both to the thermodynamic stability and the cc-helical nature of the mCD9-
LEL. Lastly, the identification of redox conditions that optimize protein yield may be
critical for the extension of our methodology to other tetraspanin-LELs. For studies in
Chapter 6, we selected the redox condition consisting of 2mM GSH/0.5mM GSSG as it
both optimized yield and minimized off-pathway tetraspanin-LEL isomers (Figure 2.5C).
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Discussion
In this chapter we present evidence that the LEL of mCD9, a prototypical
tetraspanin, is an independently folding domain. mCD9-LEL can be expressed without a
large fusion partner. The properly oxidized species can be purified to homogeneity and is
approximately one-third a-helical and dimeric. The ca-helical, dimeric nature of the
mCD9-LEL protein most likely depends on attaining of a proper disulfide-bonding
pattern.
We chose to restrict our studies of the murine tetraspanin CD9 to a single domain
of the molecule: the large extracellular loop. This strategy allows significant technical
simplification, as subsequent experiments are not complicated by the necessity of adding
detergents. All of our biophysical characterization is done in phosphate-buffered saline.
However, we note that this strategy excludes the transmembrane regions, which not only
constitute a significant portion of the tetraspanin molecule but also has distinguishing
sequence conservation(Stipp, Kolesnikova et al. 2003), implying evolutionary
significance beyond anchoring the protein in the lipid bilayer of the cell. Furthermore,
this strategy does not allow the exploration of the short extracellular loop, which has
largely been ignored by the tetraspanin community. Lastly, it also does not allow the
exploration of post-translational modifications. Most importantly, palmitoylation has
been shown to play significant roles in tetraspanin function (Yang, Kovalenko et al.
2004). These issues will be further addressed in Chapter 5.
Regardless, our experiments illustrate a straighforward investigative avenue to
explore tetraspanin function in general, and CD9 in particular. By expressing the mCD9-
LEL protein in Escherichia coli, we are readily able to express and purify milligram
quantities of pure protein. Although using a prokaryotic expression system precludes the
inclusion of glycosaccharides (the CD9-LEL has no predicted glycosylation sites), it
allows fast and cheap expression of mutant constructs (see Chapter 4). An attempt to
express the CD9-LEL in S2 insect cells has not been successful to date (Jack Lawler,
personal communication). Using a hexahistidine purification tag, we eliminate the
necessity to add a large fusion partner such as glutathione-S-transferase (Zhu, Miller et
al. 2002) or maltose binding protein. Although the hexahistidine tag is not ideal for
immunoprecipitation experiments (as it binds many metal-chelating proteins), it adds
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little molecular weight to the protein of interest, further simplifying subsequent
biophysical analysis. Lastly, the use of a hexahistidine tag allows the purification of
recombinant proteins under denaturing conditions.
A critical component of our purification strategy is the use of reverse-phase
HPLC. By purifying our nickel-purified mCD9-LEL protein over C18 chromatography,
we were able to eliminate contaminating higher order oligomers, bringing our protein
purity up significantly (as assessed by SDS-PAGE). In actuality, the purity of the nickel-
purified mCD9-LEL protein (which was estimated at 85% in Figure 2. iB) significantly
overestimated protein purity. As assayed over a C18 column with a fine elution gradient,
the KMC8 immunoreactive mCD9-LEL species (P1) was estimated to be a mere 20%.
We were pleasantly surprised that a C18 reverse-phase column could separate protein
species with identical molecular weight but different disulfide-connectivities at pH 2. It
should be noted that for a protein the size of the mCD9-LEL (i lkDa), the suggested
reverse-phase column is either C4 or C8, as C18 is recommended for shorter synthetic
peptides. We have not tested the chromatographic performance of the mCD9-LEL
protein on C4 or C8 reverse-phase columns.
Circular dichroism analysis proved to be a powerful analytical tool for the study
of the mCD9-LEL. Our circular dichroism measurement of the mCD9-LEL protein, with
a 0222 of approximately -11,000 corresponds to one-third average, global helical content
(Chen Yang). For example, coiled-coils, which contain almost complete c-helicity,
exhibit a circular dichroism 0222 of between -30,000 and -35,000 (O'Shea, Rutkowski et
al. 1989). These circular dichroism measurements of the mCD9-LEL protein are
consistent with predictions of its secondary structure content.
As all tetraspanins-LELs are predicted to have significant cc-helicity, circular
dichroism may allow us to identify well-folded tetraspanin-LEL species, even without
clearly defined, conformation-specific antibodies such as the clone KMC8. By
monitoring the c-helicity of the mCD9-LEL protein over a range of temperatures, we
concluded that the mCD9-LEL protein is a very stable protein. Thermal denaturation
data may allow us a rapid, if qualitative, methodology to assay the stability of mCD9-
LEL variants. Most importantly, it directly suggests that the mCD9-LEL protein is
folded at physiological temperatures (37°C), which is critically important in analysis of
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inhibition data (Chapter 7). Thermal renaturation data also allow us to identify
incubation times and temperatures where the mCD9-LEL will no longer be folded (ie.
>80°C) which may prove useful in later experiments (Chapter 6). Lastly, the
autonomously folding nature of the mCD9-LEL suggests that there are no kinetic traps in
the folding landscape of the mCD9-LEL (Pain 1994).
Our sedimentation equilibrium suggests that the mCD9-LEL protein behaves as a
globular, ideal protein species (Laue, Shah et al. 1992). Although this experimental
method is tedious, it allows us to characterize carefully the oligomerization of the mCD9-
LEL under equilibrium conditions (versus gel filtraion). Empirically, the minimum
sequence size for a protein to exhibit a stable tertiary structure is approximately 50 amino
acids (Dyson and Wright 1991). Evidence of a dimeric mCD9-LEL may explain the
relatively high thermal stability of the 83-amino acid protein.
Although our attempts to map the disulfide connectivities was not technically
tractable, the isolation of two mCD9-LEL species with identical molecular weights
suggested that the difference in the chromatographic properties of these variants lay in
their disulfide connectivities. The ability of a redox mix to significantly alter the yields
of the two mCD9-LEL species (relative to random oxidation) strongly suggests that
disulfide connectivities result in the observed shift in reverse-phase elution times.
Equimolar yields of the two mCD9-LEL species under random oxidation (due to
denaturing conditions) also points to the importance of disulfide connectivity in
determining tx-helicity. Lastly, the greater yield of mCD9-LEL P1 under redox
conditions suggests that the a-helical mCD9-LEL species is in a lower thermodynamic
state than its disulfide-shuffled variants. For the remainder of this thesis, we will refer to
the mCD9-LEL P1 species as the mCD9-LEL protein.
A soluble, properly folded form of the mCD9-LEL protein and the general
methodology described in this chapter may assist both in studying the intrinsic nature of
the mCD9-LEL protein, its cell biological roles, and the functions of other tetraspanin-
LELs. In this thesis, we both build upon and expand the methods and results described
within this chapter.
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mCD9-LEL Construct
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Figure 2.1 Preparation of Recombinant CD9-LEL. A) Schematic diagram of the mCD9-LEL
protein sequence. The region encoding the murine CD9-large extracellular loop (LEL) was
amplified by PCR and inserted in the pET24a expression vector with a C-terminal hexahistidine
tag. B) The mCD9-LEL protein was partially purified using Ni-column chromatography and
analyzed by nonreducing SDS-PAGE: Lane 1) preinduced BL21/pLysS cells; Lane 2) induced
BL21/pLysS cells; Lane 3) insoluble fraction; Lane 4) 6 M guanidine-HCI solubilized fraction;
Lane 5) elution from Ni-column; Lane 6) molecular weight marker.
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Figure 2.2 HPLC Purification and Analysis of mCD9-LEL. A) HPLC purification profile of Ni-
purified mCD9-LEL. Three peaks corresponding to oxidized mCD9-LEL were identified. The first
two eluted proteins, designated mPI and mP2, were analyzed further. B) Peaks were analyzed by
Coomassie blue staining and Western blotting. Equal amounts of protein were loaded onto 18%
SDS-PAGE under reducing or non-reducing conditions, and blotted onto Hybond-C. Blots were
probed with KMC8 and HRP-conjugated anti-rat secondary antibody. KMC8 recognizes only the
nonreduced form of mP1.
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Figure 2.3 Circular Dichroism Characterization of mCD9-LEL Isomers. A) CD spectra of 10 [M
mPl(O) or mP2 () at 25°C in PBS. The minima at 208 and 222 nm for mP1 indicate that the
protein is highly helical. B) Temperature dependence of the CD signal at 222 nm for the mP1 (0)
and mP2 (0) species. Thermal denaturation is indicated by the filled symbols and thermal
renaturation is indicated by the open symbols. Protein concentrations were 10 ~tM in PBS. mP2
has little organized structure, whereas mP1 has a significant at-helical structure that unfolds at
high temperature and refolds upon cooling.
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Figure 2.4 Equilibrium Sedimentation of mP1 and mP2 at 25°C in PBS at 20,000 rpm. If the
experimental data fit a single species model, a single experimental molecular weight can be
derived by comparing the radius2/2 versus log absorbance (In). Deviation from the predicted
oligomeric molecular weight is revealed by the residuals from this line. In an idealized case,
residuals off the predicted slope should be random. The deviations in the data from the linear fit
are plotted (upper). A) mP1 data closely fit a dimer model with random residuals around the
predicted dimeric molecular weight. B) mP2 data reveal an oligomerization state of 1.16 with
nonrandom residuals, indicating a predominantly monomeric species with some aggregation.
Lines expected for monomeric, dimeric, and trimeric oligomerization states are indicated for
comparison.
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Figure 2.5 Glutathione Reduction/Oxidation Mix Effects on mCD9-LEL Variant Yields.
Equivalent quantities of oxidized, reduced mCD9-LEL in denaturing buffer was rapidly diluted
into redox conditions. Protein samples were mixed for 5 hours, acidified, and analyzed by
reverse-phase HPLC. Protein content, as monitored at 229 nm, was analyzed over time to collect
an HPLC profile. Reduced glutathione (GSH) concentrations are indicated in the upper-left
corner of each set of HPLC profiles. Oxidized glutathione (GSSG) concentrations are indicated to
the right of each individual HPLC trace. Under conditions with no reduced or oxidized
glutathione present, mPI and mP2 are indicated. mPl, which is the a-helical dimeric mCD9-LEL
variant is indicated in red. Under conditions with a reduced/oxidized glutathione mix, the mPI
protein peak is indicated with red arrow. As these samples were analyzed in an automated
fashion, protein abundance (as assessed by area under the peak) is quantitative and may be directly
compared between HPLC traces.
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Chapter 3
Structural Studies of the Murine CD9 Large
Extracellular Loop
These experiments were conceived by Christopher C. Liu and Peter S. Kim. All
experiments were carried out by Christopher C. Liu. We thank Vladimir Malashkevich
for technical assistance with protein crystal trials, Peter Carr for technical assistance with
both NMR instrumentation and analysis of data, and Steve Johnston for technical
assistance with structural homology modeling. All errors are my own.
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Introduction:
We have described a methodology by which we can express and purify to
homogeneity a single disulfide-bonded species of the murine CD9-LEL. The mCD9-
LEL is autonomously folding, a-helical, and dimeric in nature. Our experimental
observations of the mCD9-LEL are consistent with a study in which the structure of the
human CD81-LEL was solved by x-ray crystallography (Kitadokoro, Bordo et al. 2001).
The hCD81-LEL structure consists of five a-helices (designated A-E) (Figure
3.1). The regions corresponding to helices A, B, and E, which appear to be conserved
among all tetraspanin family members, form a dimerization (stalk) subdomain of the
tetraspanin-LEL. These helices bracket a hypervariable region or head subdomain
(Kitadokoro. Bordo et al. 2001). Among tetraspanins, the head subdomain varies in
length and number of disulfide bonds(Boucheix and Rubinstein 2001). The two
subdomains are clearly demarcated by a conserved cysteine motif characteristic of
tetraspanins. Although the hCD81-LEL head subdomain consists of two a-helices (C and
D), the CD9 head subdomain is not predicted to be a-helical (Seigneuret, Delaguillaumie
et al. 2001). Our observation that the mCD9-LEL is approximately one-third ct-helical
roughly matches the predicted secondary structure content of the CD9 dimerization
subdomain. Furthermore, sedimentation equilibrium data clearly show that the mCD9-
LEL is a dimer at low concentrations in physiological buffer. This suggests that the dimer
seen in the hCD81-LEL structure is also observed in solution and that dimer formation of
tetraspanin-LELs is conserved and biologically significant.
Often, detailed structural knowledge of a protein gives a deeper understanding of
the functional properties of that protein. Although both sequence and solution studies
strongly suggest that the CD9-LEL adopts a similar global structure to the hCD81-LEL
(Seigneuret, Delaguillaumie et al. 2001), we initiated structural studies to derive atomic
level resolution of the CD9-LEL. We chose to pursue three parallel experimental
methodologies: x-ray crystallography, nuclear magnetic resonance, and structural
homology modeling. As the human and mouse CD9-LEL share 89% sequence similarity,
we chose to use the hCD9-LEL sequence for our homology model studies.
A detailed, structural basis for mCD9-LEL function would lay the foundation for
probing the molecular nature of the mCD9-LEL protein and may also serve as a template
6(0
for both the rational design of inhibitory molecules and of dominant-negative constructs.
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Materials and Methods:
Crystal Trials:
The mCD9-LEL protein, devoid of salt and buffer, was prepared by dissolving
lyophilized protein in H20 at 9.5mg/ml. Protein concentration was determined using
Edelhoch's reagent and monitored for aromatic absorbance at 280nm. Crystals were
screened using the sitting drop method in 48-well plates. One P1 drops of protein
solution were mixed with 1-1l of each crystallization solution from the Hampton Sparse
Matrix Screens I and II (Hampton Research). One hundred pls of mother liquor was used
for vapor diffusion. All crystal trials were set up and incubated in a 20°C humidity-
controlled room and crystal chambers were assayed under a dissection microscope after
2, 7, 14, and 28 days. All crystallization trials were undertaken in two independent trials.
Nuclear Magnetic Resonance Analysis
The mCD9-LEL protein, devoid of salt and buffer, was prepared by dissolving
lyophilized protein in 50mM deuterated acetic acid/100mM NaCl/10%2H2 0/adjusted to
pH 5.5 with NaOH. NMR experiments were performed at 760pM protein (8mg/ml). 'H
NMR experiments were performed by using a Bruker (Billerica, MA) AMX spectrometer
operating at 500 MHz and 25 C. Data were processed with Felix 98.0 (Molecular
Simulations) on Silicon Graphics computers and all spectra were referenced using 2,2-
dimethyl-2-silapentane-5-sulfonic acid (DSS) (Sigma).
After data collection from nuclear magnetic resonance analysis, the mCD9-LEL
solution was recovered. Protein sample was diluted into a matching buffer as used for
NMR analysis and quantifed with Edelhoch's buffer by monitoring absorbance at 280 nm
(Edelhoch 1967). The pH of the buffer was checked with a pH buffer strip. Circular
dichroism spectra were monitored as in Chapter 2.
Homology Modeling
The hCD81-LEL and hCD9-LEL sequences were aligned with Clustal using the
BLOSUM62 matrix (Jung and Lee 2000). The three-dimensional coordinates for the
hCD81-LEL structure (1G8Q) were downloaded from the Protein Data Bank (PDB).
This structure contains two molecules in the crystallographic asymmetric unit
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(Kitadokoro, Bordo et al. 2001). As there are two protein chains (designated Chain A
and Chain B) with similar, but non-identical structures, the PDB file was deconvoluted
into individual protein chains prior to modeling. Two disulfide-bond constraints were
placed on the hCD9-LEL model: between cysteine 41/cysteine 70, and between cysteine
42/cysteine :56 respectively. These disulfide-bond connectivities correspond to the
connectivities observed in the hCD81-LEL structure. The hCD9-LEL was modeled
separately onto either the hCD8 1-LEL ChainA or Chain B with MOE-HOMOLOGY
(Chemical Computing Group), resulting in two similar, but non-identical models.
Secondary structure analysis was conducted with the PHD prediction algorithm through
the ProSite (Rost, Sander et al. 1994) web-based portal.
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Results:
Protein Crystallization Trials of the mCD9-LEL
To explore the structural basis underlying the c-helical, dimeric nature of the
mCD9-LEL molecule, we attempted protein crystal trials (Hendrickson 1991). Large
quantities of the a-helical, dimeric mCD9-LEL protein were purified as described in
Chapter 2 and no contaminant was detected by SDS-PAGE, reverse-phase
chromatography, or mass spectrometry. For expediency we chose to use the sitting drop
methodology (which is a variant of standard hanging drop methods) coupled with two
commercially available sparse matrix screens (Page and Stevens 2004). In all, one
hundred disparate crystallization conditions were tested. All conditions were tested in
two replicates, yielding highly similar results. Protein solutions were observed over time
and classified into clear (no precipitate), precipitate (appearance of "dust" in the drop
chamber), and oil (appearance of a diffracting film at the surface of the protein solution).
Although precipitating conditions were observed and catalogued (Figure 3.2), we
determined that successful identification of crystallizing conditions would require
significant amounts of time and material. Given the limited size of the murine CD9-LEL
and the derivation of a workable homology model (see below), this avenue of analysis
was not pursued further.
Nuclear Magnetic Resonance Studies of the mCD9-LEL
Concurrent with crystal trials, we began initial structural studies by nuclear
magnetic resonance. Due to protein limitations, we used a 8mg/ml protein sample in
10% 2H20 at pH5.5. One-dimensional proton spectra revealed multiple significant peaks,
although peak dispersion was far from ideal (Figure 3.3) (Evans 1995). Empirically, it
has been observed that approximate global secondary structure may be measured through
peak chemical shift changes, without the need for specific proton assignment (Wishart
and Sykes 1994). These chemical shift regions have been designated secondary
structural signature regions. Qualitatively, we see (i) no evidence for -strands (4.85-
5.9ppm), (ii) significant helical structure (3.4-4. 1ppm), and (iii) significant random coil
(8.2-9ppm).
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Total correlated spectroscopy reveals numerous cross peaks (Figure 3.4).
Focusing on the helical fingerprint region did not reveal many well-dispersed
amide/alpha cross-peaks (Figure 3.5). To explore possible acid denaturation of the
mCD9-LEL protein at pH5.5, we recovered our protein sample and analyzed a-helicity
by circular dichroism at lowered pH (Figure 3.6). Our analysis revealed that although
there was some loss of a-helicity, the protein still appeared to be significantly helical.
Homology Model Construction of the hCD9-LEL
There is significant sequence similarity among tetraspanin family members
(Seigneuret, Delaguillaumie et al. 2001). For structural homology modeling, we chose to
model the human CD9-LEL sequence onto the only existing tetraspanin structure: human
CD81-LEL (Figure 3.1B). There are two amino-acid chains in the hCD81-LEL
crystallographic asymmetric unit. For simplicity, we deconvoluted the crystal structure
coordinates and modeled the hCD9-LEL molecule onto either hCD81A or hCD81B,
resulting in two models, designated hCD9ModA and hCD9ModB respectively (Figure
3.7B)
A basic homology program, MOE, was able to derive an averaged hCD9-LEL
model with no steric clashes. This program derived a model of the hCD9-LEL that is
composed of five a-helices, similar to the published hCD8 1-LEL structure (Kitadokoro,
Bordo et al. 2001)(Figure 3.7). However, secondary-structure prediction of the hCD9-
LEL using the program PHD predicted the region modeled as helix C to be in an
extended (non-helical) conformation (Figure 3.1A). Furthermore, the hCD9-LELModA
and ModB minimized solvent exposure of the dimerization interface, resulting in a more
compact intermolecular surface than in the hCD81-LEL interface (Figure 3.8). Although
our model gives us a basis upon which to begin molecular dissection of the mCD9-LEL
dimer, it clearly is not completely accurate. In summary, we believe that the tertiary
structure and the majority of the secondary structural elements of our hCD9-LEL model
are accurate. However, we have low confidence in the side-chain rotamers of our model.
Complete coordinates of the hCD9-LEL protein modeled to both Chain A and Chain B
are included in the appendix.
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Discussion
In this chapter, we present three avenues of experimentation to derive detailed
structural analysis of the murine CD9-LEL protein. As the mCD9-LEL protein may be
readily purified in large quantities, attempts at x-ray crystallographic and nuclear
magnetic resonance structural determination were inititated.
With the advent of multiwavelength anomalous diffraction techniques
(Hendrickson 1991), solving a protein crystal structure has become much less labor-
intensive than in previous years. However, the ability to derive well-ordered protein
crystals is still a major limiting factor (Page and Stevens 2004). It is nearly impossible to
determine crystallization buffer conditions intuitively. We initiated crystallization trials
with the mCD9-LEL protein with this significant caveat in mind. As a result, we
restricted our crystallization trial conditions to commercially available sparse matrix kits.
Our ability to identify precipitating, but not crystallization conditions of the mCD9-LEL
protein on a first-pass basis is not surprising. Subsequent to these crystal trials, Francoise
Martin and Peter Monk (University of Sheffield) have repeated our experiments with no
success. Martin and Monk are currently testing crystallization conditions for the
humanCD63-LEL protein (see Chapter 6) in collaboration with us.
There are many reasons why our crystal trials may have failed. Given the small
size of the mCD9-LEL protein, it is possible, that the C-terminal hexahistidine tag
precluded the formation of well-ordered interchain contacts. The Bolognesi group's
hCD81-LEL protein also contained an uncleaved C-terminal hexahistidine tag
(Kitadokoro, Galli et al. 2001). Although their crystal trials were successful, it is difficult
to extrapolate between proteins, however phylogenetically similar they are (Boucheix and
Rubinstein 2001). We do note that of various tetraspanin-LEL proteins we have studied,
the hCD81-LEL is the most easily purified of the family (Chapter 6).
Our nuclear magnetic resonance experiments qualitatively confirmed our circular
dichroism data (Wishart, Sykes et al. 1991). However, the mCD9-LEL protein appeared
to contain significant unstructured regions. Circular dichroism analysis at lowered pH
did not reveal significant unfolding. Another possible reason for non-resolved cross-
peaks could be due to low protein concentration. To circumvent these problems, we
considered large-scale expression and purification of the mCD9-LEL protein with 3C or
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15N isotope metabolic labeling. However, given the relative success of our structural
homology modeling, we decided not to pursue detailed structural analysis further.
CD9 is the most homologous tetraspanin to CD8 1, especially in respect to their
sequences in the large extracellular loops (for phylogeny, see Chapter 1). Between the
human CD9-LEL and human CD81-LEL, there is 18% identity and an additional 16%
homology for an overall sequence similarity of 34%. In actuality, this underrepresents
the similarities between the CD9-LEL and CD81-LEL as the putative dimerization
subdomains have increased similarity. On the other hand, a hypervariable region in the
LEL structure demarcated by a strictly conserved cysteine amino-acid residue pattern has
very low sequence similarity.
By definition, our structural homology modeling resulted in a hCD9-LEL
structure that was very similar to the hCD8 1-LEL structure. Given the sequence
similarity between helix A, helix B, and helix E of the hCD81-LEL and the
complementary sequence regions of hCD9-LEL (Figure 3. 1A), we have confidence in
our homology model of the dimerization subdomain of the hCD9-LEL. We believe that
our model of this region roughly represents the buried, hydrophobic dimerization
interface conserved among many tetraspanins. However, our efficient strategy of
modeling the hCD9-LEL onto individual hCD81-LEL chains, whose hydrophobic
dimerization interface is normally capped, while minimizing the hydrophobic effect is
clearly flawed. As a result, direct molecular dissection of this interface is necessary (see
Chapter 4).
More seriously, forcing the putative head domain of the hCD9-LEL protein to fit
secondary structural elements of the hCD81-LEL is grossly flawed. Although we
surmise that the unique disulfide bonding pattern is conserved among tetraspanins-LELs,
(and thus severely restricts the global conformation of the head subdomain), we have low
confidence in the ability of our homology model to predict surface exposed amino acid
residues. Again, further molecular biological analysis of the head domain is necessary.
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AhCD9-LEL -SHKDEVIKEVQEFY-KDTYNKLKTKD-EPQRETLKAIHYALNGLAGGVEQFISDI PKKDVLET-FTVKSPDAIKEVFDNKF-H-
A B C D E
hCD81-LEL FVNKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTALTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGK
ChaiII I I
hCD1-LE I FVNKDQIAKDVKQFYDQALQQAWVVDDDANNAKAVVKTFHETLDCCGSSTL TAL TTSVLKNNL CPSGSNIISNL FKEDCHQKIDDLFSGK I
ChainBl Ii I
(
Figure 3.1 Sequence Alignment of hCD9-LEL and hCD81-LEL. A) Schematic diagrams of the
primary sequence for the hCD9-LEL and hCD81-LEL are shown. These sequences were aligned
in Clustal and gaps in the alignment are denoted with a hyphen. Human CD9-LEL putative
disulfide-bond connectivities are indicated with lines. Human CD81-LEL disulfide-bond
connectivities are as indicated in the structure shown in B. Human CD9 predictions of a-helices
by the red boxes above the sequence. Observed human CD81-LEL a-helices are represented in
red. Amino acid residues in the hCD81-LEL Chain B for which an electrostatic surface potential
was generated (as shown in B) are indicated in a gray box. B) The hCD81-LEL Chain A is
depicted in flat ribbon, with a-helices indicated in red. Helix A, B, C, D, and E are indicated by
arrows on Chain A. Chain B is depicted in Ca stick mode and an electrostatic surface potential
was generated around the amino-acid residues indicated in A. Figure prepared using DS
ViewerPro.
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Precipitating conditions:
Hampton ID # Precipitant Buffer Salt
I-4 2M AS Tris 8.5
I-6 30% Peg 4K Tris 8.5 .2M Magnesium
chloride
1-13 30% Peg 400 Tris 8.5 .2M trisodium
citrate
1-14 28% Peg 400 Hepes 7.5 .2M CaC12
1-16 1.5M LiSO4 Hepes 7.5
1-17 30% PEG 4K Tris 8.5 .2M lithium sulfate
1-22 30% Peg 4K Tris 8.5 .2M sodium acetate
1-23 30% PEG 400 Hepes 7.5 .2M magnesium
chloride
1-33 4M sodium formate
I-38 1.4M trisodium Hepes 7.5
citrate
1-39 2%Peg 400/2M AS Hepes 7.5
1-41 10%IP/20%PEG 4K Hepes 7.5
1-45 18% PEG 8K NaCacodylate 6.5 .2M zinc acetate
1-47 2M AS Na Acetate 4.6
II-1 10% PEG 6K 2M NaCI
II-14 2M AS .1M Nacitrate 5.6 .2M KnaTartarate
II-25 1.8M AS Mes 6.5 .01M CoCl
II-27 25% PegMME550 Mes 6.5 ZnSo4
II-28 1.6M tri-sodium -
citrate pH6.5
II-30 10% PEG Hepes 7.5
6K/5%MPD
II-32 1.6M AS Hepes 7.5 .1M sodium citrate
II-34 1M sodium acetate Hepes 7.5 .05M cadmium
sulfate
II-36 4.3M NaCI Hepes 7.5
II-37 10% PEG 8K/8% Hepes 7.5
ethylene glycol
II-38 20% Peg 10K Hepes 7.5
II-41 IM lithium sulfate Tris 8.5 .O1M nickel
chloride
II-42 12% glycerol Tris 8.5 1.5M AS
anhydrous
II-44 20% EtOH Tris 8.5
II-45 20% PEG MME Tris 8.5 .O1M Nickel
2000 chloride
II-46 30% PEGMME 550 Bicine 9.0 .1M NaCI
Figure 3.2 Precipitant Conditions for hCD9-LEL: Protein crystal trials were attempted using a
10mg/ml solution of the mCD9-LEL using the sitting drop method. Tabulated are conditions by
which the hCD9-LEL precipitated in an unordered fashion. No conditions were found with
protein crystals. Hampton Buffer ID#s are listed with roman numeral I corresponding to the
Hampton Sparse Matrix Screen I. Components of the precipitating buffers, listed as precipitant,
buffer., and salt components are as indicated.
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Figure 3.3 One-Dimensional 1H Nuclear Magnetic Resonance Spectrum of the mCD9-LEL:
Lyophilized mCD9-LEL was dissolved in 50mM deuterated acetic acid/lOOmM NaCI/10% 2H2 0
adjusted to pH 5.5. One-dimensional nuclear magnetic resonance was collected at 500MHz at
25°C. Fingerprint regions of peak chemical shifts due to secondary structure are indicated above
the spectrum by bars. These are ca-helix (3.4-4.1ppm), n-sheet (4.85-5.9ppm), and random coil
(8.2-9ppm). The 2H20 peak is indicated with an asterisk.
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Figure 3.4 Two-Dimensional 1H Nuclear Magnetic Resonance Spectra of the mCD9-LEL: Two-
dimensional NMR spectra were collected with the first dimension plotted on the Y-axis and the
second dimension plotted on the X-axis. Fingerprint regions of secondary structure corresponding
to random coil (8.2-9ppm), 1-sheet (4.85-5.9ppm), a-helix (3.4-4.1ppm), in order, are boxed in
blue on the diagonal. The expected region for a-helical amide/alpha cross-peaks is indicated with
a red box.
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Figure 3.5 Helical Cross Peak Region of the mCD9-LEL NMR spectra: Amide/alpha cross peaks
in the fingerprint a-helical region are shown. Well-dispersed stable cross-peaks are indicated with
arrows. A poorly-resolved patch of cross-peaks is indicated with an asterisk.
Circular Dichroism Wavelength Scan of mCD9-LELat pH 5.5
Wavelength (nm)
Figure 3.6 Circular Dichroism Spectrum of mCD9-LEL at pH 5.5: The circular
dichroism spectrum of the murine CD9-LEL protein was analyzed as described
previously. Protein was tested in 50mM acetic acid/100mM NaCI with the pH adjusted to
5.5 by sodium hydroxide (conditions used for nuclear magnetic resonance experiments).
The sample was blanked to a buffer reference lacking protein. A spectral minimum at
222nm was clearly evident and the spectrum was not collected to 200nm as a high
dynavoltage at low wavelengths was observed.
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Figure 3.7 Secondary Structures of the hCD81-LEL Chain A and B and hCD9-LEL
ModA and ModB: All subunits are depicted with the N- and C-terminal residues pointing
to the bottom of the page. Helices A, B, and E are depicted in a flat ribbon and the
remainder of the molecule is depicted in Ca stick. A) Individual hCD81-LEL peptide
chains extracted from the hCD81-LEL crystal structure. Helix C and Helix D are to the
rear. In the structure of the dimer, a subunit would bind to the front of the indicated
molecule (Helix A, B, and C). B) The structure of hCD9-LEL homology modeled onto
the hCD81-LEL Chain A is shown to the left. The structure of hCD9-LEL homology
modeled onto the hCD81-LEL Chain B is depicted to the right. Figure prepared using DS
ViewerPro
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Figure 3.8 The Dimer Surface Properties of hCD81-LEL and hCD9-LEL: All protein
geometries are identical to those presented in Figure 3.7. An electrostatic surface potential
was generated around all residues N-terminal and C-terminal to the head domain (non-
italicized amino acid residues in Figure 3.1).
Chapter 4
Molecular Biological Studies of the
Murine CD9 Large Extracellular Loop
These experiments were conceived by Christopher C. Liu, Richard 0. Hynes and Peter S.
Kim. All experiments were carried out by Christopher C. Liu. All errors are my own.
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Introduction:
The hCD81-LEL structure is a novel protein fold, with no sequence or structural
homology to other known domains (Kitadokoro, Bordo et al. 2001). Our biophysical
analysis of the murine CD9-LEL protein, hCD81-LEL's closest related gene, suggests
that the novel dimeric fold elucidated in the hCD8 1-LEL structure exists in solution at
biological concentrations. However, we were not able to empirically obtain detailed
structural knowledge of the mCD9-LEL. Based upon our theoretical homology model,
we designed a series of experiments to probe the molecular basis of the mCD9-LEL's a-
helical, dimeric properties.
To probe the molecular nature of mCD9-LEL oligomerization, we replaced
conserved, hydrophobic residues hypothesized to contribute to LEL-dimerization with
charged mutations. As the mCD9-LEL is proposed to exist as an anti-parallel dimer,
introduction of a single charged mutation presents two charged mutations into the dimer
interface, one on each subunit. In addition, these designed mutations also served to
promote a-helicity (Popot and Engelman 2000), which we have shown is a hallmark of
the native-fold of the mCD9-LEL. This series of experiments serves both to define the
contribution of the dimerization interface to the folding stability of the mCD9-LEL dimer
and to test the robustness of our homology model in designing a soluble, well-folded
monomeric version of the mCD9-LEL.
Concurrently, we wished to identify critical amino-acid residues for sperm-egg
fusion in the mCD9-LEL protein. Toward these ends, we epitope-mapped a function-
inhibiting a-CD9 antibody, clone KMC8 (Miller, Georges-Labouesse et al. 2000). The
identification of key residues will also serve to: (i) illustrate our rapid recombinant
protein expression and purification system in screening tetraspanin-LEL variants (ii)
derive a-helical dimeric variants of the mCD9-LEL to act as negative controls in cellular
inhibition assays (see Chapter 7); (iii) explore the mechanism of inhibitory antibody
function.
In this chapter, we describe extensive mutagenesis over both the dimerization
subdomain and the head subdomain of the mCD9-LEL protein. We also produce and
purify Fab fragments of the KMC8 antibody and demonstrate that it binds the mCD9-
LEL protein in a 2:2 macromolecular complex. These results are consistent with our
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previous biophysical characterization of the mCD9-LEL and lend insight to both the
mechanism of antibody-induced and tetraspanin-mediated cellular phenotypes.
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Materials and Methods:
Monomeric mCD9-LEL trials
Multiple point mutations in the mCD9-LEL sequence were constructed with the Quik-
Change Site-Directed Mutagenesis Kit (Stratagene) and confirmed by DNA sequencing.
By sequence alignment, we utilized the following oligos, designated CL89 through
CL100 to introduce mutations into the mCD9-LEL construct.
CL89, which mutated V 115R was
5'-CGCTAGCTAGCACCCACAAGGATGAGCGCATTAAAGAACTGC-3'.
CL90, which mutated VI 15D, was
5' -CGCTACGCTAGCACCCACAAGGATGAGGAGATTAAAGAACTGC-3 '.
CL91, which mutated L119R, was
5' -CGCTAC;CTAGCACCCACAAGGATGAGGTGATTAAAGAACGCCAGGAG-3 '.
CL92, which mutated L119D, was
5 '-CGCTAGCTAGCACCCACAAGGATGAGGTGATTAAAGAAGAGCAGGAG-3'.
CL93, which mutated V l15R/L119R, was
5' -CGCTAGCTAGCACCCACAAGGATGAGCGCATTAAAGAACGCCAGGAG-3'.
CL94, which mutated V115D/L119D, was
5' -CGCTAG-CTAGCACCCACAAGGATGAGGAGATTAAAGAAGAGCAGGAG-3'
CL95, which mutated V186R, was
5 '-CCGCTCGAGGATGTGGAACTTGTTGTTGAAGCGCTCACTGATGG-3'
CL96, which mutated V186D, was
5'-CCGCTCGAGGATGTGGAACTTGTTGTTGAACTCCTCACTGATGG-3'
CL97, which mutated F187R, was
5 '-CCGCTCGAGGATGTGGAACTTGTTGTTCGCGACCTCACTGATGG-3'
CL98, which mutated F187D, was
5'-CCGCTCGAGGATGTGGAACTTGTTGTTCTCGACCTCACTGATGG-3'
CL99, which mutated V186R/F187R, was
5 ' -CCGCTCGAGGATGTGGAACTTGTTGTTGCGGCGCTCACTGATGG-3'
CL100, which mutated V186D/F187D, was
5' -CCGCTCGAGGATGTGGAACTTGTTGTTCTCCTCCTCACTGATGG-3'
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CL89 through CL94 were used individually with CL35 (Chapter 2) to mutagenize the
mCD9-LEL construct. CL95 through CL100 were used individually with CL34 (Chapter
2) to mutagenesis the mCD9-LEL construct. Mutants were transformed into E. coli
BL21/pLysS, induced with isopropyl-beta-D-thiogalactopyranoside, and insoluble
fractions were purified over Ni-NTA agarose under denaturing conditions. SDS-PAGE
followed by silver staining was used to assess protein expression and purity. Selected
mCD9-LEL variants were further purified over reverse-phase HPLC. Biophysical
analysis was conducted as described in Chapter 2.
Alanine-scanning Mutagenesis and Epitope-Mapping of the mCD9-LEL protein
Multiple point mutations in the recmCD9-LEL sequence were constructed by
recombinant PCR (Higuchi 1990) and confirmed by DNA sequencing. These series of
oligos, which were used in pairs in conjunction with CL34 and CL35, mutated each
amino-acid residue to an alanine as follows:
To mutate L157,
CL 103: 5' -GGCATAGCTGGTCCTGCCGAGCAGTTTATCTCGG-3'
CL104: 5 '-CCGAGATAAACTGCTCGGCAGGACCAGCTATGCC-3 '
To mutate E158A,
CL131: 5'-CATAGCTGGTCCTTTGGCGCAGTTTATCTCGGACACC-3'
CL132: 5'-GGTGTCCGAGATAAACTGCGCCAAAGGACCAGCTATG-3'
To mutate Q 159A,
CL133: 5 '-CATAGCTGGTCCTTTGGAGGCGTTTATCTCGGACACC-3'
CL134: 5'-GGTGTCCGAGATAAACGCCTCCAAAGGACCAGCTATG-3'
To mutate F160A,
CL105: 5'-CTGGTCCTTTGGAGCAGGCGATCTCGGACACCTGCCCAAG-3'
CL 106: 5 '-CTTGGGGCAGGTGTCCGAGATCGCCTGCTCCAAAGGACCAG-3'
To mutate I161A,
C.L135: 5'-G(:GTCCTTTGGAGCAGTTTGCCTCGGACACCTGCCCCAAG-3 '
C L136: 5'-CTTGGGGCAGGTGTCCGAGGCAAACTGCTCCAAAGGACC-3'
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To mutate S 162A,
CL137: 5'-GGTCCTTTGGAGCAGTTTATCGCGGACACCTGCCCCAAG-3'
CL 138: 5 '-CTTGGGGCAGGTGTCCGCGATAAACTGCTCCAAAGGACC-3'
To mutate D 163A,
CL 139: 5 '-GGAGCAGTTTATCTCGGCCACCTGCCCCAAGAAACAGC-3'
CL140: 5'-GCTGTTTCTTGGGGCAGGTGGCCGAGATAAACTGCTCC-3'
To mutate L170A,
CL 107: 5 '-CACCTGCCCCAAGAAACAGGCGTTGGAAAGTTTCCAGG-3'
CL108: 5'-C'CTGGAAACTTTCCAACGCCTGTTTCTTGGGGCAGGTG-3'
To mutate L1I71A,
CL 109: 5'-CCTGCCCCAAGAAACAGCTTGCGGAAAGTTTCCAGGTTAAGCCC-3'
CLI 10: 5'-GGGCTTAACCTGGAAACTTTCCGCAAGCTGTTTCTTGGGGCAGG-3'
To mutateEl72A,
CL 141: 5' -GCCCCAAGAAACAGCTTTTGGCAAGTTTCCAGGTTAAGCCC-3'
CL142: 5'-G-GGCTTAACCTGGAAACTTGCCAAAAGCTGTTTCTTGGGGC-3'
To mutate S -173A,
CL143: 5'-GCCCCAAGAAACAGCTTTTGGAAGCTTTCCAGGTTAAGCCC-3'
CL144: 5'-GGGCTTAACCTGGAAAGCTTCCAAAAGCTGTTTCTTGGGGC-3'
To mutate FI[ 74A,
CL 11: 5 '-GAAACAGCTTTTGGAAAGTGCGCAGGTTAAGCCCTGCCC-3'
CL 112: 5'-GGGCAGGGCTTAACCTGCGCACTTTCCAAAAGCTGTTTC-3'
To mutate Q 175A,
CL 113: 5 '-CAGCTTTTGGAAAGTTTCGCGGTTAAGCCCTGCCCTGAAGCC-3'
CL 114: 5'-GGCTTCAGGGCAGGGCTTAACCGCGAAACTTTCCAAAAGCTG-3'
To mutate V176A,
CL145: 5'-CTTTTGGAAAGTTTCCAGGCTAAGCCCTGCCCTGAAGCC-3'
CL144: 5 '-GGCTTCAGGGCAGGGCTTAGCCTGGAAACTTTCCAAAAG-3'
Mutants were transformed into E. coli BL21/pLysS, induced with isopropyl-beta-D-
thiogalactopyranoside, and whole-cell lysates were crudely analyzed by Western blot for
reactivity to the antibody KMC8. Point mutants that were not recognized by the antibody
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KMC8 were chosen for further purification over metal-ion chromatography and reverse-
phase HPLC. Circular dichroism and sedimentation equilibrium analyses of mCD9-LEL
variants were carried out as described in Chapter 2. HPLC-purified mCD9-LEL variants
were reassessed for KMC8 reactivity.
KMC8 Fab generation:
Milligram quantities of purified, unconjugated KMC8 antibody (BD Pharmingen, San
I)iego, CA) were purchased. 2X crystallized papain (Sigma, St. Louis, MO) was
activated in 1 mg/ml cysteine-HCl (Pierce)/10 mM EDTA (pH 8.0) at a concentration of
I mg/ml for 1 hour prior to use. Antibody of the rat a-murine CD9 antibody, KMC8,
was digested with papain (2% w/w) for 3 hours at 37C in a circulating water bath
(Rousseaux, Rousseaux-Prevost et al. 1986). Digestion was stopped with the addition of
15 /M iodoacetamide (Sigma). Proteolytic digestion of KMC8 into Fab and Fc fragments
was tracked by nonreducing and reducing SDS-PAGE analysis. Fab fragments were
purified away from full-length IgG by gel filtration over a Superdex 200 10/30 column
(Amersham Pharmacia) in PBS at a flow rate of 0.4 ml/min using an AKTA/FPLC
(Amersham Pharmacia). Purified KMC8 Fab fragments were concentrated using a
Microcon-10 (Millipore) and final protein concentrations were determined using a Micro
BCA Protein Assay Kit (Pierce). Purity was assayed by SDS-PAGE and Coomassie
staining.
Gel filtration Studies of KMC8Fab and mCD9-LEL interactions:
Gel filtration standards in PBS (Bio-Rad) were loaded onto a Superdex 200 10/30 column
(Amersham Pharmacia) using an AKTA/FPLC (Amersham Pharmacia) to optimize
chromatographic conditions. KMC8 Fab fragments and individual mCD9-LEL variants
were analyzed for their respective apparent molecular weights at a constant flow rate of
0.4ml/min. Eluted fractions were collected every 0.5 mls. For binding studies, KMC8
Fab fragments were mixed with either mCD9-LELwt or mCD9-LELQ159A at a 1:1
molar ratio for 30 minutes at room temperature. Samples were spun at 14,000 rpm and
decanted. There was no visible precipitate. KMC8 Fab/mCD9-LEL binding was analyzed
using gel filtration with UV absorbance monitored at 280nm. Collected fractions were
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also analyzed by SDS-PAGE and subsequent Coomassie staining. mCD9-LEL levels
were detected by Western blotting with a biotinylated KMC8 antibody (BD Pharmingen)
followed by the Vectastain ABC Kit (Vector Labs, Burlingame, CA). The membrane was
developed using the ECL system and exposed to film.
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Results:
The Folding Stability of the mCD9-LEL Dimer
The analysis of multiple tetraspanin sequences strongly suggested the existence of
a conserved subdomain in all tetraspanin-LELs that mediates dimerization (for full
discussion, see Chapter Introduction). As our homology modeling suggested that this
conserved dimerization subdomain was hydrophobic in nature, we hypothesized that it
might be possible to construct a well-folded, ca-helical monomer by replacing conserved
hydrophobic: residues with basic amino acids that had a propensity to maintain an c-
helical secondary structure (Popot and Engelman 2000). Identification and
characterization of a monomeric mCD9-LEL would serve as a guide for studies with the
whole CD9 molecule and it would be straightforward to extend this rationale to the
construction of dominant-negative monomeric tetraspanin constructs.
Oligonucleotides were designed to replace conserved, buried hydrophobic
residues with either arginine (R) or aspartate (D) amino acid residues (Figure 4.1). We
constructed a series of mutations in the mCD9-LELwt plasmid, confirmed the cloning by
sequencing, and partially purified mCD9-LEL variants as described in Chapter 2 (Figure
4.2A). Upon induction, we observed variable expression, including several point
mutations that resulted only in disulfide-linked higher order oligomers. We chose
mCD9LELV11 5R/L1 19R for further study as it was highly expressed and introduced
two amino-acid charges. The mCD9-LEL*V15R/L119R protein had a similar protein
elution profile to the mCD9-LEL wild-type protein and a single species was purified to
homogeneity (Figure 4.2B). Circular dichroism and sedimentation equilibrium analysis
revealed that the mCD9LELoV1 5R/ L119R protein was both c-helical (Figure 4.3) and
dimeric (data not shown). These results suggested that the introduction of Vl 15R/L119R
residues is insufficient to disrupt dimerization of the mCD9-LEL.
We utilized our panel of oligonucleotides to generate mCD9LEL constructs with
four mutations in each amino acid chain (eight total amino-acid substitutions for the
intact dimerization interface). We chose two constructs for further analysis:
mCD9LELoV 115R/L 119R/V186R/F187R and
mCD9LEL-V 115D/L119D/V186R/F187R. Both constructs were readily expressed and
purified (Figure 4.4A and 4.4C). The mCD9LELV1 15D/L119D/V186R/F187R protein
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showed a clear a-helical structure (Chen, Yang et al. 1974). However, the
mCD9LELoV 115R/L119R/V186R/F187R protein had a peculiar a-helical circular
dichroism signal, albeit with a clear minimum at 0222nm (Figure 4.4B). Monitoring the
circular dichroism signal at 0222nm revealed that the midpoint temperature of thermal
unfolding was significantly lowered for both constructs, resulting in a significant fraction
of unfolded protein at 37°C (Figure 4.5). As these results precluded the use of these
variants under physiological conditions, we did not continue these studies. We conclude
that the hydrophobic nature of the dimerization interface is critical to maintain the folding
stability of the mCD9LELwt construct.
Epitope-Mapping of the KMC8/mCD9-LEL Binding Site
Our homology model of the head subdomain of mCD9-LEL (modeled onto the
hCD81-LEL head structure) did not match secondary structure predictions for the mCD9-
LEL in this region. As a result, it was not possible to predict surface-exposed amino acid
residues in the region bracketed by the conserved tetraspanin cysteine motifs.
Consequently, we chose to do alanine-scanning mutagenesis (Wells 1991) over much of
the presumed head subdomain of the mCD9-LEL protein domain (Figure 4. 1B).
We constructed a series of alanine-substitutions, checked for proper construction
by sequencing, and screened for reactivity to the antibody KMC8 by Western blotting
against whole E. coli lysates (data not shown). Only two mutations - glutamate 158 or
glutamine 159 to alanine -were sufficient for loss of KMC8 binding (Figure 4.6C).
These mutants were purified using the same methodology as for the wild-type protein.
The glutamine 158 to alanine mutant, denoted mCD9-LELE158A, did not yield
separable peaks (over a C18 HPLC column (Figure4.6A) and was not pursued for further
analysis. The glutamine 159 to alanine mutant, denoted mCD9-LEL-Q159A, revealed an
HPLC profile, similar to wild-type (Figure 4.6A), and two species were collected. CD
analysis allowed us to identify a properly folded species with helical content similar to
the mCD9-LELwt (Figure 4.7A), although with slightly decreased thermal stability (Tm
of 53°C vs. 58°C for wild-type) (Figure 4.7B). mCD9-LEL-Q159A is dimeric at
concentrations of 20 ytM and 50 M as assessed by sedimentation equilibrium (data not
shown). Thus, the mutant is well-folded.
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Binding of KMC8 Fab Fragments to the mCD9-LEL
Initial attempts to purify large quantities of the KMC8 antibody from its parental
hybridoma were not successful (data not shown). As a result, several milligrams of
purified monoclonal antibody KMC8 were purchased from BDPharmingen, where the
antibody was produced in a bioreactor (BD Pharmingen, personal communication).
The antibody KMC8 was successfully digested into its respective Fc and Fab
domains. Although the digestion was far from complete, yields were sufficient for our
experiments. Proteolytic KMC8 Fab fragments were fully separated from the whole IgG
molecule using gel filtration chromatography (Figure 4.8A). However, there remained a
20% contamination from the KMC8 Fc fragment (as assessed by Commassie SDS-
PAGE) that was not resolved (Figure 4.8B). Gel filtration analysis of the KMC8 Fab
fragment shows that it is a well-behaved monomer with an observed molecular weight of
37 kDa. The KMC8 Fc fragment consistently behaved as a 46-kDa protein, irrespective
of protein concentration. The mCD9-LEL protein behaved as a 21-kDa dimer
(theoretically 22-kDa) at the concentrations loaded onto the column. (Figure 4.9).
When a pre-mixed solution of the KMC8 Fab fragment and the mCD9-LELwt
protein was analyzed by gel filtration, we observed a major complex with an apparent
molecular weight of 99-kDa suggestive of a 2:2 macromolecular complex (theoretically
95-kDa) (Figure 4.10). SDS-PAGE and Western analysis of the protein content of the
99-kDa complex revealed that it was composed principally of the 37-kDa KMC8 Fab
fragment and the 11 -kDa mCD9-LEL. A novel protein peak with an apparent molecular
weight of 46-.kDA was revealed in the gel filtration analysis. SDS-PAGE analysis
identified this component as the contaminating KMC8 Fc fragment, which did not exhibit
a change in its apparent molecular weight upon addition of the mCD9-LELwt protein
(Figure 4.1 1).
These results demonstrate that the mCD9-LEL presents two apposing KMC8
binding surfaces. Furthermore, it confirms our epitope mapping studies to identify
residues of the mCD9-LEL critical for KMC8/CD9 interaction.
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Discussion:
In this chapter, we use a combination of molecular biology and biochemistry to
dissect out amino-acid residues critical for the folding stability of the mCD9-LEL
protein. By replacing hydrophobic amino-acid residues posited to contribute to
oligomerization, we show that dimerization of the mCD9-LEL protein is connected with
the intrinsic hydrophobicity of that domain. We also show that the antibody KMC8 binds
in a 2:2 complex and that this binding site is discrete from the dimerization site. The
ability of the mCD9-LEL to bind KMC8 in a 2:2 macromolecular complex reinforces our
conceptual model of the mCD9-LEL protein as a two sub-domain protein: a dimerization
sub-domain and an antigenic, non-dimerizing sub-domain (Kitadokoro, Bordo et al.
2001).
Our inability to develop a monomeric version of the mCD9-LEL is not surprising.
The large, buried, hydrophobic interface between the hCD81-LEL protein chains should
contribute significantly to the folding stability of the molecule. Our homology model
(Figure 3.7) and tetraspanin sequence conservation strongly suggest that this buried
hydrophobic interface is conserved (Seigneuret, Delaguillaumie et al. 2001).
Experimentally, we introduced charged, disruptive mutations into the
hydrophobic interface that retain a propensity to form helical secondary structures. In
retrospect, the ability of our proteins to maintain helical structure, while losing thermal
stability is expected. We hypothesized that the introduction of proline residues that
severely perturb helical structure may eliminate both the oligomerization and the folding
of the mCD9-LEL protein. Discrete from the dimerization sub-domain is a head sub-
domain, delimited by conserved cysteines in the tetraspanin's large extracellular loop.
This region is encoded by a single exon and is highly variable both among tetraspanin
family members and among species. This region is also where the vast majority of
functional amino acid residues have been pinpointed (Boucheix and Rubinstein 2001).
Through alanine-scanning mutagenesis (Wells 1991), we identified key residues
in the head sub-domain that are responsible for KMC8 antigenicity. These single alanine
mutants had minimal effects on the alpha-helical, dimeric nature of the mCD9-LEL,
while severely abrogating KMC8 immunogenicity. Our localization of amino acid
residues critical for KMC8 antigenicity to the N-terminal half of the hypervariable region
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is surprising. With the human CD8 1-LEL, critical residues have been identified between
cysteine 3 and cysteine 4, or the C-terminal half of the hypervariable region
(Higginbottom, Quinn et al. 2000). To date, most functional point mutations have been
localized to the region between cysteine 3/cysteine 4 (Kazarov, Yang et al. 2002) (Zhu,
Miller et al. 2002). These two loops (between cysteine 2/cysteine 3 and between cysteine
3/cysteine 4 are most likely in close proximity as they are restricted by the characteristic
tetraspanin disulfide connectivities.
With our gel filtration analysis, we present evidence that binding of the KMC8
antibody does not disrupt mCD9-LEL-mediated oligomerization. KMC8 is a monoclonal
rat anti-murine CD9 antibody of isotype IgG2aK. This clone was first derived by
injecting the mouse bone-marrow-derived stromal cell line BMS2 into rats and selecting
for monoclonal antibodies that inhibit production of myelioid, but not lymphoid cells
(Oritani, Wu et al. 1996). In subsequent studies, exogenous addition of this ac-mCD9
antibody has been shown to specifically inhibit sperm-egg fusion (Chen, Tung et al.
1999).
The ability of the KMC8 antibody to bind in a 2:2 complex, while preserving
dimerization, allows us to speculate about the antibody inhibition experiments. Our
observations suggest that KMC8 does not inhibit cellular functions by inhibiting the
endogenous climerization ability of the CD9 protein. Rather, KMC8 most likely serves to
disrupt CD9-ligand interactions, mediated through the head-subdomain of its large
extracellular loop. Currently, all epitope-mapped function-blocking antibodies against
tetraspanins bind to tetraspanin-LELs. We speculate that the addition of other tetraspanin
antibodies may serve to modulate cellular phenotypes through disruption of an
endogenous tetraspanin/non-tetraspanin complex, with no effect on the endogenous
tetraspanin dimer. Our studies describing key binding residues in the head-subdomain of
the CD9-LEL may also assist in the deconvolution of this endogenous cell-surface
complex.
Our molecular dissection of the mCD9-LEL although suggestive of a common
function for tetraspanins at the cell surface, leaves many outstanding questions. What is
the role of a higher-order tetraspanin cell surface complex? Are our biophysical
observations of the murine CD9-LEL complex represented on the cell surface? Lastly, is
88
the mCD9-LEL protein itself capable of disrupting endogenous cell-surface complexes?
The remainder of this thesis outlines our attempts to explore these questions.
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Figure 4.1 Targeted Mutagenesis of the Murine CD9-LEL. A) We schematically depict the
primary sequence organization of the murine CD9-LEL structure. The conserved putative
tetraspanin dimerization domain is depicted. Amino acid residues that were chosen for
mutagenesis to charged lysine (K) or arginine (R) residues are depicted below the wild-type
sequence with a "+". Amino acids chosen for alanine-scanning mutagenesis are depicted
with an "A". B) We present our homology model of the human CD9-LEL sequence
modeled onto Chain B of the human CD81 structure Chain B. The hCD9-LEL model is
depicted in solid wire with secondary structure illustrated (a-helix in red and disulfide bonds
in yellow). Amino acid side chains are illustrated in wire format. The amino acid residues
on which we ultimately focused our studies are illustrated with their Van der Waals radii in
space fill. These are labeled as Valine 115, Leucine 119, Valine 186 and Phenylalanine 187.
These hydrophobic amino acids appear to be loosely conserved among all tetraspanin-LELs.
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Figure 4.2 Expression and Purification of Murine CD9-LEL Dimerization Mutants. A) A
series of mutations in the putative dimerization motif of the mCD9-LEL molecule was
generated by PCR. These constructs were transformed into BL21/pLysS E. Coli cells and
protein expression was induced as described in Chapter 2. Insoluble protein was solubilized
and purified over a nickel-NTA drip column, eluted with imidazole, and diluted 10-fold.
Protein expression was monitored by non-reducing SDS-PAGE and assessed for both purity
and expression by silver-stain. Monomeric mCD9-LEL variants are indicated with an arrow.
Covalent dimeric mCD9-LEL variants were also observed and are indicated with double
arrows. B) A double mutation, mCD9LEL*V1 5R/L1 19R, was chosen for further study
based upon high expression of the monomeric form. Large scale cultures of this variant were
induced and purified by procedures as described in Chapter 2. We illustrate here a reverse-
phase HPLC profile of the mCD9LEL*V1 15R/L119R variant as monitored at absorbance
229nm. The purification profile of this variant was similar to that of the mCD9-LEL-wt
protein.
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Figure 4.3 Biophysical Analysis of the mCD9LEL*V1 15R/L119R Variant. A) Circular
dichroism spectrum was collected under standard conditions. Analysis reveals a spectral
minimum at 222 and 208nm, indicative of a well folded a-helical structure. All biophysical
analyses were conducted under conditions similar to those described in Chapter 2. We chose
not to analyze the second peak from the reverse-phase HPLC trace, which we assume to be a
disulfide-bonded variant of the a-helical form analyzed above.
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Figure 4.4 Purification and Biophysical Analysis of the
mCD9LEL*V 1 15R/L1 19RV 186R/F 187R and mCD9LEL*V 115D/L 119D/V 186R/F187R
Variants. Large-scale amounts of the variants listed above were expressed in E. Coli and purified
over Ni-NTA agarose as described in Chapter 2. These partially purified proteins were injected
over reverse-phase HPLC and protein content was monitored by absorbance at 229nm as
described. A) HPLC trace of the mCD9LEL*V115R/L1 19R/V186R/F187R protein, and C)
HPLC profile of the mCD9LEL*V 115D/L1 19D/V 186R/F187R protein. Note in C the significant
deviation from the typical C18 purification profile of the mCD9-LEL wild-type protein (see
Figure 2.2). The species chosen for further analysis are indicated with a red asterisk in A and C.
B and D) Circular dichroism spectra were collected under standard conditions. For both murine
CD9-LEL variants, a minimum at 222nm is clearly observed. However, in B we begin to see
deviation from a completely well-behaved a-helical structure.
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Figure 4.5 Thermal Denaturation Profiles of the Murine CD9-LEL Variants. The thermal
stability of the murine CD9-LEL variants was monitored by tracking the circular dichroism
signal of the dimerization mutant constructs at 222nm. Temperature was controlled by a
thermal jacket and the signal was monitored as described in Chapter 2. A) The thermal
denaturation profile of the mCD9LEL*V 115R/L1 19RNV186R/F87R protein is illustrated in
pink. The midpoint temprerature of thermal denaturation was derived by calculating the
second moment of the thermal denaturation profile and monitoring its transition across zero.
The midpoint of thermal denaturation is illustrated by a green arrow. Thermal renaturation is
illustrated in blue (completely matching and overlaid by denaturation profile). B) The thermal
denaturation/renaturation profile of the mCD9LEL*V 15D/L119D/V 186R/F 187R protein.
The graph is as in A.
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Figure 4.6 Purification and Antigenicity of murine CD9-LEL Variants. After crudely
assessing KMC8 antigenicity of alanine-scanned mCD9-LEL variants, two mutations:
mCD9LEL*K158A and mCD9LEL*Q159A were chosen for further study. Large-scale
amounts of mCD9-LEL variants were expressed and partially purified over Ni-NTA agarose as
described previously. Samples were analyzed by reverse-phase HPLC and protein content was
monitored by absorbance at 229nm as described. A) The reverse-phase HPLC trace of the
mCD9LEL*K158A variant revealed a recognizable, analogous profile to the mCD9-LELwt
profile. However, what we suspect is the correctly-folded protein isomer (as denoted by an
asterisk) could not be resolved from a second protein isomer. This protein variant was not
pursued further. B) The reverse-phase HPLC trace of the mCD9LEL*Q159A variant revealed
two peaks characteristic of the mCD9-LEL protein. Both peaks were purified for further
analysis. C) Western blot analysis of the mCD9LELwt and mCD9LEL*Q159A protein
antigenicities. Equal amounts of the proteins were analyzed on a 18% SDS-PAGE gel and
probed with the KMC8 antibody. At higher exposure, trace amounts of KMC8 antigenicity of
the mCD9LEL*Q159A variant could be detected. It is unclear if this is due to residual epitope
antigenicity or contaminating mCD9LELwt from the adjacent well. No other bands were
detected by Western analysis.
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Figure 4.7 Biophysical Analysis of the mCD9LEL*Q159A Variant. A) Circular dichroism
spectra were collected under standard conditions. Minima at 222 and 208nm were clearly
observed. Circular dichroism spectru of the first purifiable peak of the mCD9LEL*Q159A
variant, called Q159Apl, was markedly different from the second purifiable peak, Q159Ap2.
The Q159Ap2 circular dichroism spectrum is characteristic of a mix between a-helix and
unfolded secondary structures. B) Thermal denaturation profiles of the non-antigenic
mCD9LEL*Q159A variant reveals that it is autonomously folding. The thermal denaturation
profile of Q159Apl is charted in blue and the renaturation profile is charted in pink. Q159Ap2
is yellow and aqua, respectively. The temperature midpoint of thermal denaturation was
computed to be 53 0C.
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Figure 4.8 Fab Fragment Purification of the KMC8 Antibody. Purified KMC8 antibody was
digested with papain, and stopped with iodoacetamide. A) Digested KMC8 was loaded onto a
Superdex 200HR 10/30 column with PBS at a flow rate of 0.4ml/min using an AKTA/FPLC.
Protein content was monitored continuously at 280nm and mls of buffer post-sample injection
is graphed on the X-axis. Absorbance at 280nm is graphed in arbitrary units on the Y-axis
(profiles were multiplied by a scalar to bring all spectra into range). Protein profiles of gel
filtration standards are drawn in stippled black with reference peaks labeled. The digested
KMC8 protein profile is drawn in solid blue, with the whole IgG , Fc, and Fab fragments
labeled. Eluted fractions were collected every 0.5mls. B) Sequential, eluted fractions were
analyzed by non-reducing 12% SDS-PAGE followed (non-quantitatively) by silver stain.
Whole IgG, Fc, and Fab fragments were clearly identifiable and are labeled. The migration
position of the Fab fragment is labeled in red. Eluted fractions are labeled by the mls of buffer
eluted from the gel filtration column post-sample injection. Samples 15 and 15.5, which were
used for subsequent analyses, are labeled with red asterisks. The purification procedure was
repeated several times to yield sufficient quantities of the KMC8 Fab fragment.
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Figure 4.9 Gel Filtration Analysis of KMC8 and mCD9-LEL proteins. All proteins were
analyzed by gel filtration chromatography under similar conditions to those described in Figure
4.8. Mls of buffer post-sample injection is graphed on the X-axis and arbitrary absorbance
units at 280nm are graphed on the Y-axis. Molecular weight reference standards are identical
to those used previously and the profiles are drawn in black. The KMC8 Fab fragment profile
is drawn in red. The mCD9-LEL profile is drawn in green and the co-incubated KMC8
Fab/mCD9-LEL profile is drawn in blue. A contaminating KMC8 Fc fragment, which did not
shift upon co-incubation is indicated with a gray arrow. Apparent molecular weights of each
protein (as calculated relative to the gel filtration standards) is indicated with arrows below the
chart.
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Figure 4.10 SDS-PAGE Analysis of Eluted Gel Filtration Fractions. Sequentially eluted
sample were collected from the previous gel filtration run (drawn in blue in Figure 4.10) and
analyzed by SDS-PAGE. The fraction number is denoted at the top of the gels, with earlier
eluting fractions to the left of the gel. In the top panel, the non-reducing SDS-PAGE gel was
analyzed by Coomassie analysis and the migratory positions of the KMC8 Fab and the KMC8
Fc fragments are denoted to the right. In the bottom panel, the mCD9LEL protein (which
could not be detected by SDS-PAGE) was detected by assayed by Western blot analysis using
the antibody KMC8 as a primary antibody. Theoretical and observed (boxed) positions of the
complex relative to the eluted fractions are denoted below the bottom panel.
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Chapter 5
Oligomerization Studies of
the CD9 Protein
These experiments were conceived by Christopher C. Liu and Richard 0. Hynes. All
experiments were carried out by Christopher C. Liu. All errors are my own.
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Introduction:
Previously, we have described our biophysical, biochemical and molecular
characterization of the murine CD9-LEL protein. These results suggested that the
mCD9-LEL protein is a a-helical dimer. This dimer consists of two subdomains: a
conserved ca-helical dimerization domain, and a less conserved, antigenic region which
we propose is responsible for interacting with non-tetraspanin ligands.
Historically, tetraspanins were identified as the targets of monoclonal antibodies
that perturbed cellular proliferation, adhesion, and differentiation (Maecker, Todd et al.
1997). As a result, there are a panoply of well-characterized antibodies directed against
tetraspanins. Readily available and highly characterized antibodies against tetraspanins
directed the bulk of biochemical analysis to focus on immunoprecipitations interactions.
A wide range of binding partners have been proposed to interact with tetraspanins,
including homotypic (tetraspanin/tetraspanin) (Rubinstein, Le Naour et al. 1996) and
heterotypic (tetraspanin/non-tetraspanin) (Boucheix and Rubinstein 2001) associations.
These protein complexes may be composed of integrins (Berditchevski 2001), major
histocompatibility class proteins (Szollosi, Horejsi et al. 1996), signaling molecules
(Hemler 2003), and other tetraspanins (Rubinstein, Le Naour et al. 1996). Given the
wide range of binding partners, immunoprecipitated tetraspanin interactions have been
classified into categories based upon a series of increasingly stringent detergent
conditions (Hemler 2001). Very few heterotypic (tetraspanin/non-tetraspanin) and
homotypic (tetraspanin/tetraspanin) interactions immunoprecipitate under standard
conditions (1%TX-100). The widespread use of milder detergent conditions, such as
CHAPS and Brij97, 98, and 99 result in the precipitation of a greater variety of
tetraspanin-ligands including integrins, MHC proteins, CD4 (Imai, Kakizaki et al. 1995),
CD8 (Imai and Yoshie 1993), and each other.
A limited number of heterotypic interactions have been characterized in TX-100
or digitonin. These interactions are robust and of high stoichiometry (Stipp, Orlicky et al.
2000). Strikingly, although there has been widespread speculation about the existence of
a tetraspanin web (Levy and Shoham 2005) or tetraspanin-enriched microdomains
(Cherukuri, Shoham et al. 2004), homotypic (tetraspanin/tetraspanin) interactions are not
robust and are only detected under mild detergent conditions.
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Given the high thermal stability of the mCD9-LEL, we hypothesized that full-
length CD9 homooligomerization is robust and detectable under stringent detergent
conditions. In this chapter, we present several methodologies to probe murine CD9
oligomerization. Surprisingly, we observed CD9 oligomers only under weak detergent
conditions (CHAPS) (Chamberlain 2004) and not under stringent detergent conditions
(TX-100 or RIPA). Although in many ways inconclusive, our results are consistent with
published and unpublished data in the tetraspanin field.
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Materials and methods:
Full-Length CD9 construction and Expression:
Oligonucleotides CL191 and CL207 were designed to amplify the full-length
murine CD9 cDNAs with flanking EcoRI (5') and NotI (3') restriction enzyme sites.
CL191: 5'-CCGGAATTCATGCCGGTCAAAGGAGGCACC-3'
CL207: 5'-ATAAGAATGCGGCCGCGACCATCTCGCGGTTCCTG-3'
These sites were used to insert the mCD9 cDNA into the multiple cloning site of
pCDNA3.1 myc-HIS and pCDNA3.1V5-His eukaryotic epitope-tagged vectors
(Invitrogen). Vectors were checked for proper subcloning by DNA sequencing. Large
quantities of vector were purified from DHSo5' E. coli cells using the Qiagen Maxi-Prep
system and quantified by monitoring absorbance at 260/280nm.
Epitope-tagged vectors were transfected individually or in pairs into COS-7 cells
with the Fugene transfection kit according to manufactorer's instructions. In brief, 3 Pl
of Fugene transfection reagent (Roche) were mixed with 1 g of DNA and incubated in
100l1s of DMEM serum-free media for 20 minutes. This mix was then added in a drop-
wise fashion to freshly fed COS-7 cells in E4HG/10%FBS at 90% confluency.
Forty-eight hours post-transfection, cells were washed in PBS+Ca++/Mg++, lifted
off the plate with a scraper, aliquoted, and lysed in buffer containing either 1%CHAP,
1%TX-100 or RIPA (150mM NaC1, 20mM Tris, .1%SDS, 1%NP-40, 0.5%
deoxycholate, pH7.4). Lysates were cleared of particulates by centrifugation and murine
CD9 insoluble fraction was solubilized in X SDS-loading buffer. Total protein content
was monitored by the microBCA (Pierce) as per the manufacturer's instructions.
Immunoprecipitation of Epitope-Tagged CD9:
Anti-mouse IgG-conjugated agarose beads (Sigma) were washed in detergent
buffer and incubated with two /gs of either anti-myc or anti-V5 monoclonal antibody
(Invitrogen) for 2 hours at 4°C with agitation. Excess, unbound antibody was removed
from the antibody-bound beads by sequential centrifugation and washing (3X in total).
Concurrently, cell lysates were pre-cleared by the addition of anti-mouse IgG-conjugated
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agarose (Sigma) (without anti-epitope antibodies) for 2 hours at 40 C with agitation.
Agarose beads were removed by centrifugation. Pre-cleared cell lysates were added to
antibody-bound beads and rocked overnight at 40 C. Agarose beads were washed 3X with
detergent buffer to clear unbound proteins. Bound proteins were eluted by the addition of
LX SDS-loading buffer (Bio-Rad) and incubation at 100°C for 10 minutes. Eluted
proteins were loaded onto 12% SDS-PAGE gels and analyzed by Western blotting under
non-reducing conditions.
Cell-Surface Labelling:
Forty-eight hours post-transfection, cells were washed 3X with PBS+Ca++/Mg++.
Fresh sulfo-NHS-LC-biotin (Pierce) was added to PBS+ Ca++/Mg++ to a final
concentration of 0. lmg/ml and allowed to react for 30' at 37C/5%CO 2. Sequentially
washing and incubation with Tris-buffered saline for a total of 10' quenched the
reactions. Cells were harvested as described previously with the cross-linker-quenching
TBS replacing PBS in all solutions. Immunoprecipitation reactions were carried out as
previously described.
Gel Filtration Analysis:
Transfected cells were freshly lysed in RIPA buffer and cleared by centrifugation.
Soluble cell lysate was loaded onto a Superdex 200HR 10/30 column (Amersham
Pharmacia), pre-equilibrated with PBS at a flow rate of 0.4 ml/min using a AKTA/FPLC
(Amersham Pharmacia). Due to the complexity of the loaded proteins, tracking protein
content at 280nm did not yield meaningful information. Eluted fractions were collected
every 0.3mls and analyzed for CD9 content by Western blotting as previously described.
Native Blue Electrophoresis:
Native-blue electrophoresis (NBE) is a polyacrylamide gel electrophoresis
(PAGE) technique that uses the amphipathic qualities of the Coomassie Brilliant Blue
(CBB) protein-binding dye instead of ionic detergent to probe native macromolecular
complexes of transmembrane proteins (Schagger and von Jagow 1991). This technique
bypasses the requirement for highly pure transmembrane protein necessary in traditional
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analyses of protein complexes. Cells are lysed under detergent conditions and the
addition of excess CBB serves both to displace non-ionic detergents and to introduce a
charge onto proteins to allow electrophoresis (Schagger, Cramer et al. 1994).
For native-blue electrophoresis, a 30% acrylamide stock of 29:1 monomer to
cross-linker was made from powder. A 4X buffer solution consists of 200mM BisTris
pH 7.0 and 2M aminocaproic acid (Sigma). Buffer was mixed with the acrylamide stock
to make a 6%XO and an 18% acrylamide stock respectively. TEMED was added to .05%
and 10% AF'S was added to .5% to catalyze acrylamide cross-linking and continuous
gradient gels were poured into a 5-8XlOcm multi-gel caster (Hoefer) and overlaid with
water-saturated butanol. Upon polymerization, a 2.5% acrylamide stacker was poured
with the BisTris/amino-caproic acid buffer as above.
Transfected cells were freshly lysed in either CHAPS, TX-100, or RIPA buffers
as for immunoprecipitations. An equal volume of native-blue loading buffer (5%
CBB/1OOmM BisTris pH7.0/0.5M amino-caproic acid/pH7.0) was added and cell lysates
were loaded onto the gradient gels without boiling. Anode buffer (without CBB) was
composed of 25mM BisTris, 0.5M amino-caproic acid, pH7.0. Cathode buffer was
composed of 50mM Tricine, 15mM BisTris supplemented with .01% CBB. When the
CBB dye front reached the end of the gel, the cathode buffer was replaced without CBB
and the CBB was allowed to electrophorese off the gel. Gels were washed in H20 to
remove excess dye (which can compete with protein binding) and transferred to
nitrocellulose in 10mM CAPS pH1 1.0. Protein blots were blocked and developed with
anti-Myc and anti-V5 antibodies as previous.
Cross-Linking of CD9:
Co-transfected cells were freshly lysed in either CHAPS, TX-100, or RIPA
buffers as described previously. A fresh stock of 40mg/ml of dithio-bis succinimidyl
propionate (DSP) (Pierce) was dissolved in dimethyl sulfoxide. Whole cell lysates were
cross-linked with 0, 0.1, 0.4, or 0.8 mg/ml of DSP cross-linker (DMSO final
concentration is 1%) and allowed to incubate at RT for 1 hour. Reactions were quenched
with the addition of 1M Tris pH 8.0 to a final concentration of 200yM. 2X SDS-Loading
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buffer was added immediately and samples were loaded onto SDS-PAGE gels for
Western analysis.
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Results:
Detergent Stability of CD9 Homooligomers
Detergents of varying stringency have been used to characterize both homotypic
(tetraspanin/tetraspanin) and heterotypic (tetraspanin/non-tetraspanin) tetraspanin
interactions (Berditchevski, Zutter et al. 1996). As detergents of increasing stringency
are utilized, the complexity of immunoprecipitated protein complexes decreases. In the
presence of weak, non-ionic detergents (CHAPS), many homotypic and heterotypic
interactions occur. Under stronger, non-ionic detergent conditions (TX-100), homotypic
interactions disappear and only a small subset of strong heterotypic interactions remain
(Hemler 2003). With ionic detergents (RIPA), almost no interactions are detected
(Figure 5.1).
We utilized this array of detergents to monitor the stringency of homotypic
intraspecies tetraspanin interactions. The protein CD9 was tagged with either a V5 or
Myc epitope in similar vectors (pCDNA3. 1) and co-transfected into COS-7 cells. Protein
production was monitored by Western blot analysis and optimal expression was at 48
hours post-transfection (data not shown). Cells were lysed and aliquoted in either
CHAPS, TX-100, or RIPA buffer (Figure 5.1). We tracked fractionation of CD9 by
Western blot and although a bit of CD9 was detected in the CHAPS-insoluble portion,
minimal insoluble CD9 was detected in stronger detergents (Figure 5.2A). This figure
overrepresents the proportion of insoluble CD9, as correcting for volume, the insoluble
fraction is approximately 5 times as concentrated as the soluble portion. Cell-surface
biotinylation with a membrane-impermeable biotin cross-linker revealed that a significant
portion of CD9 was biotinylated and presumably reached the cell surface (Figure 5.2B).
CD9 molecules were immunoprecipitated by either anti-Myc or anti-V5
antibodies pre-bound to anti-mouse IgG agarose beads. Bound protein complexes were
eluted from the beads with SDS and analyzed by SDS-PAGE and Western blot analysis.
The efficiency of CD9 immunoprecipitation was analyzed by Western blot. Co-
immunoprecipitation of the complementary, co-transfected CD9 molecule was also
analyzed by Western blot. We observed co-immunoprecipitation only in weak, non-ionic
CHAPS buffer and no co-immunoprecipitation in either TX-100 or RIPA buffer (Figure
5.2C). This detergent stringency of co-immunoprecipitation was observed regardless of
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which detergent epitope-tagged CD9 was bound to agarose. The immunoreactive
doublets observed in all gels are consistent with published accounts.
Gel Filtration Analysis of CD9 Oligomerization State:
As we did not observe co-immunoprecipitation of co-transfected epitope-tagged
CD9 constructs under stringent detergent conditions, we attempted to get an apparent
molecular weight of the CD9 molecule. The native molecular weight of monomeric CD9
is approximately 25kDa (as assessed both by SDS-PAGE and the predicted molecular
weight of the protein without glycosylation).
Transfected cells were lysed in stringent, ionic detergent buffer (RIPA) and the
cell lysate was cleared of particulate matter by centrifugation. Cell lysate was loaded
onto a gel filtration column pre-equilibrated with RIPA buffer. Due to both the high
absorbance background of the RIPA buffer and protein lysate complexity, monitoring at
OD280 was not informative. As a result, protein fractions were collected, analyzed by
SDS-PAGE and Western blot analysis and CD9 elution was estimated by densitometry.
The CD9 elution profile was compared to gel filtration markers run under the same
conditions. We derived an estimated molecular weight of 130-kDa for the CD9/micellar
complex (Figure 5.3A). It is difficult to estimate an oligomeric state from these results.
Although unlikely, it is plausible that the binding of detergent molecules may add 100-
kDa to the native molecular weight of a CD9 monomer through binding to the four
transmembrane regions, native palmitoylation sites, and possibly large, exposed
hydrophobic surfaces in the CD9-LEL (Kitadokoro, Bordo et al. 2001). However, the
observed 130-kDA apparent molecular weight is also consistent with a detergent-bound
CD9-LEL dimer.
Native Blue Electrophoresis Analysis of CD9 Oligomerization State:
Although SDS-PAGE allows precise molecular weight analysis of a protein, it
does not preserve quarternary protein complexes. One method to circumvent this is to
use native-blue electrophoresis, a specialized PAGE technique (Schagger and von Jagow
1991). This technique utilizes the amphiphilic nature of the common protein dye,
Coomassie Brilliant Blue R-250 (CBB), to solubilize integral membrane proteins. By
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providing a negative charge to bound proteins, the Coomassie dye also allows all proteins
(regardless of native pI) to electrophorese and helps to limit protein aggregation. These
attractive attributes persuaded us to attempt to obtain a more precise molecular weight of
the CD9 complex than gel filtration allowed (Schagger, Cramer et al. 1994).
We lysed transfected COS cells expressing CD9 in detergents of varying
strengths. This allowed defined quarternary membrane protein complex solubilization.
Subsequent to lysis, we added CBB loading buffer to ensure membrane solubilization in
the native-blue PAGE system. After electrophoresis, proteins were transferred to
nitrocellulose and analyzed by Western blotting according to standard methods (Figure
5.4).
Cell lysates prepared with detergents of varying strengths resulted in quite
different electrophoretic mobilities. CHAPS lysis resulted in a wide migratory range of
the CD9 complexes with a much lower apparent molecular weight complex evident when
cells were lysed in stronger detergents. These results suggest that CHAPS lysis results in
much greater heterogeneity of CD9 complexes than either TX-100 or RIPA
solubilization. Migration of the 120-kD epitope-tagged LacZ (beta-galactosidase) is also
indicated (Figure 5.4). The LacZ protein contains no transmembrane segments but is
homo-tetrameric, and it is not clear if subunit binding was disrupted with CBB dye
binding. Soluble, protein markers (which contained some sodium dodecyl sulfate)
migrated as broad bands. However, we estimated the TX-100 solubilized CD9 complex
to be between 25-50-kDas in molecular weight. Lastly, it is clear that the CD9
complexes behave differently when solubilized in CHAPS versus stronger detergent. It is
difficult to draw conclusions about CD9 homooligomerization from this series of
experiments.
Cross-Linking Analysis of CD9 proteins:
Chemical cross-linkers are often used to identify protein partners in close
proximity. We chose to use a range of chemical cross-linkers at different concentrations
to explore oligomerization of CD9 molecules (Kovalenko, Yang et al. 2004). In brief,
equal amounts of the CD9 molecule were incubated with an amine-specific cross-linker
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for a period of time. The reaction was then quenched with Tris buffer (which contains an
amine) and protein complexes were analyzed by non-reducing SDS-PAGE.
DSP is a 12A cross-linker that reacts with amine groups (Figure 5.5A). With a
CHAPS solubilized CD9 lysate, addition of the DSP cross-linker resulted in a higher
molecular weight CD9 species corresponding to a covalent dimer. Higher order complex
formation was not observed when CD9 was solubilized in more stringent detergents such
as TX-100 or RIPA (Figure 5.5B). Although we tried a panel of amino-specific cross-
linkers with varying spacer arms, only DSP was successful in capturing a covalent dimer
(data not shown). These observations are consistent with the notion that stronger
detergent precludes the formation of CD9 quarternary complexes.
Detergent stability of tetraspanin-LEL proteins:
To probe the detergent stability of tetraspanin-LEL-mediated oligomerization, we
chose to estimate the apparent molecular weight of CD9 in TX-100 buffer. We chose this
detergent condition as it did not allow oligomerization between CD9 molecules. Our
biophysical analysis of the mCD9-LEL protein in isolation suggested that LEL-mediated
dimerization would be insensitive to non-ionic detergents. Gel filtration analysis of
molecular weight standards in TX-100 resulted in significant noise. However, it was
possible to estimate approximate molecular weights. Utilizing these standards, we
estimate that the mCD9-LEL in TX-100 has an apparent molecular weight of 30-kDa
suggestive of a dimer with bound detergent (data not shown). Given the hydrophobic
head domain of the mCD9-LEL, it is plausible that detergent-bound molecules may have
shifted the molecular weight of the mCD9-LEL. The observed apparent molecular
weight of the mCD9-LEL protein in the absence of detergent is 21-kDa (Chapter 4).
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Discussion.
The most common method to probe tetraspanin interactions is to observe these
interactions in a range of detergent conditions. Strong interactions are characterized in
stronger non-ionic detergents such as TX-100. Extraction of tetraspanin complexes under
weaker detergent stringency results in many binding partners. Under weaker stringency,
it is not clear if protein interactions are direct or indirect, as immunoprecipitates contain
many tetraspanin and non-tetraspanin proteins. These observations have led to the
hypothesis of a tetraspanin web, or a network of tetraspanin molecules that serves as an
organizing nucleus at the cell surface (Rubinstein, Le Naour et al. 1996).
The goal of this chapter was to utilize a panel of detergents to observe conditions
under which the CD9 molecule could form homodimers. Our biophysical analysis on
the mCD9-LEL protein suggests that LEL-mediated oligomerization is very stable. Both
a high midpoint of thermal denaturation and a large hydrophobic dimerization surface (in
the case of hCD8 1-LEL structure) suggest that a constitutive tetraspanin-LEL mediated
dimer sits at the center of the tetraspanin web.
Empirically, we have shown previously that the mCD9-LEL is structurally similar
to the hCD8 I-LEL crystal structure. If the mCD9-LEL structure is represented in the
whole molecule, there are several hydrophobic interfaces which may bind detergent
molecules. The most prominent hydrophobic domain is the four transmembrane
segments, which we assume require a desolvated environment to maintain solubility.
Furthermore., the CD9 molecule has been shown to contain six potential palmitoylation
sites (Charrin, Manie et al. 2002), further increasing the size of the CD9 membrane-
bound domains. Therefore, unlike the mCD9-LEL, which is soluble in PBS, the CD9
molecule requires detergent solubilization. The requisite addition of detergents for our
studies of the, CD9 molecule have severely limited out ability to estimate a molecular
weight for the CD9 complex (gel filtration studies). Native-blue electrophoresis, which
should give higher resolution of transmembrane protein complex molecular weight
(Schagger, Cramer et al. 1994) revealed lower approximate molecular weights than gel
filtration, but still did not eliminate the possibility of a dimer. CHAPS solubilization of
CD9 molecules revealed a broad heterogeneous spread of complexes, further reinforcing
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the difficulties to derive meaningful information in the presence of weak detergents. It is
clear that we are unable to identify a definitive oligomerization state using these assays.
Our most surprising result is the ability of strong non-ionic detergents (TX-100)
to disrupt CD9 oligomerization. There are many possible reasons for these negative
results. As noted in Chapter 1, studies of the CD9-LEL in isolation may not be
representative of the intact molecule. The presence of four transmembrane domains
(which is approximately equivalent to the molecular weight of the CD9-LEL) may
perturb the structure of the CD9-LEL domain, resulting in reduced oligomerization
capacity. The short extracellular loop and palmitoylation may also play critical roles in
mitigating CD9 oligomerization. Inhibition of palmitoylation may play a role in lateral
interactions among tetraspanins (Charrin, Manie et al. 2002).
The functional relevance of the a-helical, dimeric hCD81-LEL structure is still
widely debated in the tetraspanin community (Levy and Shoham 2005). Although some
role for tetraspanin-LEL mediated dimerization is not disputed, it is still unclear to what
degree extracellular oligomerization is a central feature of tetraspanin function. The root
of this argument lies in the amino- and carboxy-termini of the ordered portion visualized
in the hCD8 I-LEL structure (see Figure 3.1). Although each amino-acid chain's two
termini are in close proximity in the crystal structure (Kitadokoro, Bordo et al. 2001), the
antiparallel nature of the dimerization interface points each set of transmembrane 3 (N-
terminal) and transmembrane 4 (C-terminal) helices in opposite directions. I believe that
this view can be reconciled by adding an additional half-turn to the terminus of either
helix A or helix E. Given the results in this chapter, the answer may lie between
complete dismissal of the dimeric crystal structure and my rationalization. Currently, I
believe that inclusion of the tetraspanin transmembrane domains (as with the experiments
discussed in this chapter) lowers the oligomeric stability of the mCD9-LEL. These
confusing results have been discussed in more detail in Chapter 1.
Regardless of how directly our biophysical studies of the mCD9-LEL protein
correlate with tetraspanin behavior at the cell-surface, the mCD9-LEL domain in
isolation proves to inhibit fertilization, closely matching experimental studies with both
anti-CD9 antibodies and also CD9-null mice. These experiments are described in the
remainder of this thesis.
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Figure 5.1 Epitope-Tagged CD9 Transfection and Lysis: Full-length cDNAs of the murine
CD9 were tagged at the carboxyl-terminus with either a Myc-6XHis or a V5-6XHis.
These constructs were transiently transfected into COS7 cells and ubiquitous expression was
driven by the C.MV promoter. Post-transfection, cells were scraped, lysed with buffer
containing either CHAPS, TX100 or RIPA, and aliquoted. Tetraspanin-protein interactions
have been characterized by the detergent sensitivity of their association and the detergent
conditions we chose to explore are depicted.
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Figure 5.2 Epitope-Tagged CD9 Is Soluble, Cell-Surface Presented, and Associates Only in
CHAPS A) Transfected cell lysates were separated into detergent soluble and insoluble
portions and analyzed by SDS-PAGE followed by Western blot analysis against the epitope
tag. We loaded approximately 5X the amount of insoluble portion as soluble. Note that the
observed doublets are consistent with other publications. B) Post-transfection, cells were
labeled with the membrane-impermeable NHS-LC-biotin cross-linker. Cells were then lysed
under varying detergent conditions and immunoprecipitated. Bound protein was analyzed by
SDS-PAGE followed by Western blotting against either the epitope-tags or the biotin label.
C) Transfected cells were lysed under varying detergent conditions, aliqoted, and
immunoprecipitated. Bound proteins were analyzed by SDS-PAGE followed by Western
analysis against both the immunoprecipitating epitope and its complement.
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Figure 5.3 Gel Filtration Analysis of CD9/RIPA Lysate: A) Transfected cells were lysed and
cleared of particulates by centrifugation. This portion was loaded onto a Superdex200HR gel
filtration column and fractions were collected every 0.3mls. Each fraction was analyzed by
SDS-PAGE/Western analysis and protein was quantified by densitometry. Comparison to gel
filtration standards analyzed in RIPA buffer gave an apparent molecular weightfor the CD9
peak of 130-kDa. CD9 eluted over the range indicated by a red line. Maximal protein elution
is indicated by the arrow. B) Western blot analysis of CD9 at various eluting fractions.
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Figure 5.4 Native Blue-Electrophoresis: A) Picture of a transferred native-blue
electrophoresis gel after transfer to nitrocellulose. M = marker; C = CHAPS; T = TX-100; R =
RIPA. Lanes are presented in sets of three, with transfections of either Myc (M), Myc and V5
cotransfected (MV) or V5 (V) indicated. Singly epitope-tag transfections include the
complementary-tagged LacZ control. The triplet lanes with P-ME had beta-mercaptoethanol
added to 10-% volume prior to loading. M in the first and last lane denotes molecular weight
markers. B) Western blot analysis of native-blue gel with the same lane orientation as in A.
The migration position of LacZ is indicated as are myc-tagged CD9 molecules.
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Figure 5.5 DSP Cross-linking of CD9: A) Chemical diagram of the bi-functional amine
specific DSP cross-linker. B) Transfected cells expressing the V5/CD9 protein were lysed
under varying detergent conditions. The concentration of DSP cross-linker is indicated below
the Western blot with the negative control indicated in the leftmost lane. All samples were
analyzed by 12% non-reducing SDS-PAGE/Western. Bands corresponding to a covalent
dimer and trimer are indicated with red arrows to the left of the blot.
Chapter 6
Purification and Characterization of Human
Tetraspanin Large Extracellular Loops
These experiments were conceived by Christopher C. Liu and Peter S. Kim. All
experiments were carried out by Christopher C. Liu. All errors are my own.
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Introduction:
We have described the biophysical, biochemical, and molecular analysis of the
murine CD9-LEL. Our results with the large-extracellular loop in isolation have not
completely translated into experiments with the intact molecule, indicating that other
domains of the protein (short extracellular loop, transmembranes, palmitoylation) may
contribute to the state of oligomerization of the murine CD9 protein (Charrin, Manie et
al. 2002). Does our characterization of the mCD9-LEL as an c-helical dimer translate to
other tetraspanin family members?
There are 28 mammalian tetraspanins, with many orthologues characterized in
Drosophila,(Fradkin, Kamphorst et al. 2002) (Todres, Nardi et al. 2000) C.
elegans,(Moribe, Yochem et al. 2004) and zebrafish (Maecker, Todd et al. 1997). Of
this diverse family of genes, CD9 and CD81 represent two similar members with the
simplest large-extracellular loops as determined by length, disulfide-bonding pattern, and
glycosylation (Seigneuret, Delaguillaumie et al. 2001). More complex tetraspanin-LELs
may contain six, seven, or even eight cysteine residues in this domain. Although widely
expressed, there are several tetraspanin-family members that are both restricted in
function and expression (Levy, Todd et al. 1998). Most notably, the uroplakins form a
uroepithelial lining of the bladder and are essential for the maintenance of organellar
plasticity (Wu, Lin et al. 1994). Uroplakins are expressed at such high concentrations on
the bladder epithelium that they form two-dimensional lattices which are amenable to
electron microscopic analysis (Min, Zhou et al. 2003).
By applying our methodology to more canonical tetraspanin family members, we
explore the limits of our technology as applied to tetraspanin-LELs of greater complexity.
As most tetraspanins (but not CD9 or CD81) have putative glycosylation sites in their
respective large extracellular loops, what role does this have on the folding stability of
the LELs? Do other tetraspanin-LELs have similar biophysical characteristics? May we
develop an array of useful reagents to study the range of cellular functions in which
tetraspanins are involved? Will these tetraspanin-LELs serve as functional controls in
inhibition assays? With a panel of tetraspanin-LELs, we may also explore the possibility
of tetraspanin-LEL-mediated hetero-oligomerization. This chapter describes the
expansion of our methodology to the purification and characterization of human
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tetraspanin-L-ELs.
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Materials and methods:
Construction of human tetraspanin-LEL constructs:
Human tetraspanin cDNAs were kindly provided by Martin Hemler (Dana-Farber
Cancer Institute, Harvard Medical School, Boston, MA). Oligonucleotide primers
(Research Genetics) were designed to amplify the tetraspanin-LEL domain based upon
the region predicted to lie between transmembrane 3 and transmembrane 4.
For cloning of the human CD9-LEL, we used
CL77: 5'-C(GCTAGCTAGCTCCCACAAGGATGAGGTGATTAAGG-3'
('L78: 5'-C(-GCTCGAGGTGGAATTTATTGTCGAAGACCTC-3'
For cloning of the human CD63-LEL, we used
CL87: 5'-CGCTAGCTAGCAGAGATAAGGTGATGTCAGAGTTTAATAAC-3'
CL88: 5'-CCGCTCGAGCACATTTTTCCTCAGCCAGCCC-3'
For cloning of the human CD8 I1-LEL, we used
CL85: 5 '-CGCTAGCTAGCTTTGTCAACAAGGACCAGATCGCC-3'
CL86: 5'-CCGCTCGAGCTTCCCGGAGAAGAGGTCATCGATC-3'
For cloning of the human CD151-LEL, we used
CL79: 5'-CGCTAGCTAGCGCCTACTACCAGCAGCTGAACACGG-3'
CL80: 5'-CCGCTCGAGCCTCAGGTGCTCCTGGATGAAGGTC-3'
For cloning of the human CO-029-LEL, we used
CL127: 5'-CGCTAGCTAGCAAATCTAAGTCTGATCGC-3'
CL128: 5'-CCGCTCGAGATTTTTTGCCAAGAAGTC-3'
Human tetraspanin-LEL fragments were PCR-amplified and inserted between the
NheI and XhoI restriction sites of the carboxy-terminal hexahistidine expression vector
pET24a (Novagen). All resulting plasmids were sequenced to check for errors.
Plasmids were transformed into BL21/pLysS competent cells (Novagen) for
protein expression as described previously (see Chapter 2). In brief, expressed proteins
from inclusion bodies were solubilized in guanidine-HCl buffer and partially purified
over Ni-NTA chromatography (Qiagen). The solubilized protein was then lowered to
121
pH2 and analyzed by reverse-phase C18 HPLC with protein content monitored as
absorbance at 229nm.
Qualitative dot-blot Analysis and Purification of Human Tetraspanin-LELs:
HPLC-eluted protein peaks were collected and centrifuged under vacuum to
remove the acetonitrile. For qualitative dot blots, 1 microliter of each peak was added to
dry nitrocellulose membrane and air-dried. Membranes were blocked for 2 hours at room
temperature and the Westerns were developed by a standard protocol (see Chapter 2).
Protein immunoreactivity was probed with the following mouse anti-human monoclonal
antibodies (all from BD Pharmingen): mouse anti-human CD9 clone M-L13, mouse-anti-
human CD63 clone H5C6, mouse anti-human CD81 clone JS-81, and mouse anti-human
CD151 clone 14A2.H1 at 1:1000 dilutions.
Simulated Disulfide-Bond Shuffling:
For simulated disulfide-bond shuffling experiments, oxidized tetraspanin-LEL
proteins in denaturing buffer (6M Guanidine-HCl, pH 8.0) were diluted 10-fold into PBS
containing 2mM reduced glutathione/0.5mM oxidized glutathione. The glutathione-
containing protein solution was mixed overnight, brought to pH 2.0 with 5% HOAc,
clarified by filtration through a 0.21jM syringe filter, and loaded onto a reverse-phase
HPLC under standard conditions. Observed peaks were analyzed as above.
Biophysical Analysis:
Purified, immunoreactive human tetraspanin-LEL species were monitored for
helicity and thermal denaturation by circular dichroism as described in Chapter 2. All
proteins were monitored at 10M concentrations at 25°C. For thermal denaturation and
renaturation profiles, proteins were heated in a step-wise fashion to 80°C before
renaturation. When an antibody was unavailable, individual tetraspanin-LEL HPLC-
purified protein peaks were lyophilized and monitored for helicity by circular dichroism.
For oligomerization state analysis, human tetraspanin-LELs were loaded in PBS onto a
Superdex200HR column as described in Chapter 4.
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Heterodimer Experiments:
To probe for heterodimer formation, lyophilized tetraspanin-LELs were
resuspended in PBS and mixed individually and together to a final concentration of
LIO1M each. Samples were heated in a Stratagene Robocycler PCR machine (Stratagene)
to 75°C for 10 minutes and allowed to gradually cool to room temperature. Protein
samples were analyzed using a PhastGel automated electrophoresis system (Amersham
Pharmacia) with precast pH 3-9 isoelectric focusing (IEF) gels (Amersham Pharmacia)
with IEF standards (Amersham Pharmacia). Coomassie Brilliant Blue was used to
develop IEG gels by standard techniques.
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Results:
Expression of Human Tetraspanin-LEL Proteins
Previously, we had cloned and sequenced full-length human tetraspanin cDNAs
into the retroviral expression vector pMig (data not shown) (Liu, Constantinescu et al.
2000). Tetraspanin-LELs were sublconed into the pET24a vector and protein expression
was induced and partially purified using nickel chromatography. Protein expression and
purity were monitored by 18% SDS-PAGE under non-reducing conditions (Figure 6.1).
As expected, each tetraspanin-LEL was purified as a ladder of covalently disulfide-
bonded species. The uniform migration pattern of each oligomer is typical of non-
glycosylated proteins. Varying quantities of purified protein and ratios between
individual oligomers were also observed, with the human CD81-LEL protein exhibiting
very few contaminating bands. HPLC-purified hCD9-LEL was loaded onto the gel as a
molecular weight comparison. Empirically, tetraspanin-LELs tend to migrate faster than
their predicted molecular weights, consistent with published observations (Kovalenko,
Yang et al. 2004). However, the observed migratory patterns of tetraspanin-LELs,
relative to one another was as expected. The hCD151-LEL, hCD63-LEL, and hCO-029-
LELs all contain six cysteines and are greater in length than either hCD9-LEL or hCD81-
LEL.
Purification and Characterization of Four-Cysteine Containing Tetraspanin-LEL
Proteins
Due to high sequence identity between the murine CD9-LEL and the human CD9-
LEL, we concentrated our initial efforts on the hCD9-LEL. As expected, the hCD9-LEL
had a similar protein elution profile over C18 reverse-phase HPLC as the mCD9-LEL
protein (Figure 6.2A). By dot blot analysis, immunogenicity of an antibody directed
against the hCD9-LEL protein was also restricted to a single HPLC peak, clearly
distinguishable from other isomers (Figure 6.2B). This antibody had no cross-reactivity
to other tetraspanin-LEL species. Circular dichroism analysis characterized the hCD9-
LEL protein as a a-helical dimer (Figure 6.3A). Monitoring the circular dichroism signal
of the hCD9-LEL protein over a range of temperatures revealed that this protein is
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autonomously folding. A midpoint of thermal denaturation was measured at 600C,
indicative of' a stably folded protein (Figure 6.3B).
The human CD81-LEL was readily purified and crystallized as a glutathione-S-
transferase fusion protein by the Bolognesi group (Kitadokoro, Bordo et al. 2001). In E.
coli, we expressed and partially purified significant quantities of the hCD81-LEL protein
(Figure 6.4A). Separation of hCD81-LEL species over C18-reverse phase HPLC resulted
in a significantly different elution profile from hCD9-LEL. Furthermore, hCD81-LEL
species eluted at much higher concentrations of organic buffer, suggestive of a greater
overall hydrophobic content.
Given the success of our anti-hCD9 antibody to recognize specific, well-folded
HPLC peaks, we developed a novel, rapid assay to assess the immunogenicity of various
tetraspanin-LEL peaks using dot blot analysis. Our analysis of hCD81-LEL variants
revealed that the second, not the first, C18 resolvable peak was recognized by our
antibody (Figure 6.4A). Unfortunately, it was not feasible to purify biochemical
quantities of hCD81 -LEL both due to the cross-contamination from the first (non-
immunoreactive) eluting peak and low protein yield.
To resolve these problems, we turned to the disulfide-shuffling experiments
previously described in Chapter 2. A rapid screen of reduced and oxidized glutathione
conditions directed us to a redox mix of 2mM reduced glutathione/0.5mM oxidized
glutathione. By diluting randomly oxidized hCD81-LEL protein (with an elution profile
as in Figure 6.4A), we dramatically changed the protein content of individual hCD81-
LEL isomers (Figure 6.4B). After disulfide shuffling, we saw five individual resolvable
protein peaks. The major peak, hCD81-LEL P3, was immunogenic and clearly resolved
from contaminating, non-immunoreactive hCD81-LEL isomers. Biophysical analysis of
this immunoreactive hCD81-LEL species revealed that it was also a Ca-helical dimer
(Figure 6.5A and Figure 6.5B).
Purification and Characterization of Six Cysteine-Containing Tetraspanin-LEL
Proteins
The human CD63 protein is glycosylated and contains six cysteines forming three
disulfide-bonds (Hotta, Ross et al. 1988). Separation of randomly- oxidized hCD63-LEL
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isomers over C18-reverse phase HPLC revealed multiple peaks. Unfortunately, none of
these peaks were immunoreactive to an a-hCD63 antibody (Figure 6.6A). Disulfide
shuffling under similar conditions to the hCD81-LEL protein resulted in significant
repositioning of hCD63-LEL peaks. Surprisingly, there was a dramatic shift of all peaks
to elution at a higher organic solvent concentration. The most prominent of these peaks
was immunoreactive by dot-blot analysis (Figure 6.6B), although there are presumed to
be several minor, contaminating hCD63-LEL variants. Biophysical analysis of the
immunoreactive hCD63-LEL protein was shown to be an a-helical dimer (Figure 6.7A).
Monitoring the circular dichroism signal of the hCD9-LEL protein over a range of
temperatures revealed that this protein is autonomously folding. The midpoint of thermal
denaturation was measured at 640 C, slightly higher than the hCD9-LEL. There also
appeared to be increased cooperativity of folding (relative to hCD9-LEL) and incubation
at 80°C resulted in loss of some native-like structure (Figure 6.7B).
We also attempted to purify two different tetraspanin-LELs; the hCD151-LEL
and the hCO-029-LEL (Horejsi and Vlcek 1991). Although we also had an antibody for
the hCD151-LEL, we were unable to isolate an immunoreactive hCD151-LEL species
(Figure 6.8A), even after extensive disulfide-shuffling experiments (Figure 6.8B).
Disulfide shuffling of the hCD151-LEL protein also resulted in a shifting of the protein
elution profile to higher organic solvent conditions. Irregularities in the HPLC trace are
due to nonideal HPLC performance. We did not have an antibody towards the hCO-029
protein. Random oxidation of the hCO-029 protein yielded a daunting number of
resolvable peaks (Figure 6.9A). Disulfide shuffling lowered the number of protein peaks
and shifted resolvable proteins to more aqueous elution conditions (Figure 6.9B).
Although we attempted to purify some hCD151-LEL and hCO-029-LEL species and
assessed their "native-like" conformation by circular dichroism spectroscopy, we were
unable to identify species that exhibited a a-helical structure (data not shown).
Heterodimer Formation of Tetraspanin-LEL Proteins
Our biophysical analysis of human tetraspanin-LELs indicates that each of our
purified proteins is autonomously folding. These proteins are denatured at high
temperatures and can spontaneously regain native-like a-helicity if the temperature is
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lowered. Our thermal denaturation and renaturation analyses allow empirical
determination of the thermal limits of tetraspanin-LEL refolding. For example, when the
murine CD9-LEL is denatured to 1000C it will not spontaneously renature. These results
are not surprising as under the circular dichroism conditions tested, the murine CD9 is
thermally denatured for approximately 1 hour.
Our thermal denaturation profile indicates that heating tetraspanin-LELs to 75°C
for 10 minutes does not restrict the reattainment of native ct-helicity. As a result, we
mixed CD9 and CD81 individually and in pairs at RT, thermally denatured the proteins,
and allowed spontaneous renaturation. Complex formation was analyzed under native
conditions by isoelectric focusing electrophoresis.
As expected, individual human CD9-LEL and CD8 1-LEL proteins focused as
single bands. When the CD9-LEL and CD81-LEL were mixed, denatured, and renatured,
we observed no novel bands (data not shown). We would expect a heterodimer to both
focus to an intermediate pI and also to decrease the intensity of individual CD9-LEL and
CD81-LEL focused bands. This experiment suggests that the CD9-LEL and CD81-LEL,
which are phylogenetically similar tetraspanin-LELs, do not preferentially form
heterodimers.
127
Discussion:
In this chapter, we describe our experiments to purify three human tetraspanin-
LELs: hCD9-LEL, hCD63-LEL, and hCD81-LEL. These three proteins were all stable,
autonomously folding, a-helical and dimeric in nature. Although we successfully
expressed and partially purified the hCD151-LEL and hCO-029-LEL proteins, we were
unable to purify a a-helical form of these proteins, suggesting that these nickel-purified
proteins were not well folded.
Our biophysical characterization of three distinct tetraspanin-LELs strongly
suggests that a conserved a-helical, dimeric sub-domain is conserved. Biophysical
analysis of the folding stability of the hCD9-LEL, hCD8 I-LEL, and hCD63-LEL
revealed that each is approximately equal in thermal stability. The denaturation and
renaturation profiles of hCD81-LEL were particularly striking. Among all three
tetraspanin-LELs characterized, it exhibited the most cooperativity of folding, with
almost no loss of secondary structure before unfolding. This observation is consistent
with high yields of the hCD81-LEL protein relative to the hCD9-LEL and hCD63-LEL.
Our methodology is not readily applicable to tetraspanin-LELs of greater
complexity. There are many potential reasons for this. The CD9 and CD81 large
extracellular loops are some of the simplest tetraspanin-LELs both in length and in
number of disulfide connectivities. Our ability to isolate an cc-helical, dimeric version of
the CD63-LEL, which has three disulfide bonds, is encouraging, although we were not
able to expand this methodology to the CD151-LEL, which is of comparable length and
complexity to the CD63-LEL. Another reason for this deficit may be a critical
contribution of glycosylation to the folding of tetraspanin-LELs. The length of the short
extracellular loops (SELs) of all tetraspanins is conserved among all tetraspanins
(Seigneuret, Delaguillaumie et al. 2001). Although we surmise that the SEL most likely
does not contribute to the folding stability of the tetraspanin-LEL, this hypothesis can not
be dismissed. We speculate that the success of our methodology with the CD9-LEL,
CD81-LEL, and CD63-LEL may be expanded to closely related tetraspanin-LELs, but
not to tetraspanin-LELs with sequence similarity to either the CD151-LEL or the CO-
029-LEL proteins (for tetraspanin-LEL phylogeny, see Chapter 1).
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Other prokaryotic expression systems have been used to study tetraspanin-LELs.
Peter Monk's group has reported the purification of a panel of tetraspanin-LELs fused to
glutathione-S-transferase. They report successful purification of the hCD9-LEL
(Barreiro, Yanez-Mo et al. 2005), hCD81-LEL (Flint, Maidens et al. 1999), and
surprisingly., the hCD151-LEL (Peter Monk, personal communication). However,
attempts to express and purify the hCD63-LEL did not yield sufficient material (Peter
Monk, personal communication). These proteins were affinity purified over a glutathione
column and the presence of a large carrier protein precluded further analysis. By SDS-
PAGE, contaminating protein or proteolytic degradation was evident (Higginbottom,
Takahashi et al. 2003).
Currently, we are collaborating with Peter Monk to crystallize both the hCD9-
LEL and the hCD63-LEL proteins. Initial trials with the hCD9-LEL protein have not
yielded well--ordered protein crystals, consistent with our results in Chapter 3. Crystal
trials with the hCD63-LEL (which would yield the first structural insight into a
tetraspanin-LEL with three disulfide-bonds) are currently in progress.
If the lack of glycosylation precludes tetraspanin-folding, it will be necessary to
use eukaryotic expression systems to express tetraspanin-LELs. Unfortunately, an
attempt to express and purify the hCD9-LEL in S2 insect cells did not readily yield
protein expression (Jack Lawler, personal communication). There are no published
attempts to express tetraspanin-LELs in glycosylation-permissive eukaryotic systems.
There were multiple motivations to expand out methodology to other tetraspanin-
LEL family members. One motivation was to search for heterodimers. Our observation
that the murine CD9-LEL is a o-helical dimer, coupled with strong sequence
conservation among tetraspanin-LELs, suggested the possibility of heterodimers.
However, our experimental analysis of the human CD9-LEL and the human CD81-LEL
did not corroborate this hypothesis. These results are consistent with the published
literature (Charrin, Manie et al. 2002; Charrin, Manie et al. 2003). By
immunoprecipitation, tetraspanins have only been observed to co-IP under mild (less
stringent than TX-100) detergent conditions, suggesting that heterodimerization does not
occur (Rubinstein, Le Naour et al. 1996).
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Although it is imperative that we do not overinterpret our data, we believe that
without biophysical and biochemical analysis of tetraspanin-LELs, results with these
reagents may be difficult to interpret. Our ability to express tetraspanin-LELs that are
clearly misfi:lded (and by analogy, nonfunctional) emphasize the difficulties in purifying
tetraspanin-LEL reagents. In the remainder of this thesis, we describe experiments with
our panel of folded, native-like tetraspanin-LELs in a variety of cellular assays.
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Figure 6.1 Expression and Partial Purification of Human Tetraspanin-LELs. Human-
tetraspanin LELs (defined as the region between predicted transmembrane 3 and
transmembrane 4 from the reference sequence) were cloned into the pET24a Histag expression
vector in a similar way to the mCD9-LEL and verified by sequencing. Large-scale batches of
protein were expressed in E. Coli and partially purified over Ni-NTA agarose as described in
Chapter 2. These partially purified proteins were analyzed over 18% SDS-PAGE under non-
reducing conditions, followed by silver staining. The tetraspanin name is labeled above each
lane. With the hCD9-LEL, reverse-phase HPLC purified protein was loaded onto the gel as a
molecular weight reference. Molecular weight standards are also included in the righ-most
lane. Differences between the molecular weight of the human tetraspanin-LELs correspond
roughly to the predicted molecular weight of the molecule and roughly represent the
complexity (length) of the respective tetraspanin-LELs. These partially purified protein
fractions were utilized for subsequent purification procedures.
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Figure 6.2 Purification of the Human CD9-LEL. A) Partially purified hCD9-LEL was
resolved into individual peaks using reverse-phase C18 chromatography as described in
Chapter 2. Protein content was continuously monitored at absorbance 229nm and the
approximate concentration of buffer B (90%acetonitrile/10%H20/. 1%TFA) is indicated below
the trace. Protein peaks that were chosen for further study are labeled as P1, P2, etc.. B)
Qualitative dot blot analysis was used to screen multiple tetraspanin-LEL peaks. In brief,
protein eluted from the reverse-phase C18 column was centrifuged under vacuum to remove
acetonitrile and lpl was applied to dry nitrocellulose. The nitrocellulose was blocked with 4%
BSA and treated as a standard Western. The peak identity(from 6. 1B) is denoted above the dot
blot and the molecule is denoted to the left. The Western was developed using anti-hCD9.
Note that the anti-hCD9 antibody recognizes only hCD9P2, with minimal cross-reactivity both
to other hCD9 peaks and also to other tetraspanin-LELs.
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Figure 6.3 Biophysical Characterization of the Human CD9-LEL: A) Large quantities of the
immunoreactive hCD9-LEL-PI and non-immunoreactive hCD9-LEL-P2 (see Figure 6.2) were
purified as described previously. Circular dichroism spectra were collected under standard
conditions and revealed a spectral minima at 222nm, indicative of a well folded a-helical
structure. The spectrum profile of hCD9-LEL-P1 is charted in blue and the profile of hCD9-
LEL-P2 is pink. B) The thermal stability of the human CD9-LEL variants was monitored by
tracking the circular dichroism signal of the proteins at 222nm as described in Chapter 2. The
thermal denaturation profile for hCD9-LEL-P1 is charted in blue and the renaturation profile is
charted in pink. The midpoint of thermal denaturation is indicated.
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Figure 6.4 Purification of the Human CD81-LEL. A) Partially purified hCD81-LEL (see
Figure 6.1) was resolved into individual peaks using reverse-phase C18 chromatography as
described in Chapter 2. Protein content was continuously monitored at absorbance 229nm and
the approximate concentration of buffer B (90%acetonitrile/10%H20/. 1%TFA) is indicated
below the trace. Protein peaks that were chosen for further study are labeled as P1 through P5,
with P4 and P5 not shown on the HPLC trace. Qualitative dot blot analysis surprisingly
revealed strong immunoreactivity in the hCD81-LEL P2, with a minor immunoreactivity from
the hCD81-LEL P1, presumably through cross-contamination of collected fractions. B) An
oxidized/reduced glutathione mix was used to shuffle the disulfide-bonds in hCD81-LEL. In
brief, oxidized, denatured, partially-purified hCD81-LEL was rapidly diluted ten-fold into
phosphate-buffered-saline containing freshly dissolved 2mM reduced glutathione and .5mM
oxidized glutathione. After an overnight incubation at RT, the protein solution was clarified
by both centrifugation and filtration, and analyzed by reverse-phase C18 HPLC as above. The
resulting protein peaks eluted with a significantly different protein elution profile. Qualitative
dot blot revealed that the the most abundant protein species (P3) was immunoreactive.
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Figure 6.5 Biophysical Characterization of the Human CD81-LEL: A) Large quantities of the
immunoreactive human CD81-LEL P3 (see Figure 6.4B) were purified as described
previously. Circular dichroism spectrum was collected under standard conditions and revealed
a spectral minimum at 222nm, indicative of a well folded a-helical structure. B) The thermal
stability of the human CD81-LEL protein was monitored by tracking the circular dichroism
signal of the tetraspanin-LEL at 222nm as described in Chapter 2. The thermal denaturation
profile is charted in blue and the renaturation profile is charted in pink. The midpoint of
thermal denaturation is indicated.
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Figure 6.6 Purification of Human CD63-LEL. A) Partially purified hCD63-LEL (see Figure
6.1) was resolved into individual peaks using reverse-phase C18 chromatography as described
in Chapter 2. Protein content was continuously monitored at absorbance 229nm and the
approximate concentration of buffer B (90%acetonitrile/10%H20/. 1%TFA) is indicated below
the trace. Protein peaks that were chosen for further study are labeled as P1 through P5, with
P4 off-scale. Qualitative dot blot analysis revealed no immunoreactivity in any of these
protein peaks. B) Simulated refolding with an oxidized/reduced glutathione mix (as in Figure
6.4B) resulted in a significantly different protein elution profile, with protein peaks eluting at
much higher concentrations of buffer B (indicated below the trace). Qualitative dot blot
revealed that the the most abundant protein species (P3) was immunoreactive.
o\
cu
Circular Dichroism Wavelength Scan of hCD63-LEL-P3
o
Ecmr
E
U
6)
v
cb
Wavelength (nm)
Thermal Denaturation/Renaturation of
0
-2000
T -4000
E -6000
-8000
-10000
-12000
-14000
hCD63-LEL-P3
Temp (0-80)
Figure 6.7: Biophysical Characterization of the Human CD63-LEL: A) Large quantities of
the immunoreactive human CD63-LEL P3 (see Figure 6.6B) were purified as described
previously. Circular dichroism spectrum was collected under standard conditions and revealed
a spectral minimum at 222nm, indicative of a well folded a-helical structure. B) The thermal
stability of the human CD63-LEL variants was monitored by tracking the circular dichroism
signal of the tetraspanin-LEL at 222nm as described in Chapter 2. The thermal denaturation
profile is charted in blue and the renaturation profile is charted in pink. The midpoint of
thermal denaturation is indicated.
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Figure 6.8 Analysis of the hCD151-LEL. A) Partially purified human CD151-LEL (see
Figure 6.1) was resolved into individual peaks using reverse-phase C18 chromatography as
described in Chapter 2. Protein content was continuously monitored at absorbance 229nm and
the approximate concentration of buffer B (90%acetonitrile/10%H20/. 1%TFA) is indicated
below the trace. Protein peaks that were chosen for further study are labeled as P1 through P7,
with P7 not shown on the HPLC trace. Qualitative dot blot analysis revealed no
immunoreactivity in any of the 7 peaks. B) Simulated refolding with an oxidized/reduced
glutathione mix resulted in significant shifts of protein peaks relative to randomly oxidized
human CD151-LEL. However, there were still no detected immunoreactivity of the peaks,
despite prolonged exposure (data not shown).
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Figure 6.9 Analysis of the hCO-029 LEL. A) Partially purified human CO-029-LEL (see
Figure 6.1) was resolved into individual peaks using reverse-phase C18 chromatography as
described in Chapter 2. Protein content was continuously monitored at absorbance 229nm and
the approximate concentration of buffer B (90%acetonitrile/10%H20/.1%TFA) is indicated
below the trace. B) Simulated refolding with an oxidized/reduced glutathione mix resulted in
significant shifts of protein peaks relative to randomly oxidized human CO-029-LEL (above).
As there were no clearly resolvable peaks, this protein was not pursued further.
Chapter 7
The Role of Tetraspanins in Cell-Cell Fusion
The majority of these experiments were conceived by Christopher C. Liu, Richard 0.
Hynes and Peter S. Kim. CD9 inhibition of sperm-egg fusion experiments was conceived
in collaboration with Guo-Zhang Zhu and Paul Primakoff. Inhibition studies of in vitro
fertilization experiments were carried out by Guo-Zhang Zhu. Macrophage fusion
experiments were conceived and carried out by Partha Varadarajan and Peter Monk. We
thank Arjan van der Flier for technical assistance with myoblast fusion assays. All other
experiments were carried out by Christopher C. Liu. All errors are my own.
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Introduction:
Our primary interest in studying the murine tetraspanin CD9 was to use our
knowledge of CD9 as a means to study mammalian sperm-egg fusion. Sperm-egg
binding and fusion is the first developmental step in the creation of a new organism
(Stein, Primakoff et al. 2004). Although this phenomenon has been observed to occur for
well over a century, the molecular mechanisms underlying this critical developmental
step have not been clearly elucidated.
For the past two decades, panels of monoclonal antibodies have functionally
implicated many genes in the sperm-egg binding and fusion event (Primakoff and Myles
1983). This list most notably includes ADAMI and ADAM2: proteins on sperm which
bind to their integrin receptor partners on the egg (Myles, Kimmel et al. 1994).
Antibodies against ADAM1 inhibit sperm-egg binding and fusion (Primakoff, Hyatt et al.
1987). Unexpectedly, targeted deletion of the ADAM 2 gene had no effect on sperm-egg
fusion (Cho, Bunch et al. 1998) (Figure 7.1). Equally surprising, targeted deletion of the
murine CD9 gene results in almost a complete ablation of sperm-egg fusion, with no
effect on sperm-egg binding (Kaji, Oda et al. 2000; Le Naour, Rubinstein et al. 2000;
Miyado, Yamada et al. 2000).
CD9 is expressed on oocytes (Le Naour, Rubinstein et al. 2000). Although there
is also strong expression of CD9 on platelets, monocytes, and pre B cells (Clay,
Rubinstein el: al. 2001) (Miao, Vasile et al. 2001), CD9-null mice did not exhibit strong
phenotypes in these cell types. Strikingly, CD9-null females were almost (but not
completely) incapable of offspring. Studies showed that this effect was due not to a
defect in sperm-migration up the female reproductive tract (as was seen with ADAM1
null-mice) or to sperm-zona pellucida interactions. Furthermore, in in vitro fertilization
studies, sperm could bind to zona-stripped oocytes at wild-type levels. However,
deletion of the CD9-gene resulted in almost no penetration of the oocyte membrane by
sperm, as assessed by exit from M2 arrest and second polar body extrusion (Kaji, Oda et
al. 2000). Lastly, intracytoplasmic sperm injection (ICSI) of CD9-null oocytes
(bypassing the membrane fusion event) resulted in normal initiation of development
(Miyado, Yamada et al. 2000).
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Exogenous addition of a rat monoclonal anti-murine CD9 antibody, clone KMC8,
was previously shown to effectively inhibit sperm-egg fusion, with no effect on binding
in an in vitro fertilization assay (Chen, Tung et al. 1999; Miller, Georges-Labouesse et al.
2000). These antibody-inhibition experiments served to direct our studies to the
extracellular domain of CD9, specifically the large extracellular loop (LEL). In
collaboration with Paul Primakoff's laboratory (UCDavis), we tested the efficacy of our
mCD9-LEL mimics in in vitro fertilization assays (Zhu, Miller et al. 2002). The full
reprint of our studies is included in Appendix A.
Here, we also describe our attempts to expand on the fertilization inhibition
studies by isolating and identifying CD9 binding partners on the oocyte. To overcome
the critical biochemical limitations to the gamete-fusion model we explore a previously
described role for CD9 in a myoblast fusion system (Tachibana and Hemler 1999).
Currently, we do not believe the inhibition of CD9 and CD81 on the myoblast fusion
system is replicable. Lastly, we describe experiments on the role of CD63 in another
homotypic cell-cell fusion assay: foreign-body-induced macrophage fusion (Takeda,
Tachibana et al. 2003). This series of experiments not only explore the role of
tetraspanin-LELs in cell-cell fusion, but also suggest that our recombinant, soluble
tetraspanin-LELs serve to disrupt endogenous tetraspanin functions.
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Materials and methods
In vitro Fertilization Assay:
Gametes from CD9 wild-type and null mice were collected (Zhu, Miller et al.
2002) as described in Appendix A. In brief, sperm was collected from the caudal
epidydymis and allowed to capacitate prior to in vitro fertilization. Oocytes were
collected from the oviducts of super-ovulated females and cumulus cells and the zona-
pellucida coat were enzymatically removed. Eggs were visually inspected for
maintenance of M2 arrest. The GST-CD9-LEL was constructed and purified using
standards methods as described in the appendix. Our mCD9-LEL protein was purified
and characterized as described in Chapter 2. The GST-CD9-LEL and mCD9-LEL were
incubated with individual gametes at 300g/ml and 250jg/ml respectively for 3 hours.
The complementary gamete was then added for a 40 minute insemination period and
fertilization indices were quantified by microscopy.
For CD9-rescue of fertilization-incompetent CD9-null oocytes, CD9-null oocytes
were collected as described above. Plasmids containing either the full-length murine
CD9 wild-type or murine CD9 variant cDNAs fused to green fluorescent protein were
linearized and mRNAs were synthesized by in vitro transcription. Each CD9-null oocyte
was microinjected with 30pg of mRNA and allowed to express the CD9 wild-type or
CD9 variant protein for 28 hours prior to in vitro fertilization assays as above.
mCD9F174A and mCD9SFQ(173-175)AAA Large Extracellular Loop Purification
and Analysis.
Plasmids encoding full-length murine CD9 with the mCD9F174A and mCD9SFQ(173-
175)AAA mutations were provided by Zhu GZ and Primakoff P; originally constructed
by Rubenstein E and Boucheix C. The portion of the murine CD9 cDNA corresponding
to the large extracellular loop was PCR-amplified using CL34 and CL35 (for sequence,
see Chapter 2), and subcloned into pET24a. Proper subcloning was checked by DNA
sequencing through the open reading frame. Protein expression was induced in
BL21/pLysS cells and purified as described in Chapter 2. Circular dichroism and
sedimentation equilibrium experiments were performed as described previously.
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Oocyte collection and Immunoprecipitation with mCD9-LEL variants
Eight-week-old FVB females were superovulated and eggs collected by standard
procedures (Hogan, Beddington et al. 1994). In brief, superovulated FVB mice were
cervically dislocated and Fallopian tubes were isolated. Oocytes were collected in
freshly prepared M199 media with a dissecting microscope and treated with
hyaluronidase to remove cumulus cells. Oocytes were washed and treated with pronase
for 6-10' to remove the zona pellucida. Oocytes washed in M199 media were then
visually inspected for M2 arrest and culled. All gametes were handled and incubated
under a mineral oil overlay. Oocytes were lysed in 20mM Tris-buffered saline/0.5% NP-
40 (Sigma) supplemented with a protease inhibitor cocktail (Boehringer Ingelheim).
Either mCD9-LELwt or mCD9SFQ(173-175)AAA were added to a final protein content
of .lmg and incubated at 40C for 3 hours. A 101 bed-volume of pre-equilibrated Ni-
NTA agarose (Qiagen) was added for 1 hour. The immunoprecipitate was subsequently
washed in an empty spin column (Vendor). Bound proteins were eluted by boiling in
SDS-Loading buffer and analyzed by SDS-PAGE.
Myoblast Fusion Assay
The murine myogenic cell line C2C12 was obtained from the American Type
Culture Collection. Cells were cultured in DMEM/20% fetal bovine serum at
subconfluency. For differentiation and syncytium assays, C2C12 cells were grown on
sterilized coverslips coated with 2% gelatin. At confluency, DMEM/20%FBS growth
medium was replaced with DMEM/2% horse serum to induce differentiation (Tachibana
and Hemler 1999). At subsequent time points, coverslips were washed in PBS and fixed
for 10' in 4% paraformaldehyde/PBS. Cells were stained with phalloidin-TRITC and
FITC-conjugated mouse anti-desmin and visualized using both fluorescent and Nomarski
optics. Antibodies recognizing murine CD9 and murine CD81 (or an isotyped antibody
control) was added at 10Opg/ml either concomitantly with the addition of horse serum or
at 3 days post-differentiation. Functional activity of the anti-CD9 antibody was assayed
by removing C2C12 culture medium for use as a primary antibody in standard Western
analysis with the mCD9-LEL protein as antigen.
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Macrophage Fusion Assay:
Peripheral blood was bled from healthy donors of both sexes with informed
consent according to a protocol approved by the ethical committee, University of
Sheffield.
Peripheral blood in 1% heparin was layered over a mixture of Ficoll-Hypaque
(Amersham Pharmacia) at a ratio of 2:1 and centrifuged at 400g for 35 minutes. A
mononuclear cell layer consisting of lymphocytes, monocytes, and platelets was cleanly
separated from both blood plasma and eythrocytes with a Pasteur pipette. Mononuclear
cells were washed and plated on plastic in RPMI/10%FBS for overnight incubation.
Non-adherent cells (such as lymphocytes) were separated from adherent macrophages in
cell-culture dishes by aspiration. The plates were washed thoroughly with 3xlOml
volume of pre warmed RPMI without FBS to ensure all non-adherent cells are removed.
Isolated cells were composed of 80-95% macrophages and the remainder being
lymphocytes. The adherent macrophages would then be harvested or cultured further.
Macrophages were plated in either 96-well microtiter plates (Takeda, Tachibana
et al. 2003) or Lab-Tek® chamber slides at a density of 5 X 105 /chamber. Macrophages
were stimulated to undergo homotypic fusion with 10yg/ml of the lectin concanavalin A
(Sigma) for 72 hours at 370 C (Takashima, Ohnishi et al. 1993). Concurrent with the
addition of concanavalin A, recombinant hCD9-LEL proteins were added at a
concentration of 20yg/ml (or lower concentrations as indicated). The fusion index was
calculated as the ratio of total number of nuclei in fused cells/total number of nuclei by
visual inspection.
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Results:
CD9-LEL Inhibition Studies of Fertilization
In collaboration with Paul Primakoff's group, we tested two variants of soluble,
recombinant, murine CD9-LEL mimics: our previously characterized mCD9-LEL
protein with a C-terminal HisTag, and also a glutathione-S-transferase-fused mCD9-LEL
(constructed and purified by Guo-Zhang Zhu and Paul Primakoff) for inhibition in a
fertilization assay. Wild-type murine gametes were isolated and cultured under standard
conditions. Recombinant proteins were added individually to either capacitated sperm or
zona-free eggs and incubated for 3 hours prior to insemination (mixing of the gametes)
for 40 minutes and quantification of fertilization. Three parameters were measured: (1)
fertilization rate FR = the percentage of eggs that fuse with at least one sperm; (2)
fertilization index FI = total number of fused sperm/total number of eggs: and (3) the
mean number of sperm bound at the equator of the egg.
When sperm were pre-incubated with either mCD9-LEL or GST-mCD9-LEL,
there was no significant effect on either fertilization rate, fertilization index, or sperm-egg
binding (Figure 7.2A). However, pre-incubation of soluble recombinant CD9-LELs with
eggs, resulted in significant inhibition of both fertilization rate and fertilization index,
with no significant effect on sperm-egg binding (Figure 7.2A). At high concentrations,
although both constructs resulted in significant inhibition, the mCD9-LEL his-tagged
construct was significantly more potent than the GST-tagged construct (Figure 7.2B).
Neither constuct resulted in complete inhibition (see discussion).
CD9 Rescue Studies of CD9-Null Eggs
To test for recovery of fertilization potential in CD9-deficient oocytes, mRNAs
encoding either the wild-type or mutant CD9 variant mRNAs were synthesized and
injected into CD9-deficient oocytes. As expected, CD9-null oocytes did not allow
sperm-egg fusion. This gamete-fusion defect was significantly rescued by expression of
the wild-type CD9 cDNA. However, a point mutation in the mCD9-LEL, F174A
abrogated the ability of the mCD9 transcript to rescue the CD9-null phenotype (Figure
7.3A). Injection of this cDNA had no effect on sperm-egg binding (Figure 7.3B). Post-
injection, CD9 expression was monitored by immunofluorescent staining and Western
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blot analysis (Appendix A) There was no detectable differences in CD9 expression as
compared to wild-type oocytes. A triple mutation in the CD9-LEL, SFQ(173-175)AAA
did not have an effect on the immunoreactivity of CD9, consistent with confirming our
earlier KMC8 epitope analysis (Chapter 4). These results support the critical role of the
CD9-LEL in sperm-egg fusion.
Characterization of Non-Fertilization Permissive CD9 Variants
Microinjection of full-length CD9 mRNAs rescued the CD9-null gamete fusion
phenotype. Both wild-type and variant CD9 constructs were shown to be expressed and
presented at the cell surface of CD9-null eggs. These variants were still recognized by
the fertilization-inhibiting KMC8 antibody and were in a segment of the mCD9-LEL
separate from our epitope-mapping experiments (Chapter 4 and Figure 7.4A). As a
result, it was unclear if the rescue deficiency of the CD9-LELoSFQ(173-175)AAA
construct might be due to a global change in the CD9-LEL structure. To test for this
possibility, we subcloned, expressed, and purified the mCD9.F174A and mCD9-
LEL°SFQ(173-175)AAA variants as soluble, recombinant LELs. Circular dichroism
analysis revealed that these constructs had comparable a-helical content to the wild-type
mCD9-LEL (Figure 7.4B). Although the two mCD9-LEL variants had decreased thermal
stability (Tm = 52 and 48°C), thermal denaturation analysis of a-helical content revealed
significant protein stability (Figure 7.5A, B). Most importantly, the mCD9-LEL variants
would have had comparable a-helical structure under the physiological conditions where
the in vitro fertilization assay was performed. The inhibitory effect of these LEL proteins
in an in vitro fertilization assay was not performed.
Immunoprecipitation of mCD9-LEL oocyte binding partners:
We hypothesized that the mCD9-LEL protein inhibited sperm-egg fusion by
binding to and disrupting an endogenous egg surface protein complex (Zhu, Miller et al.
2002). To explore this possibility, we attempted immunoprecipitation experiments of our
mCD9-LEL protein with an oocyte lysate.
Approximately 200 wild-type oocytes were collected from twelve super-ovulated
FVB females. Eggs were lysed under mild detergent conditions (0.5% NP-40) and
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incubated with mCD9-LELwt or the fertilization-incompetent mCD9-LELoSFQ(173-
175)AAA proteins. Nickel-NTA agarose was used to isolate both mCD9-LEL variants
and their respective binding partners. Immunoprecipitates were checked for equal
starting material and complete washing until binding background was negative (Figure
7.6). Upon elution, there were no significant differencesbetween proteins
immunoprecipitated by the mCD9-LELwt and mCD9-LELSFQ(173-175)AAA proteins
(Figure 7.7). As it was necessary to silver-stain before detection of immunoprecipitated
bands, these experiments were deemed intractable (also see discussion).
The Effects of Tetraspanin-LELs on Myoblast Fusion:
To further study cell-cell fusion, we turned to a system where larger biochemical
quantities could be obtained. The regulated homotypic fusion of individual myoblasts to
form myotubes is an essential step in muscle development (Schnorrer and Dickson 2004).
Previously, it has been shown that CD9 is upregulated concomitant with myosin heavy
chain and desmin, markers for myoblast differentiation (Tachibana and Hemler 1999).
Furthermore, anti-CD9 and anti-CD81 antibodies inhibited and delayed homotypic
myoblast fusion in the murine myogenic cell line C2C12. The ability to culture and
differentiate large quantities of these cells made myoblast fusion an attractive alternative
cell-cell fusion system to gamete fusion.
We obtained the C2C12 cell line and monitored in vitro differentiation into
myotubes by microscopy. Greater than 60% of mononuclear C2C12 cells reproducibly
fused into multinucleated myotubes (data not shown). Qualitatively, the addition of the
antibodies against CD9 and CD81 did not affect either the rate or the formation of
myotubes (data not shown). Addition of antibodies against CD9 and CD81 three days
post-differentiation also had no effect on either the rate or the formation of myotubes,
conflicting with the previously published study. When these antibodies were recovered
post myoblast differentiation, they were shown to retain wild-type activity as assayed by
Western analysis (data not shown). These studies suggest that the tetraspanin antibodies
were not degraded over the duration of the assy. Lastly, the addition of micromolar
quantities of hCD9-LEL or hCD81-LEL had no effect on myogenic ability. Without a
significant difference in fusogenic ability, we did not pursue these experiments further.
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The Effects of Tetraspanin-LELs on Macrophage Fusion:
A recent paper showed that antibodies to CD9 and CD81 promoted macrophage
fusion (Takeda, Tachibana et al. 2003). On the other hand, preliminary studies by the
Monk group showed inhibition by recombinant GST-CD63-LEL fusion proteins. To test
both for the inhibitory effects of our tetraspanin-LELs and as a feasibility study for
biochemical studies, we initiated a collaboration to study macrophage fusion.
We measured the index of macrophage fusion in the presence or absence of our
hCD9-LEL, hCD63-LEL, and hCD81-LEL proteins. We observed significant inhibition
solely in the presence of the hCD63-LEL protein, implying specificity (Figure 7.8A).
Surprisingly., the hCD63-LEL protein was incredibly potent, with an ICo in the
nanogram/ml range (Figure 7.8B), suggestive of catalytic activity. This result was
especially puzzling as we envision a structural role for tetraspanin-LELs in membrane
fusion, not a catalytic one. Compared with GST-fused tetraspanin-LELs, our
hexahistidine-tagged hCD63-LEL exhibited significantly higher potency.
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Discussion
Sperm-egg fusion is a critical step in development (Hogan, Beddington et al.
1994). The controlled fusion of gametes to restore diploidy is essential to the formation
of a proper embryo. Onset of development without sperm-egg fusion (parthenogenesis)
or excess sperm-egg fusion (polyploidy) results in severe developmental defects (Gilbert
2003). The phenomenon of sperm-egg membrane fusion, which has been visualized by
electron microscopy for many decades, is an intensely studied topic of interest not only to
developmental biologists, but also to membrane-fusion researchers in general
(Hernandez, Hoffman et al. 1996).
Until recently, the genes involved in sperm-egg fusion were not known. Although
various proteins were implicated to play a role in this biological process (most notably
ADAMs (Cho, Bunch et al. 1998) and integrins (He, Brakebusch et al. 2003)), mouse
genetics has refined their role as non-essential (Kaji, Oda et al. 2000; Le Naour,
Rubinstein et al. 2000; Miyado, Yamada et al. 2000). On the other hand, mouse genetic
experiments have clearly implicated the tetraspanin CD9 as playing an essential role in
this process. In the fertilization field, the identification of CD9 has been a mixed
blessing. For the first time, a gene was clearly defined as being a central player in this
process. On the other hand, very little is known about the role of CD9 on the egg surface
and the mechanisms by which it is necessary for sperm-egg fusion. Subsequent to the
identification of CD9 as an essential gene in sperm-egg fusion, research progress has
been disappointingly slow.
The phenomenon of membrane fusion has been most extensively studied in viral-
fusion and vesicle-fusion systems (Eckert and Kim 2001) (Jahn, Lang et al. 2003). The
identification of proteins directly involved in these membrane-fusion processes has
allowed the process to be both reconstituted and specifically inhibited. Extrapolating
from our knowledge of viral and vesicle membrane fusion proteins, the tetraspanin CD9
does not appear to be a fusogen: a protein that directly mediates membrane apposition
and mixing (for further discussion, see Chapter 1). Current hypotheses envision CD9 as
playing a supporting, albeit essential, role to a sperm-egg fusogen. Currently, the identity
of this hypothetical protein is unknown.
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Our in vitro inhibition experiments indicate that the CD9 gene does not act as a
receptor for sperm (Zhu, Miller et al. 2002). Although deletion of the CD9 gene had no
effect on sperm-egg binding (and currently, sperm-egg binding proteins on the egg have
not been identified), sperm-egg binding and fusion may be decoupled events. Our
inhibition data not only shows that CD9 serves a role in cis on the egg surface, it also
suggests that our mCD9-LEL protein is a specific inhibitor of endogenous CD9 function.
Extrapolating on the role of CD9 in cis on the egg surface, we hypothesized that
the mCD9-LEL protein serves to disrupt endogenous heterotypic CD9/non-CD9 protein
complexes on the egg surface. However, immunoprecipitation experiments with the CD9
protein and its non-functional analogue, mCD9-LELSFQ(173-175)AAA did not prove
fruitful. It may be possible that although mutation of the mCD9-LEL SFQ residues is
sufficient to inhibit rescue experiments, it is insufficient to inhibit CD9-partner
interactions.
Gamete quantities are also too severely limited for this system to be
biochemically tractable. In a Herculean effort, the Primakoff lab committed 8 personnel
to a month of collecting oocytes to yield a lysate of approximately 100,000 eggs. An
immunoprecipitation experiment with an antibody against murine CD9 yielded integrins
and other known CD9-binding proteins, but no proteins with restricted oocyte expression
patterns (Paul Primakoff, personal communication). These experiments prompted us to
identify other, more biochemically tractable cell-cell fusion systems (Chen and Olson
2005).
Our in vitro inhibition experiments should be considered with several caveats in
mind. The inability of several point mutations in the CD9 large extracellular loop to
rescue CD9 activity suggests the importance of the CD9-LEL domain to sperm-egg
fusion (Higginbottom, Takahashi et al. 2003). This result, coupled with KMC8 antibody
inhibition data, also suggests that the proper presentation of the CD9-LEL is necessary
for sperm-egg fusion. Ideally, we would like to see the effects of the mCD9-
LEL-Q159A, mCD9-LEL ·F174A, mCD9-LELS 173A/F 174A/Q1 75A variants on
sperm-egg binding and fusion. We would also like to see dose dependence of inhibition,
which was not performed.
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Most importantly, although our inhibition is statistically significant, maximal
inhibition was not very impressive. The inability to inhibit greater than 60% of sperm-
egg fusion was also seen when GST-mCD9-LEL proteins were independently tested for
inhibition activity (Higginbottom, Takahashi et al. 2003). It may be possible that the
membrane-bound form of CD9, which is in a high avidity complex with cis-fusion
partners, is too tightly complexed to allow complete inhibition.
Surprisingly, a recent study by the Okabe group has identified a sperm protein,
izumo, to function analogously to CD9 on the sperm cell (Inoue, Ikawa et al. 2005).
Genetic studies show that izumo is essential for sperm-egg fusion, not binding and this
phenotype is recovered by transgenic rescue experiments. A monoclonal antibody
against izumo inhibits in vitro fertilization (the means by which izumo was cloned) and
intracytoplasmic sperm injection (to bypass sperm-egg fusion) resulted in the normal
onset of development. The protein izumo consists of a single extracellular novel IgG fold
and also is not presumed to directly mediate membrane fusion. Izumo does not bind the
CD9-LEL as assayed by immunoprecipitation (Okabe, personal communication).
Currently, an optimal strategy to identify a sperm-egg fusogen is unclear.
The closest functional analogue to the sperm-egg fusion system is a homotypic
cell-cell fusion system: the fusion of single-nucleated myoblasts to multi-nucleated
myotubes (Schnorrer and Dickson 2004). Upon induction, myoblasts differentiate and
fuse with one another in an ordered, linear fashion. Many genes implicated in sperm-egg
fusion have been characterized to have analogues in a myoblast-fusion system, such as
ADAM15 (Yagami-Hiromasa, Sato et al. 1995). To date, no essential myoblast-fusion
protein has been identified (although many essential myoblast differentiation genes in
Drosophila have (Schnorrer and Dickson 2004)). Although functionally analogous,
many genes involved in myoblast differentiation and fusion do not directly translate to
sperm-egg fusion, and vice versa.
The proteins CD9 and CD81 have been implicated in myotube formation
(Tachibana and Hemler 1999). Given the ability to grow large quantities of precursor
myoblasts and the significant inhibition presented by antibodies against CD9 and CD81,
we hoped to replicate these results as a source for biochemical studies on cell-cell fusion.
Unfortunately, we did not see significant inhibition of myoblast fusion with antibodies
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against CD9, CD81, or soluble, recombinant forms of CD9 or CD81. No other papers
have implicated CD9 and CD81 in myoblast fusion and, currently, we do not believe that
CD9 and CD81 play a role in myoblast fusion.
Another system for homotypic cell-cell fusion is macrophage fusion. The
induction and formation of multi-nucleated macrophage giant cells (osteoclasts), cells
containing several hundred nuclei after the introduction of a foreign body (such as a
splinter), have been medically observed for some time (Takashima, Ohnishi et al. 1993).
In vitro, this phenomenon can be reproduced by the addition of a lectin, concanavalin A,
to macrophages. Whether homotypic macrophage fusion is a true cell-cell fusion event
or "phagocytosis gone terribly wrong" is still wide debated to this day.
In collaboration with Peter Monk, we show a small but significant inhibition of
homotypic macrophage fusion with the hCD63-LEL, but not hCD9-LEL or hCD81-LEL.
There are many puzzling aspects of these results. The ICO of fusion inhibition
(nanogram/ml) is incredibly low. All other inhibition studies with tetraspanin-LELs have
shown ICOs in the microgram/ml range (see Chapter 1). Although a role for tetraspanins
in macrophage fusion has previously been characterized (Takeda, Tachibana et al. 2003),
these results suggested that endogenous CD9 and CD81 inhibited, not promoted,
macrophage fusion, the reverse of sperm-egg fusion data. Antibodies against CD63 had
no effect on macrophage fusion in their hands. Lastly, soluble CD9-LEL and CD8 1-LEL
promoted macrophage fusion at microgram/ml quantities.
In summary, we have addressed the role of tetraspanins in three independent cell-
cell fusion systems. Although our results are most significant in the sperm-egg fusion
system, limited biochemical quantities preclude further exploration of the role of CD9 in
this system. Our exploration of CD9 on other cell-cell fusion systems has not made
significant headway. In conclusion, it is not clear if the CD9 protein will be fruitful in
bootstrapping to a cell-cell fusogen in the near future. However, our addition of
recombinant mCD9-LEL protein shows both that the endogenous CD9 acts in cis on the
egg-surface and that tetraspanin-LELs may function to inhibit endogenous tetraspanin
functions.
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Figure 7.1 Model of Molecules Thought to Play a Role in Sperm-Egg Fusion; A schematic of
cell surface proteins on both the sperm (bottom) and the egg (top). ADAM 1 and ADAM2
have been previously caller fertilin-a and fertilin-0 respectively. These proteins contain a
disintegrin domain and have been shown to bind to the egg surface a6P 1 integrin heterodimer.
Through gene-deletion experiments, these proteins are no longer thought to play an essential
role in sperm-egg fusion. Cyritestin is an ADAM family member thought to function upstream
of ADAM1/2 in the sperm-egg binding and fusion cascade. The CD9 protein is expressed on
the egg and has been shown to be essential for sperm-egg fusion. Its role in mediating sperm-
egg fusion is unknown.
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The Effect of mCD9-LEL on Fertilization Rate
Control Sperm Egg
B
The Effect of GST-mCD9-LEL and mCD9-LEL on in vitro Fertilization
Incubation Pre-incubated Number of Fertilization Fertilization Sperm bound
Protein Gamete Eggs Tested Rate (%) Index per Equator
GST Egg 78 100_0 1.5-0.15 6.2±0.5
GST-mCD9-LEL Egg 86 60±5.1 0.6±0.05 5.7±0.5
GST-mCD9-LEL Sperm 63 97±3.0 1.1±0.11 7.1±1.6
Buffer (PBS) Egg 56 83+3.5 0.83±0.04 4.6±0.3
mCD9-LEL Egg 76 43±2.6 0.42±0.02 4.8±0.4
mCD9-LEL Sperm 67 75±5.2 0.75±0.05 4.5±0.3
Figure 7.2 The mCD9-LEL inhibits Sperm-Egg Fusion. A) Murine sperm and egg cells were
isolated in defined media as described in the methods. Gametes were independently pre-
incubated with the recombinant mCD9-LEL protein for 3 hours. Gametes were then mixed for
40 minutes and the fertilization rate (percentage of eggs that fuse with at least one sperm) was
measured. The control sample is gametes non-incubated with recombinant proteins (and this
fertilization rate (83% of eggs) was set to 100%). Pre-incubation of the mCD9-LEL protein
with sperm resulted in a small and non-significant (P>0. 1) decrease in fertilization rate. Pre-
incubation of the mCD9-LEL protein with eggs resulted in a significant (P< 0.002) decrease in
the fertilization rate. In vitro fertilization experiments were done on multiple occasions and
yielded similar results. B) Comparisons of multiple mCD9-LEL constructs on in vitro
fertilization rate. The in vitro fertilization assay was similar to that conducted above. In this
table, fertilization rate was quantified as above. Fertilization index was measured as the total
number of fused sperm/total number of eggs. The number of sperm bound at the equator of the
zona-stripped eggs were also measured. Inhibition data for Glutathion-S-transferase (GST)
tagged mCD9-LELs (constructed by Guo Zhang) are also included, showing significant
(P<0.02), but less substantial inhibition than our mCD9-LEL construct (P<0.002).
Recombinant mCD9-LEL variants had no significant effect on sperm-egg binding (P>0.1).
Values are means ± s.e.m. This experiment was conducted by G-Z. Zhu with tetraspanin
reagents provided by C.C. Liu.
Recovery of Fusion
B
Incubation Fertilization Fertilization Sperm bound Number of
Protein Rate (%) Index per Egg Replicates
WT eggs 66 0.83 14 5
KO eggs +WT 55 0.85 12 4
KO eggs + F174A 13 0.2 12 4
KO eggs + blank 1 0.02 14 5
Figure 7.3 Microinjection of the Full-Length Murine CD9 cDNA Rescues the Null-
Phenotype. A) Wild-type sperm cells were collected as before. Eggs of varying genetic
backgrounds were also harvested and used in in vitro fertilization assays. CD9-null eggs are
denoted as KO. The fertilization rates of microinjected cDNA transcripts encoding the full-
length wild-type CD9 gene (denoted WT) or with a single point mutation (denoted F174A) are
also graphed. B) Tabulated data of the fertilization rate, fertilization index, sperm bound/egg
and number of replicates for the conditions listed in Figure 7.2A. This experiment was
conducted by G-Z. Zhu with tetraspanin reagents provided by C.C. Liu.
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Figure 7.4 Biophysical Analysis of Fertilization Defective mCD9 Mutants: A) The murine
CD9-LEL primary sequence is shown with predicted a-helical elements depicted with red bars
above the sequence. The point mutation (Q159A) that abrogates KMC8 immunogenicity is
denoted with a green asterisk. A series of mutations (SFQ173-175AAA) which did not allow
recovery of the CD9-null phenotype are also listed as red asterisks. B) Murine CD9-LEL point
mutations were subcloned into pET24a from full-length constructs by polymerase chain
reaction using the oligonucleotides CL34 and CL35. Protein was expressed and purified using
Ni-NTA agarose and C18 reverse-phase HPLC as described in Chapter 2. HPLC profiles did
not deviate from the canonical CD9 trace (data not shown). Circular dichroism analysis
revealed that both the F174A mutation (designated FA) and the SFQ triple mutant (M3)
exhibited characteristic minima at 222 and 208nm, indicative of an a-helical structure. For
circular dichroism data on Q159A, see Figure 4.7.
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Figure 7.5 Thermal Stability of Fertilization defective mCD9 mutants. A) The thermal
stability of the mCD9-LEL*F174A variant (FA) was monitored by tracking the circular
dichroism signal of the fertilization defective mutant at 222nm as described in Chapter 2. The
thermal denaturation profile is charted in blue and the renaturation profile is charted in pink.
The midpoint of thermal denaturation is indicated. B) The thermal stability profile of the
mCD9-LEL*S173A/F174A/Q175A triple mutant (M3). The chart is graphed as in Figure
7.4A.
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Figure 7.6 Immunoprecipitation of Egg/CD9 Interactions. Eggs from superovulated FVB
female mice were harvested under standard conditions. Eggs were stripped of both cumulus
cells and zona pellucida and assessed for maintenance of meiosis 2 arrest. Eggs were lysed in
1% NP-40 and cell surface protein content was assessed by SDS-PAGE and Coomassie
staining (Lane 2) The supernatant was split into two aliquots, incubated with either mCD9-
LELwt or the fertilization non-permissive mCD9-LEL*S173A/F174A/Q175A variant. After
incubation and immunoprecipitation with Nickel-conjugated agarose beads, the non-bound
fractions (lane 3; 8) and washes (lanes 4-7; 9-12) were assayed by SDS-PAGE. Molecular
weight markes are in lane 1.
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Figure 7.7 Elution Profile of CD9-LEL/egg Interactions: An egg lysate was incubated with
0.1mg of mCD9-LELwt or mCD9-LELS 173A/F174A/Q175A protein and
immunoprecipitated. Total protein content was eluted by boiling with 2X SDS-Loading Buffer
and analyzed by SDS-PAGE followed by silver-staining. The stacker of the SDS-PAGE gel is
included. The mCD9-LEL variants have a molecular weight of approximately 11-kDa and
were allowed to run off the gel (as they would have been severely overdeveloped). The protein
profile eluted from the mCD9-LELwt is labeled as WT and the protein profile eluted from the
mCD9-LEL*S173A/F174A/Q175A protein is labeled as M3. Molecular weight standards are
to the right of the gel.
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Figure 7.8 Macrophage Fusion Assay. A) Effects of recombinant tetraspanin-LELs on
macrophage fusion. Concentration of all exogenously added proteins are in nanograms/ml.
Standard error bars and P values are included above each bar. NS stands for not-significant (P
= >.05). B) Dose dependence curve of hCD63-LEL inhibition. Glutathione-S-transferase
fused hCD63-LEL inhibition is graphed as GST-CD63. When this construct was cleaved to
remove remove the GST tag, inhibition is graphed as cleaved CD63. Our hCD63-LEL is
graphed as His6-CD63. This experiment was conducted by p Varadarajan with teraspanin
reagents provided by C.C. Liu.
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Chapter 8
Tetraspanins and Integrin Interactions
These experiments were conceived by Christopher C. Liu, Jun Takagi, Richard 0. Hynes,
and Timothy Springer. All integrin reagents were constructed by Jun Takagi and all
tetraspanin reagents were constructed by Christopher C. Liu. Jun Takagi conducted all
solid-phase ELISA assays. Christopher C. Liu conducted all other experiments. All
errors are my, own.
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Introduction
Integrins are an important class of cell-surface proteins that mediate cellular
adhesion to the extracellular matrix. There are 24 mammalian integrins, each comprised
of an ct-subunit and a n-subunit and having specific, non-redundant functions (Hynes
2002). Integrins play major roles in development, immune functions, leukocyte traffic,
and human disease.
A striking feature of integrins is their ability to rapidly (<Isec) activate and
mediate cellular adhesion. The abilities of integrins to change conformation (affinity),
cluster (avidity), and to bind the cytoskeleton (anchoring) all may contribute to this rapid
activation timeframe (Takagi and Springer 2002). Recently, several studies have
emphasized the critical role of integrin transmembrane domains in the regulation of
adhesion (see discussion), which may play a role in both affinity and avidity (Li, Babu et
al. 2001; Luo, Springer et al. 2004). However, the majority of research describes affinity
changes in the integrin extracellular domain (Takagi, Petre et al. 2002). Multiple
antibodies have been described that specifically recognize, or even induce, integrin
conformers in high or low affinity states (Humphries 2004).
Recently, the structure of the ccVf33 extracellular domain was solved by x-ray
crystallography. Unexpectedly, the integrin structure was crystallized in a bent
conformation, completely at odds with the canonical view of integrins as a headpiece
attached to an extended stalk-like domain (Figure 8.1). Both electron micrographic and
molecular design studies have revealed that integrins may exist in both a bent, inactive
conformation and a straightened, active conformation and that these two conformers are
in dynamic equilibrium. Furthermore, antibodies thought to modulate integrin affinity
may also modulate integrin conformations (Takagi, Beglova et al. 2001).
In this chapter, we utilize both a panel of recombinant integrin extracellular
domains and our three recombinant, tetraspanin-LELs to probe putative tetraspanin-
integrin interactions. With both solid-phase ELISA and cell-based integrin binding
assays, we show that tetraspanin-LELs bind integrins in a cation-dependent manner.
Although there are clear rankings in integrin-tetraspanin binding, we could not decipher a
pair-wise set of interactions. These interactions could be inhibited or enhanced by
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antibodies that modulate integrin affinity, although a specific tetraspanin binding pattern
to integrins in high or low affinity states could not be deduced.
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Materials and Methods:
Recombinant Integrin Extracellular Domains:
Wild-type, human extracellular portions of integrin alpha and beta subunits were
fused to the 30-residue acid and base a-helical coiled-coil peptides (also called Velcro for
their specific heterodimerization properties) (O'Shea, Lumb et al. 1993) respectively,
with one cysteine mutation at the N-terminal end. In the beta subunits, a seven-amino
acid recognition sequence for TEV protease was inserted before the base peptide (Takagi,
Erickson et al. 2001). These fragments were stably introduced into CHO lec 3.2.8.1 cells.
Cell-culture supernatants containing secreted, soluble integrin fragments were purified
using Ni-NTA agarose (Qiagen) followed by anion-exchange (monoQ) and gel filtration
(Superdex200HR) chromatographies. Recombinant integrin fragments were stored at
0.5-1mg/ml at 40C in TBS containing mM CaCl 2 and lmM MgCl2. release of the C-
terminal clasp was achieved by incubation with 250U/ml TEV protease (Invitrogen) at
25°C for 16hr.
Recombinant tetraspanin-LEL variants:
Soluble, recombinant versions of the hCD9-LEL, hCD63-LEL, and hCD81-LEL
were expressed and purified as previously described. The hCD9-LEL*Q161A and
hCD9-LEL°E160A/Q161A proteins were designed by sequence alignment to the mCD9-
LELoQ159A variant described in Chapter 4. Point mutations were constructed by
recombinant PCR (Higuchi 1990) and expressed and purified under similar conditions to
the hCD9-LEL protein. Folding stability of the hCD9-LEL variants was monitored by
circular dichroism as described in Chapter 2. Antibodies to the hCD9-LEL, hCD63-LEL,
and hCD81-LEL were described in Chapter 6.
Enzyme-linked Immunosorbent Assay Analysis:
Recombinant tetraspanin-LELs were dissolved in H2 0 at 2mg/ml. Protein stocks
were subsequent diluted to lOg/ml in TBS and 501s were bound to each ELISA well at
4°C overnight. All wells were blocked with 1% bovine serum albumin for 2 hours at RT.
Soluble, recombinant integrin fragments were added to each well under varying buffer
conditions for 2 hours at RT and washed once with TBS. Ten pg/ml of biotinylated a-
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velcro antibody (which recognizes the C-terminal fusion tag) was added in TBS/lmM
Mn with 1% BSA for 30' at RT and washed 3X with TBS/Mn++. Horse-radish
peroxidase streptavidin/1% BSA was added for 15' at RT, washed 4X with TBS/Mn and
developed using 2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid (ABTS).
Absorbance was monitored at 415nm.
TetraspaniIn Binding to Cell-Surface Integrins:
K562 cells are human myelogenous leukemia cells that express the a51I integrin
at high levels. K562 cells were stably transfected with either aIIbIf3 or the a4 integrin
(to express cx41) in conjunction with endogenous levels of the a5pl1 integrin. For FACS
analysis, K562 cell lines were preincubated in PBS containing either mM CaCl2/lmM
MgCl2 or 5mM EDTA for 45' at RT. Cells were incubated with for 30' with .2mg/ml of
hCD9-LEL and anti-CD9 antibody M-L13. Incubation with either hCD9-LEL alone or
antibody M-L13 alone was used as negative controls. All samples were then incubated
with PE-conjugated anti-mouse IgG for detection. All samples were analyzed in a
FACS-Caliber machine, positively selected for live cells by forward and side scatter.
Gated cells were then analyzed for hCD9-LEL binding by analysis along the FL2 axis
with compensation adjusted to background.
For cell-binding assays, K562 variants were washed in PBS containing either
lmM CaCl2 /lmM MgC12 or 5mM EDTA and then incubated with hCD9-LEL at .2mg/ml
for 45' at RT. Cells were washed, lysed in RIPA buffer, and total protein was quantified
using the microBCA kit (Pierce). Equal amounts of total protein were loaded onto an
SDS-PAGE gel and bound hCD9-LEL protein was quantified by Western blotting.
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Results:
Cation-Dependence of Tetraspanin/Integrin Binding
We used an ELISA assay to test pairwise interactions between tetraspanin-LELs
and recombinant integrin fragments under a variety of conditions. As both tetraspanin-
LELs and integrins contained a hexahistidine tag, this epitope could not be used to probe
interactions. As a result, in all solid-phase ELISA binding assays, tetraspanin-LELs were
bound to plates. Integrins were then added under a variety of conditions and the presence
of bound integrin was detected with an antibody against the acid-base coiled coils (which
replace the integrin transmembrane domains) (Takagi, Erickson et al. 2001).
Previously, it has been shown that Manganese (Mn) and a cyclic peptides RGD
will activate integrins and EDTA, which sequesters cations, will inhibit integrin
activation (Hynes 2002). Our results showed binding of tetraspanin-LELs with the
cIIbi3 integrin above non-specific bovine serum albumin (BSA) background. Pre-
incubation of integrin fragments with EDTA significantly increased tetraspanin binding
(Figure 8.2A). However, there did not appear to be differences between aIIbi3
interactions with the hCD9-LEL, hCD63-LEL or hCD81-LEL. Binding of the hCD9-
LEL with a5f31 fragment was minimal. Given these results, we expanded our panel of
integrins and restricted our cation conditions to either Calcium (low-binding) or EDTA
(high-binding) buffers. Again, we observed consistently higher binding under conditions
without cations (Figure 8.2B). However, there did not appear to be a specific
tetraspanin/integrin binding pattern (Figure 8.2C). The hCD63-LEL consistently
exhibited higher binding than either hCD9-LEL or hCD8 1-LEL,which both exhibited
similar effects. Strikingly, tetraspanin-LELs appeared to bind as tightly to full-length
cIIbf33 integrin as to a mini-cIIb[3 domain, which contained only the head domain.
K562 are leukemia cells that endogenously express only the integrin cp511
heterodimer. We tested hCD9-LEL binding to either K562 cells or variants stably
expressing acIIb33 or a4p1 in addition to the endogenous a5f1 integrin heterodimer. We
used two different techniques to analyze binding of hCD9-LEL binding to K562 variants:
FACS analysis and also whole-cell lysates.
Our hCD9-LEL proteins were tagged at their C-termini with a hexahistidine tag.
However, a FITC-conjugated anti-HisTag antibody did not work by FACS (data not
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shown). As a result, we probed a panel of monoclonal antibodies against CD9. One
monoclonal, clone M-L13, detected hCD9-LEL without interfering with binding. K562
variants were pre-incubated with PBS containing either divalent cations (+/+) or EDTA.
By FACS we observed that, with all K562 variants, pre-incubation in the presence of
cations increased binding of the hCD9-LEL protein (Figure 8.3). K562 variants
expressing cIIbI33 or a411 (in addition to cz5P1) exhibited stronger binding. The
K562/c4I3 cell line had the greatest sensitivity to cations (Figure 8.3).
We further tested binding of the hCD9-LEL protein to K562 variants using
whole-cell lysates. The hCD9-LEL was bound to K562 variants incubated under varying
cation conditions and equal amounts of whole-cell lysates were analyzed by SDS-PAGE
and Western blotting. Again, we observed higher cell-surface tetraspanin-integrin
binding in the presence of cations (Figure 8.4A). EDTA dramatically lowered hCD9-
LEL binding. These results correlated with the results seen by FACS (Figure 8.3),
although they are the inverse of our solid-phase ELISA results. Taken as a whole, they
suggest that cations modulate tetraspanin-LEL/integrin binding.
Integrin Tail-Release Effects on Tetraspanin/Integrin Binding
All recombinant integrin fragments had their C-terminal transmembrane regions
replaced with heterodimeric coiled-coil sequences. A disulfide-bond introduced into the
coiled-coil further increased constitutive oligomerization, bringing the integrin stalk
domains into close proximity. The close proximity of integrin stalks has been shown to
hold integrins in an inactive state (Figure 8. 1A). A TEV protease cleavage site was
inserted between the beta integrin subunit and its base peptide fusion. Treatment with the
TEV protease released the integrin stalk constraint and resulted in activation of ligand
binding (Takagi, Erickson et al. 2001).
We tested whether TEV protease cleavage (and the release of the intersubunit
constraint) perturbed tetraspanin/integrin interactions. Although a decrease in binding
was observed when the c6134 constraint was released, in general TEV treatment (and
subsequent integrin activation) had no effect on tetraspanin/integrin interactions (Figure
8.4B).
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Antibody Inhibition of Tetraspanin/Integrin aIIb[53 Binding
As tetraspanin-LELs bound most strongly to the recombinant cIIb33 fragment
(Figure 8.2C), we tested the effects of a panel of anti-cdIIb33 antibodies on
tetraspanin/integrin interactions. A single monoclonal antibody, 10E5, inhibited
caIIbIf3/CD9 interaction and reduced binding to background levels (Figure 8.5A). The
10E5 antibody not only inhibited CD9/aIIbI33 interactions, it reduced binding in all
tetraspanin-L,ELs/aIIb3 interactions (Figure 8.5B). In the case of the hCD63-LEL, this
binding was not reduced to background, possibly suggestive of significant non-specific
background. When the hCD9-LEL was tested for antibody-dependent binding to aIIb133
under cationic conditions, no antibody inhibition was observed (8.5C). The addition of
two small molecule acivators to the aIIb33 integrin, EF5154 and cyclic-RGD did not
perturb integrin binding. These interactions were probed in Ca/Mg as the small molecule
EF5154 does not bind in EDTA. These results are consistent with the notion that high
affinity integrin conformers bind weakly to tetraspanins by solid-phase ELISA analysis.
Tetraspanin Specificity in Tetraspanin/Integrin Binding
To test further the specificity of tetraspanin-LEL/cIIb33 integrin interactions, we
utilized a panel of anti-tetraspanin antibodies. As these antibodies presumably bind the
head subdomain of tetraspanin-LELs, we hypothesized that they would serve to inhibit
tetraspanin/integrin interactions. Anti-tetraspanin antibodies were pre-incubated with
each tetraspanin post-binding to ELISA plates and then binding was compared to anti-
aIbP33 10E5 inhibition (Figure 8.6A). Although 10E5 consistently lowered binding to
background levels, antibodies against tetraspanins had minimal effect. Only in the case
of anti-CD63 was there a significant inhibition of interaction, comparable to 10E5
inhibition. Inhibition of hCD63-LEL/cIIbf33 interaction by the anti-CD63 antibody was
specific. As expected, anti-tetraspanin antibodies did not inhibit aIIb33 interactions with
non-recognized tetraspanins (Figure 8.6B)
With the hCD9-LEL, we constructed, expressed, and purified two hCD9-LEL
variants that are analogous to the mCD9-LEL species that fail to bind KMC8 (as
described in Chapter 4). The hCD9-LELoQ161A and hCD9-LEL°E160A/Q161A
variants had comparable biophysical characteristics to the hCD9-LELwt (data not
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shown). These variants were tested for binding to acIIb33 under divalent cation
conditions (Figure 8.6C). We did not observe any difference in binding among all the
hCD9-LEL variants, suggesting that interaction is not mediated by this region of the
hCD9-LEL head sub-domain.
Anti-a41 Antibody Modulation of Interaction:
Using BSA background as a negative control and hCD81-LEL/c431 integrin
binding under cationic conditions as a positive control, we tested antibody modulation of
this specific interaction. A panel of antibodies revealed that one anti-1 antibody, clone
4B4 reduced binding to background levels (Figure 8.7A). Another anti-P1 antibodies,
clone TS2/16, actually increased binding although TS2/16 and 4B4 have overlapping
epitopes and compete with each other for binding (Takada and Puzon 1993). A series of
anti-a4 antibodies also inhibited binding, although the pattern of inhibition did not match
known inhibitory antibody functions (Figure 8.7A). These surprising results were
reproducible, with clones TS2/16, SG7, and L25 augmenting binding and clones 4B4,
5D5, 8F2, and HP1/7 inhibiting binding (Figure 8.7B).
Specificity of Anti-a41 Antibody Modulation of Binding:
To test for the specificity of hCD8 1-LEL/a43 1, binding between the hCD8 1-LEL
protein and a531 integrin was tested under cationic conditions. No increase by either of
the augmenting antibodies, clones TS2/16 or SG7, was observed (Figure 8.8A). The
inhibitory antibody 4B4 also had no effect, although this could be due to the lack of
resolution under these experimental conditions. Specificity of hCD81-LEL/a4P31
interaction was also probed by testing binding between the hCD81-LEL protein and
ca6i4 integrin under cationic conditions. Screening a panel of anti-c6 antibodies revealed
a clone, S198, that inhibited interaction (Figure 8.8B). As before, anti-P4 antibody
clones 5D5, 8F2, and HP1/7 inhibited binding. Surprisingly, inhibition by the anti-I31
antibodies, 4E34 suggests that perhaps antibody-mediated inhibition was non-specific
(Figure 8.8B). Furthermore, it was observed that the majority of inhibitory antibodies
were ascites, an effect also observed with CD81 binding to aIIb[i3 integrin (data not
shown).
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With our cell-based binding assay, we preincubated K562 cells expressing
endogenous (x51 integrin with a series of modulating antibodies before probing binding
with the hCD9-LEL protein. All buffers contained Ca/Mg and whole-cell lysates were
quantified, equated, and loaded onto 18% non-reducing SDS-PAGE. Nucleoporin was
used as a loading control. The anti-131 antibodies, 13, AG89, TS2/16, and SG89
increased interaction (Figure 8.9). Disturbingly, the anti-ca4 antibody, L25, which
augments c4 binding but should have no effect in this assay, increased hCD9-LEL
binding. These results were reproducible and densitometry analysis suggested that clone
TS2/16 induced a 5-fold increase in hCD9-LEL binding and was dose-dependent on
hCD9-LEL concentrations (data not shown).
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Discussion.
In this chapter, we utilize three different techniques to show the influence of
various cations on binding between tetraspanins and integrins. These cation-dependent
effects were observed with a large number, but not all, of integrins tested. Furthermore,
they were observed with three different, soluble, tetraspanin-LELs. Surprisingly, we
observed inverted cation-dependent effects depending upon the assay used. With solid-
phase ELISA binding, we observed higher binding under cation-deficient, or inactivating,
conditions. However, with cell-binding assays, we observed higher binding under cation-
activating conditions. The simplest explanation for this discrepancy is to assume the
ELISA binding assays, which contain minimal binding components, is authentic and that
tetraspanin-LELs bind inactivated integrins.
In the case of our cell-binding assays, where we see increased binding under
cation-positive or integrin active conformations, our inverted observations to the ELISA
binding experiments may be explained by endogenous CD9, which has been shown to be
present in low copies on K562 cells (Mannion, Berditchevski et al. 1996). If interaction
between CD9 and integrins is real, endogenous CD9 molecules may be constitutively
bound to inactive integrins on K562 cells. Under inactivating conditions (EDTA), this
endogenous cis interaction would preclude the binding of exogenous, soluble forms of
the CD9-LEL. However, release of this CD9/integrin complex by cation-induced
integrin activation could expose novel, low-affinity binding sites and allow interaction of
soluble CD9-LELs in trans with cell-surface integrins. The low-affinity of tetraspanin-
LEL interactions is also suggested by our inability to observe CD9-LEL/cdIIb3 integrin
binding by gel filtration analysis, which only detects high affinity interactions (data not
shown).
Our observed cation-dependence of tetraspanin/integrin interactions is not in
concordance with several published reports (Mannion, Berditchevski et al. 1996)
(Longhurst, White et al. 1999), which suggest that modulation of integrin affinity does
not affect tetraspanin/integrin interactions. Longhurst et. al. observed the association of
CD9 with l:Ibf3 (and also the GPlb/V/IX complex) using CHAPS solubilization. An
activating antibody, D3, inhibited CD9/aIIbf33 immunoprecipitation, but the interaction
was not cation dependent (Longhurst, White et al. 1999). Mannion et. al. shown the
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cation independence of CD81/a4[ 1 interaction. However, the introduction of two point
mutations to the c4 subunit that inhibit adhesion, D346E and D408E also inhibit
immunoprecipitation (Mannion, Berditchevski et al. 1996). Association between CD81
and a4[51 is only observed in CHAPS or weaker detergents. The binding inhibition of
extracellular antibodies (which may disrupt the tetraspanin/integrin binding site)
described by Longhurst et. al. is encouraging. However, similar to the results described
in this chapter, many of these observations are discordant with one another. How would
an activating antibody decrease binding and yet not be cation-dependent? We
hypothesize that the use of weak detergents (such as CHAPS and even weaker detergents,
such as Brij58) to observe interactions causes tetraspanins and integrins to constitutively
and non-specifically associate with one another through their hydrophobic domains. This
constitutive effect may mask the conformational-dependence of tetraspanin-integrin
interactions.
It is possible that under integrin activating conditions, extracellular tetraspanin
binding to integrins is minimal. However, binding was significantly increased in the
presence of inactive integrins (as with our solid-phase ELISA assays), and induction of
the inactive conformation may expose a tetraspanin-LEL binding site. Cation-dependent
tetraspanin-IEL/integrin binding strongly suggests that this interaction may depend upon
different integrin conformations. To test this hypothesis, we used the Tev protease to
activate integrins by releasing an artificial coiled-coil clasp (Takagi, Erickson et al.
2001). However, release of the integrin inactivation constraint did not significantly affect
tetraspanin-I,EL/integrin binding. Lastly, we queried tetraspanin-LEL/integrin
interactions in both solid-phase binding and cell-binding assays with modulating
antibodies. Although these antibodies were also able to modulate tetraspanin/integrin
interactions, they did not suggest preferred binding of tetraspanins to either activated or
inactivated integrin conformational state (Takagi, Petre et al. 2002). As we noted that a
number of antibodies produced as ascites all had inhibitory effects on tetraspanin-LEL
binding, regardless of their function, we have low confidence in these results.
Lastly, to test the specificity of our tetraspanin-LEL binding, we constructed two
point mutations in the human CD9-LEL that we hypothesized would serve to disrupt
heterotypic interactions. Unexpectedly, these mutations had no effect on the interactions
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between the CD9-LEL and integrins, suggesting a lack of specificity in our observations.
Furthermore, the addition of antibodies that recognize tetraspanin-LELs (and supposedly
block heterotypic interactions) had no inhibitory effect on interactions. These results do
not support the specificity of our tetraspanin-LEL/integrin binding experiments.
However, unlikely, it may be possible that the dimeric, not the variable, subdomain of
tetraspanin-LELs does not mediate our observed interactions. However, this hypothesis
is not supported by our cell-binding assays, where we incubated integrin-expressing cells
with tetraspanin-LELs at concentrations where the tetraspanin-LELs would be dimeric.
Lastly, addition of the mCD9-LEL protein, which is thought to interact with the platelet
integrin aIIb133(Longhurst, White et al. 1999), had no effect on the activation or
aggregation kinetics of human platelets in a aggregometer assay (data not shown).
Unlike our initial results showing the cation-dependence of tetraspanin/integrin
interactions, all of our latter experiments suggest a discouraging lack of binding
specificity. Regardless, many reports suggest the role of tetraspanins in regulating cell
migration. For example, antibodies against CD9, CD81, a3 integrin, and 131 integrin
inhibit in vitro keratinocyte wound-healing (Penas, Garcia-Diez et al. 2000). Antibodies
against CD63 inhibit melanoma cell migration and overexpression of CD63 increased 31
integrin mediated adhesion and migration (Radford, Mallesch et al. 1995). Whether
tetraspanin-dependent modulation of integrin-mediated adhesion and migration is direct
or indirect is unclear.
In summary, we have presented a series of experiments to directly reconstitute
and probe teltraspanin/integrin interactions. These experiments suggest that commonly
observed interactions between tetraspanins and integrins occur through the extracellular
portions of these molecules. However, we were not able to decipher a pair-wise binding
pattern (i.e., all tetraspanin-LELs bound equivalently to acIIbf3), although these data did
roughly correlate to published observations (none bound well to caV33 integrin). Most
importantly, we were unable to show specificity of tetraspanin-LEL interactions either
through the addition of putative function-inhibiting antibodies or the introduction of
putative non-heterotypic interacting mutations.
174
/
A-I
-- ~r .rij- -1l Irc
I "
4r 1h.
"i4a. X Fwaur 7
Cations, tail release, modulating
antibodies, tetraspanins (?)
Figure 8.1 Global Conformational Rearrangements of Integrin Heterodimer Structures: A)
Integrins in a bent form (left-most structure) have been shown to be inactive. Straightening of
the integrin heterodimer to an active conformation can occur either by ligand binding or
through the cytoplasmic domains, resulting in the straightening and the separation of the
integrin legs (middle/right diagrams). B) Two proposed models for global rearrangement of
integrin structure are through either the switch-blade or flick-knife model, or an angle-poise
model. The orientation of the integrin heterodimer relative to their respective transmembrane
domains is unknown. Experimentally, it has been shown that global integrin conformational
changes can occur through either cations, tail release, or modulating antibodies. It is unknown
if tetraspanin molecules regulate integrin conformations.
Figure 8.2 ELISA Analysis Reveals Cation-Dependent Tetraspanin/Integrin Interactions:
A) The hCD9-LEL, hCD63-LEL, and hCD81-LEL proteins were bound to ELISA plates at
lOg/ml. Recombinant a5fp1or caIIb33 integrin (10jg/ml) was incubated in TBS
supplemented with either lmMCa/lmMMg (red), 2mM Mn (blue), 4mM EDTA (yellow),
2mM Mn + 200M GRGDNP for a5131 and GRGDSP aIIbP3 (Green). Bovine serum
albumin (black) was added as a negative control. The stippled lines indicate background
binding, as set to BSA. B) The hCD9-LEL (blue), hCD63-LEL (red), and hCD81-LEL
(green) proteins were bound at 5/g/ml to ELISA plates. Recombinant cIb3, mini-cdIIb33,
caVI33, cVI 1, ca531, ca6134 at 5/g/mlwere incubated in TBS supplemented with either
lmMCa/lmM.Mg (thatched) or 2mM EDTA (solid). Baseline was set to the BSA control
(stipple line). C) The hCD9-LEL (blue), hCD63-LEL (red), and hCD81-LEL (green)
proteins were bound at 5pg/ml to ELISA plates. Recombinant IIb33, mini-acIIbf3, aVP3,
caVf3, a5131, x6134, a431, a41i7 at 5/g/mlwere incubated to the plates in TBS
supplemented with 2mM EDTA (solid). This ELISA experiment was conducted by J. Takagi
using tetraspanin reagents provided by C. C. Liu.
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Figure 8.3 FACS Analysis of Cation-Dependent Tetraspanin/Integrin Interactions: K562 cells
expressing endogenous a531 and stably transfected aIIbp3 or ct4(fll) integrins were washed
and incubated in phosphate-buffered saline containing either ImM Ca2+/lmM Mg 2+ or 5mM
EDTA for 1 hour at 40 C. Cells were washed and co-incubated with the hCD9-LEL protein
(final concentration 2mg/ml) and a 1:100 dilution of a-CD9 antibody, clone M-L13, for 1 hour
at 40C. Subsequently, cells were washed IX in PBS/cation and incubated with a 1:100 dilution
of PE-conjugated anti-mouse IgG. Cells were washed 1X and analyzed by FACS. Forward
and side scatter gates were optimized to select for live cells. Region 2 was defined by K562
samples with either no hCD9-LEL protein or no M-L13 antibody. Under these conditions,
<0.5% of K562 cells fell in region 2. Increasing PE fluorescence (CD9 binding) is indicated in
the FL2 range. Percentages of region 2 cells under various conditions are indicated in
parentheses. This experiment was conducted by C.C. Liu using cells provided by J. Takagi.
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Figure 8.4 Cell-Surface Integrin Binding of Tetraspanins: A) K562 cells expressing
endogenous a5pl and stably transfected aIIbP3 or a4(fl1) integrins were washed and
incubated for 1 hour at RT in phosphate-buffered saline containing either ImM Ca2+/ImM
Mg2+ or 5mM EDTA. Cells were washed and incubated with the hCD9-LEL protein (final
concentration 2mg/ml) for 1 hour, washed in PBS/cation and lysed in RIPA buffer. Insoluble
portion was cleared by centrifugation and cell lysate was quantified with the microBCA kit.
Equal amounts of protein were loaded on 18% non-reducing SDS-PAGE and probed for
hCD9-LEL with the antibody 72F6. B) Tetraspanins were bound to ELISA plates as
previously described. Integrins with C-terminal coiled-coil clasps were released with 250U/ml
of TEV protease by overnight incubation at RT. Non-cleaved integrins were incubated with
TEV-negative buffer. Integrins were added to tetraspanin-ELISA plates and developed under
standard conditions. TEV protease addition is indicated under each set of data.
Experiment in A was conducted by C.C.Liu and ELISA in B was conducted by J. Takagi using
tetraspanin reagents provided by C. C. Liu.
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Figure 8.5 cIIb303 Binding to Tetraspanins: To further explore aIIb133 binding to
tetraspanin-LELs, we used a series of anti-integrin modulating antibodies. A) The hCD9-
LEL protein was bound to ELISA plates. Integrin caIb[3 was incubated with a panel of
modulatory antibodies listed. No antibody addition is listed as cont(rol). B) To test
binding inhibition by the anti-aIIb[3 antibody 10E5, tetraspanin-LELs were bound as
before. The acIIb[3 integrin was incubated in 2mMEDTA with either no-antibody (blue),
non-modulating antibody (red), or the modulating 10E5 antibody (green). Baselines are set
to the BSA background control. C) To test the effects of associating drugs, the hCD9-LEL
was bound to ELISA plates. Integrin ctIIb33 binding was tested as before, except instead
of 2mM EDTA, TBS was supplemented with mM Ca2 +/lmM Mg2+. As indicated,
integrin aIIbP3 was supplemented with 1OOyM EF5154 or GFGDSP.
This experiment was conducted by J. Takagi using tetraspanin reagents provided by C. C.
Liu.
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Figure 8.6 Tetraspanin Antibody and Point Mutation Effects on cIIb[3 Binding: To test
specificity of txIIb33/tetraspanin interactions, hCD9-LEL, hCD63-LEL, and hCD81-LEL
were bound to ELISA plates as before. A) Integrin aIIb[3 was incubated in TBS/EDTA to
ELISA plates with either no antibody (blue), an antibody against the bound tetraspanin (red),
or the inhibitory 10E5 antibody (green). Background is indicated with a stippled line. B)
Tetraspanin-LELs were bound to the plate and incubated with aIIb33 integrin in
TBS/EDTA. Anti-CD9 (pink), anti-CD81 (green), anti-CD63 (orange) or 10E5 (red) were
added at 20g/'ml. No antibody addition (blue) and BSA (black) were used as positive and
negative controls respectively. Background binding is indicated with stippled lines. C) To
test specificity of human CD9-LEL interactions, two point mutations were constructed
hCD9-LEL-Q161A and hCD9-LELE15A/Q161A and bound to ELISA plates. caIIb3
integrin was incubated with TBS/lmM Ca2 +/lmM Mg2 +and background binding is indicated
with a stippled line.
This ELISA experiment was conducted by J. Takagi using tetraspanin reagents provided by
C. C. Liu.
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Figure 8.7 Antibody Modulation of a4•1/Tetraspanin Binding: The hCD81-LEL was bound
to ELISA plates. a4P~ integrin was incubated in TBS/lmM Ca2+/lmM Mg 2+with a 1:100
dilution of the indicated antibody (either from a 1mg/ml stock or ascites). A) BSA background
was set to 0 and the stippled line indicates binding without the addition of antibody. B) An
independent replicate of A. Stippled lines indicate background (bottom line) and baseline
binding (top line). The function of anti a4 integrin antibodies is indicated with either an I
(inhibitory) or N (non-blocking) or ? (unknown). Antibodies that have overlapping epitopes
are indicated with an asterisk. This experiment was conducted by J. Takagi using tetraspanin
reagents provided by C. C. Liu.
a4bl binding to CD81(-BG)
25
2
ua 1.5
S1
0.5
0
mh~b
Ba6etb4 binding to CDS1(CaIMg)
BSA no S195 S196 S198 GoH3 3E1 8235 8247 505 8F2 HPl17 484
mAb
X X X X
Figure 8.8 Specificity of a431 Antibody Effects: A) To test the specificity of anti-Pl
antibodies, hCD81-LEL was bound to ELISA plates. a5P1 integin heterodimer was incubated
with plates in TBS/lmM Ca2+/lmM Mg 2+ with antibodies at 1:100 dilution. B) To test binding
to a5p•, hCD81-LEL was bound to ELISA plates. a634 integrin was incubated with plates in
TBS/lmM Ca2+/lmM Mg 2+ with antibodies at 1:100 dilution. Antibodies against the a4
integrin are indicated with a red X. Stippled lines indicate both background binding (lower
line) and baseline binding (upper line). This ELISA experiment was conducted by J. Takagi
using tetraspanin reagents provided by C. C. Liu.
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Figure 8.9 Antibody Modulation of Cell-Surface Integrin Binding: K562 cells expressing
endogenous 0a501 were washed in PBS/lmMCa/lmMMg, aliquoted, and incubated with a
1:25 (40mg/ml or ascites dilution) in 50Als for 15' at RT. Fifty pls of a 2mg/ml solution of
hCD9-LEL (for a final concentration of lmg/ml protein) was added to the cells and incubated
for 45' at RT. Cells were washed 3X in PBS+/+. Cells were lysed in RIPA buffer with
protease inhibitor cocktail (Boehringer) and insoluble portion was cleared for by
centrifugation. Protein content was monitored by microBCA assay and equal amounts were
loaded onto 18%SDS-PAGE. Westerns were developed using the anti-human CD9 antibody
clone 9F27. Anti-nucleoporin antibody was used as a loading control. Antibodies against ct4,
aS, and 01 integrin subunits are indicated. This experiment was conducted by C.C. Liu using
reagents provided by J. Takagi.
Chapter 9
Conclusions and Future Directions
This discussion was written by Christopher C. Liu with helpful discussion and editing
from Richard 0. Hynes. All conclusions and errors are my own.
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Introduction
This thesis has described a rapid methodology to purify and characterize
tetraspanin-LELs. Biophysical and molecular biological analyses show that the CD9-
LEL, CD63.-LEL, and CD81-LEL are all ca-helical dimers composed of a conserved
dimerization subdomain and a variable subdomain, consistent with a published crystal
structure of the human CD81-LEL. We are readily able to purify a single conformational
species of each tetraspanin-LEL dimer. These reagents can be used to inhibit endogenous
tetraspanin functions, further suggesting that our tetraspanin-LEL proteins are
biologically relevant. The discussion and future directions of these inhibition studies
(fertilization and hepatitis C infection) are discussed in Chapter 7 and the Appendix,
respectively. In this chapter, we discuss future experiments that are both a natural
extension of the work described in this thesis and may also serve to lend the most insight
into tetraspanin functions.
Tetraspanin Extracellular Domains
The first area of focus of this thesis has been on the biophysical characterization
of tetraspanins-LEL domains in vitro. We have purified and characterized three different
tetraspanins-LELs, including many variants of the murine CD9-LEL. As the hCD8 1-
LEL sructure has proven to be instrumental in developing our conceptual framework for
tetraspanin functions (Kitadokoro, Bordo et al. 2001), we have attempted (and failed) to
derive atomic-level structures of other tetraspanin-LELs. Structural studies of other
tetraspanin-LELs would add significantly to the mutagenesis analyses described in this
thesis. More detailed biophysical techniques to measure the binding kinetics of one
tetraspanin monomer to another, such as isothermal calorimetry, may also prove useful.
Currently, we have not measured the binding and dissociation constants of tetraspanin
oligomerization, although biophysical and mutagenesis studies indicate that tetraspanin-
LELs are obligate homodimers.
In many ways, the global stability, small size, dimeric nature and cooperativity of
folding of tetraspanin-LELs suggest that these proteins are ideal substrates for oligomeric
protein folding and design studies (Cordes, Davidson et al. 1996). Based upon structural
and sequence homologies (Seigneuret, Delaguillaumie et al. 2001), it may be possible to
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further stabilize the tetraspanin-LEL homodimers either through introducing an
interchain disulfide-bond or by designing a single-chain tetraspanin-LEL dimer (Root,
Kay et al. 2001). These studies may serve both to validate further the quarternary
structure of the tetraspanin-LEL dimer and to increase both the stability and potency of
tetraspanin-LELs in inhibition experiments.
Our 'observations of well-folded homodimeric tetraspanins-LELs immediately
suggested the attractive possibility of heterodimers, especially as multiple homotypic
tetraspanin interactions have been observed. Experimentally, we saw no evidence of
preferential heterodimerization between the hCD9-LEL and the hCD8 1-LEL. The role of
specific protein dimerization and oligomerization is of key importance in regulating
biological functions (Klemm, Schreiber et al. 1998). Protein oligomerization serves not
only to increase functional diversity combinatorially, but also to regulate receptor avidity
and to define spatio-temporal boundaries of signaling complexes. The small size and
global stability suggests the possibility of rationally designing heterodimeric tetraspanin-
LELs (Keating, Malashkevich et al. 2001).
Our initial attempts to disrupt dimerization and to design a monomeric, folded
version of the murine CD9-LEL were not successful. However, we have not completely
exhausted the possibilities in this avenue of research. By introducing intramolecular,
buried disulfide bonds, it may be possible to stabilize further each independent
tetraspanin-LEL subunit (Betz 1993). Such stabilization, coupled with a more rigorous
attempt to introduce polar and charged amino acid residues into the dimerization interface
may allow the design of a monomeric tetraspanin-LEL. A monomeric tetraspanin-LEL
variant would allow researchers to explore the contribution of tetraspanin-LEL
dimerization to inhibition experiments. Currently, we view tetraspanin-LELs as
dominant negatives, serving to disrupt endogenous heterotypic complexes at the cell
surface. It is unclear if the bivalent nature of the tetraspanin dimer is essential to their
inhibititory effects.
As technology for peptide synthesis advances, the relatively short length of
tetraspanin-LELs (-80 amino-acids) will allow chemical synthesis of these molecules
(either by standard synthesis reactions or through sequential peptide ligation). The ability
to synthesize tetraspanin-LELs chemically would allow the incorporation of covalent
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cross-linkers into the amino acid chain that do not disrupt heterotypic interactions but
allow direct cross-linking to heterotypic binding partners. The molecular dissection of
the KMC8 epitope as presented in this thesis lays the groundwork for the design of these
tetraspanin-LEL variants. These reagents, used in tandem with our studies on both the
inhibitory effects of recombinant tetraspanins-LELs and their interactions with integrins
would serve to decipher the complex roles of tetraspanins-LELs. The ability to
covalently cross-link tetraspanins-LELs to their specific binding partners would also
assist in clearly mapping heterotypic interaction domains.
Inhibitory Effects of Soluble Tetraspanin-LELs.
Our primary, motivating interest in tetraspanins was, and still remains, their
unique roles in membrane fusion (Stein, Primakoff et al. 2004). The proteins directly
responsible for cell-cell fusion remain unknown. Given the recent, significant advances
in viral-cell and vesicle-vesicle fusion (Earp, Delos et al. 2005), an understanding of cell-
cell fusion at the molecular level would be a giant advance towards our appreciation of
this fascinating topic
CD9, which was shown to be essential for sperm-egg fusion, did not fit our view
of a membrane fusogen. To further explore the role of CD9 in membrane fusion, we
developed a methodology to produce and purify the CD9-LEL. A well-characterized,
soluble CD9--LEL could be useful in several ways. Logically, if CD9 does not play a
direct role in catalyzing membrane fusion, it may bind to either a sperm or an egg protein
that does. We made the CD9-LEL and a series of folded, characterized mutants with this
series of experiments in mind.
Indeed, our CD9-LEL protein exhibited significant, but far from complete
inhibition of fertilization (Zhu, Miller et al. 2002). Furthermore, pre-incubation of the
CD9-LEL protein with either sperm or egg cells suggested that endogenous CD9
functions on the egg surface, and not as a sperm receptor. We, and others, have
attempted to identify CD9 binding partners on the egg surface with no luck.
The search for a heterotypic CD9 binding partner is far from complete. The
inhibitory activity of our CD9-LEL protein has is a small, but significant step forward
towards our understanding of how CD9 functions on the egg surface. As limited
1 9)
numbers of egg cells is a significant technical hurdle for classical biochemistry, it may be
possible to find oocyte specific binding partners through either screening a Xgtl 1 phage
library (Mierendorf, Percy et al. 1987), or expression cloning in eukaryotic cells. The
reversible effect of PSG17-mediated inhibition on CD9, suggests that CD9 does not
function as a chaperone to a membrane fusogen (Ellerman, Ha et al. 2003). Our ability to
rescue CD9-null oocytes with de novo expression of CD9 also suggests that CD9 may
serve to increase affinity or avidity of other, essential proteins in sperm-egg fusion (Zhu,
Miller et al. 2002).
The ubiquitous binding nature of tetraspanins-LELs makes the development and
characterization of CD9-LEL variants described in this thesis essential for this series of
experiments. Coupled with the possible generation of novel, covalent cross-linking CD9-
LELs described above, we remain optimistic that CD9 may serve as a conduit to
bootstrap towards a sperm-egg fusogen. Our inability to make greater headway into
probing the molecular mechanisms underlying sperm-egg fusion remains a point of deep
disappointment for us.
Recently, we initiated a collaboration with Jane McKeating to utilize our
recombinant tetraspanins-LELs to study another membrane fusion event: the infectivity
of hepatitis C. For some time, hepatitis C (HepC) envelope proteins have been known to
bind to the tetraspanin CD81 (Pileri, Uematsu et al. 1998) (Flint, Maidens et al. 1999).
As CD81 expression is not limited to HepC permissive cells (Levy, Todd et al. 1998) , it
has been hypothesized to function as a viral co-receptor (McKeating, Zhang et al. 2004).
Recent advances in replicating the hepatitis C lifecycle, including genomic replication
(Blight, Kolykhalov et al. 2000), viral pseudotyping (Hsu, Zhang et al. 2003), and finally,
the full HepC viral lifecycle (Lindenbach, Evans et al. in press) may serve to accelerate
the pace of flavivirus research. Lastly, the detailed mechanism of HepC glycoprotein
mediated membrane fusion is converging with the better understood retroviral and vesicle
fusion systems (Earp, Delos et al. 2005).
Our results showing specific inhibition of HepC infectivity with the CD81-LEL is
not novel. Multiple groups have produced and shown inhibition with similar reagents
(Flint, Maidens et al. 1999; Higginbottom, Quinn et al. 2000; Petracca, Falugi et al.
2000). However, our methodology to produce and characterize highly purified CD81-
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LELs and their non-inhibitory variants results in significantly greater potency of
inhibition (unpublished results). These reagents may serve to both probe hepatocyte
specific CD81-LEL binding partners (in a manner similar to that described for
fertilization) and also to probe the mechanism of HepC glycoprotein function. In
collaboration, Jane McKeating will utilize both our reagents and the ability to produce
high HepC viral titers to search for escape mutants from CD81-LEL mediated inhibition.
Lastly, the greater potency of our reagents will allow us to test inhibition of HepC
virions in a SCID mouse model system transplanted with human hepatocytes (Meuleman,
Libbrecht et al. 2005) in collaboration with both Jane McKeating and the Leroux-Roels
laboratory. If these in vivo inhibition experiments are successful, I expect that the CD81-
LEL protein may be commercialized.
Tetraspanin Interactions in the Membrane
Shortly after the identification of tetraspanins as a family of proteins (Oren,
Takahashi et al. 1990), the concept of a tetraspanin web was raised (Rubinstein, Le Naour
et al. 1996). Almost a decade after this hypothesis, the existence of a tetraspanins web, or
the ability of tetraspanins to spatially organize complexes at the cellular membrane,
remains contentious.
A large body of literature suggests that tetraspanins bind in a robust,
stoichiometric, heterotypic fashion with other membrane proteins (integrins
(Berditchevski 2001) and immunoglobulin superfamily members (Stipp, Kolesnikova et
al. 2003). This interaction is mediated through the tetraspanins-LEL (Kazarov, Yang et
al. 2002). When the stringency of these techniques is lowered , significantly greater
numbers of interactions are also observed, including homotypic tetraspanins interactions
(Berditchevski, Zutter et al. 1996), MHC proteins, CD4 (Imai, Kakizaki et al. 1995), CD8
(Imai and Yoshie 1993), CD36 (Miao, Vasile et al. 2001), and a larger array of integrins
(Berditchevski 2001).
An outstanding question raised and unresolved in this thesis is the role of
tetraspanin oligomerization at the cell surface. Both the structure of the CD81-LEL
(Kitadokoro, Bordo et al. 2001) and our characterization of tetraspanins-LELs as helical
dimers immediately suggested that tetraspanins-LELs might play a central role mediating
192
oligomerization at the cell surface. However, many biochemical attempts to probe this
function, including some described in this thesis, have been attempted without resolving
conclusively the nature or even the validity of these proposed interactions.
Our biophysical and molecular analysis of a number of tetraspanins-LELs is
internally consistent and suggests that dimerization is a key factor in the folding stability
of the tetraspanins-LEL. Surprisingly, we were not able to detect oligomers with intact
CD9 molecules, in direct disagreement with our biophysical data. We have no choice but
to conclude that either our biophysical data is incorrect, is not biologically relevant, or
that the inclusion of other tetraspanin domains serves to mitigate the oligomerization of
tetraspanins--LELs.
We do not believe our biophysical data to be incorrect. Our observations that the
tetraspanins are ac-helical dimers composed of two subdomains is consistent with a large
body of literature, including structure (Kitadokoro, Bordo et al. 2001), sequence
(Seigneuret, Delaguillaumie et al. 2001), and antibody-induced effects (Maecker, Todd et
al. 1997). On the other hand, dimerization of tetraspanins-LELs may be biologically
irrelevant. Both sequence conservation and disulfide-bonding patterns strongly suggest
that a large hydrophobic patch exists in the tetraspanins-LELs (Seigneuret,
Delaguillaumie et al. 2001). However, this surface does not necessarily need to mediate
dimerization. It is possible, however unlikely, that the tetraspanins small extracellular
loop (SEL) may serve to cap this surface. As SELs are short (Maecker, Todd et al.
1997), 15-20 amino acids in length, chemical synthesis of this tetraspanins domain and
the analysis of its influence on both the biophysical properties of tetraspanins-LELs and
tetraspanins-ILEL mediated inhibition are intriguing. Lastly, multiple observations that
tetraspanins-LELs specifically inhibit functions and that these inhibitory effects match
both mouse model and antibody-induced effects support the biological relevance of our
methodology.
Our experiments with the intact CD9 molecule raise the probability that other
tetraspanins hydrophobic domains may serve to mitigate tetraspanin-LEL mediated
oligomerization. The presence of conserved, polar residues in all tetraspanins
transmembrane segments suggests an evolutionarily conserved role (Stipp, Kolesnikova
et al. 2003). Although our null hypothesis is that the crystal structure the CD81-LEL is
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consistent with the existence of a tetraspanins dimer on the same lipid bilayer, this
assumption is still quite controversial. To reconcile, the antiparallel structure of the
CD81-LEL, it is necessary to envision a flat, planar tetraspanins dimer lying in close
proximity to the lipid bilayer. It is conceivable that the hydrophobic, putative
dimerization interface lies embedded into the lipid bilayer, similar to a peripheral
membrane protein.
To ideally resolve these issues, we propose that it is necessary to characterize
tetraspanin molecules in isolation, in reconstituted lipid vesicles. Reconstitution of
purified tetraspanin molecules would allow the use of both fluorescence resonance
energy transfer (FRET) or fluorescence recovery after photobleaching (FRAP) to probe
the oligomerization state of tetraspanins. These studies, coupled with the mutagenesis
studies described in this thesis, would allow precise measurements of the contribution of
each tetraspanin domain to oligomerization - if indeed it occurs. Reconstitution of
tetraspanins with heterotypic partners would also explore the potential influence of
heterotypic partners on oligomerization and avidity regulation. Lastly, synthesis of
tetraspanin transmembrane segments in isolation and subsequent introduction into lipid
vesicles would directly measure the contributions of these domains to oligomerization,
which has been alluded to, but not directly explored.
Given the technical difficulties underlying reconstitution of intact tetraspanins
into lipid bilayers, we also propose an alternative methodology. In parallel with the
tetraspanin variants that abolish heterotypic interactions, it may be possible to use
rapamycin-induced FKBP dimerization to induce tetraspanin dimers (Klemm, Schreiber
el: al. 1998). By artificially inducing high-avidity homo- or hetero- oligomeric tetraspanin
complexes, it may be possible to decipher the contribution of oligomerization to
endogenous tetraspanin functions.
The ideas and future directions described here are not novel. The study of
membrane proteins, their functions, and their oligomerization states is complex. In this
thesis, we have taken a traditional approach to study membrane proteins, by largely
ignoring the hydrophobic domains. It appears that in tetraspanins, even more so than
other transmembrane proteins, the effects of hydrophobic domains may not be ignored.
However, given the complexity and contribution of different domains to the endogenous
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functions of transmembrane proteins, these studies must be undertaken. Recently, the
integrin field has undergone a renaissance of ideas, both with the description of global
conformational changes long known to occur, and a strong indication that lateral
association of transmembrane segments may modulate extracellular domain functions
(Hynes 2002). The concept of lateral association between tetraspanin transmembrane
segments is appealing and needs to be explored in full detail.
The idea of a tetraspanin-enriched microdomain (TEM), similar to that observed
with lipid rafts, is both alluring and fraught with controversy. Various experimental
approaches, including tetraspanin palmitoylation and detergent-insoluble flotation
gradients hint at the existence of a TEM (Cherukuri, Shoham et al. 2004). However,
current techniques lack the resolution or rigor to resolve outstanding issues. Without
detailed analysis of tetraspanin partitioning into and out of high avidity complexes, this
idea will remain in the hypothesis stage. In this thesis, we have presented detailed
molecular analysis regarding the tetraspanin-LEL segment. These insights, in
conjunction with mutations of conserved amino acid residues in each tetraspanin
transmembrane segment and the techniques described above may shed light on TEMs.
Curre ntly, an active avenue of tetraspanin research is the generation and analysis
of tetraspanin knock-out mice. Targeted deletion of CD82 (a prostate metastasis
suppressor (I)ong, Lamb et al. 1995)) and CD63 are eagerly anticipated. Transgenic
rescue of tetraspanin-null mice (which has only been described with CD9-null oocytes in
Chapter 7) with multiple tetraspanin variants may also begin to decipher tetraspanin-LEL
finctions. Analysis of detergent-solubilized tetraspanin complexes, potential recruitment
of these complexes into TEMs, and the contribution of tetraspanin palmitoylation to
complex formation (Charrin, Manie et al. 2002; Charrin, Manie et al. 2003) also remain
active areas of research. Detailed analysis of these hydrophobic tetraspanin domains,
coupled with an increasing cognizance of tetraspanin-LEL-mediated functions, may serve
to reveal the underlying function of all tetraspanins.
Over the course of this thesis it has become evident that without the reconstitution
and analysis of specific tetraspanin domains in isolation and together, an inclusive
understanding of endogenous tetraspanin functions will prove difficult. The approaches
taken in this thesis underscore the parallel approach I have taken to explore tetraspanin
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functions relative to the rest of the field. Rather than the deletion of specific genes (a
reverse genetic approach (Hemler 2001)) or the sequential characterization of cellular
tetraspanin complexes (a deconvolution approach), we have sought to characterize the
roles of a specific tetraspanin domain (a reconstitution approach). This reconstitution
approach has both allowed the development of novel hypotheses for tetraspanins
functions and also the precise exploration of tetraspanin-LEL mediated inhibition.
The success of reverse genetics and deconvolution has served to reveal a panoply
of exciting, novel roles for tetraspanins in many diverse cell types, functions, and model
organisms (Hemler 2003). However, our reconstitution approach has yet to reach full
concordance with these other approaches and a unifying theory of tetraspanins function is
unclear. When these approaches meet and merge, hopefully with the completion of the
experiments described in this chapter, we believe that tetraspanins will fully reveal their
central roles, which we propose is in regulating both the affinity and the avidity of
membrane proteins.
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Appendix A
Specific hCD81-LEL inhibition of
Hepatitis C Infection
These experiments were conceived by Christopher C. Liu, Jane McKeating, and Richard
0. Hynes. All tetraspanin reageants were constructed by Christopher C. Liu. All
inhibition of Hepatitis C pseudotyped virions assays was performed in the laboratory of
Jane McKeating. Non-pseudotyped Hepatitis C virions (HepCpp) was made and
analyzed by Brett Lindenbach.
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Tetraspanin CD81-LEL Inhibition of Hepatitis C Infection
The experiments described in this appendix were initiated over the summer of
2004 through a series of discussions with Jane McKeating at the FASEB Tetraspanin
2004 meeting. Since my undergraduate studies, I have followed research on Hepatitis C
infectivity and the mechanisms offlaviviral membrane fusion closely and with great
interest. It is quite an honor to both finally study and contribute reagents to this body of
research. However, I must admit that Jane McKeating intellectually drives this
collaboration and I am merely providing useful reagents. As a result, Ifeel the series of
experiments described below are not worthy of a full chapter in this thesis. A
publication, appended in this thesis, has already risen from this fruitful collaboration.
The most prominent role for a tetraspanin in infectious disease is CD81, which
has been characterized as a receptor for the flavivirus Hepatitis C (Pileri, Uematsu et al.
1998).
Hepatitis C virus (HCV) is a major cause of liver disease, with over 170 million
infected individuals worldwide. Currently, HCV infection is the major cause of liver
transplants in the United States and current drug therapies are mostly ineffective (De
Francesco and Rice 2003). A member of the flaviviradae viral family, HCV encodes two
envelope genes, El and E2, believed to be type I transmembrane proteins that mediate
viral entry (Fields 2001). These proteins have been structurally categorized as class II
membrane fusion molecules (see Chapter 1) (Earp, Delos et al. 2005). It has been shown
that recombinant, soluble versions of the HCV E2 proteins bind a number of cell-surface
proteins, including CD81 (Pileri, Uematsu et al. 1998; Flint, Maidens et al. 1999),
scavenger receptor class B (SR-B 1) (Scarselli, Ansuini et al. 2002), dendritic cell-
specific ICAM 3-grabbing nonintegrin (DC-SIGN) (Pohlmann, Zhang et al. 2003), and
low-density lipoprotein (LDL) (Wunschmann, Medh et al. 2000).
The best characterized of these putative HCV receptors is CD81. Although CD81
is necessary for HCV infection of liver cells, CD81 expression alone is insufficient to
mediate viral entry, suggesting that other factors are necessary (McKeating, Zhang et al.
2004). Furthermore, CD81 is expressed on a diverse array of cell types, many of which
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are not susceptible to HCV entry. As a result, CD81 has been characterized as a HCV
co-receptor. Soluble, recombinant CD81-LELs have been shown to bind the
pseudotyped hepatitis C virions (Pileri, Uematsu et al. 1998; Flint, Maidens et al. 1999).
Binding of HepC pseudotyped virions is dependent on the CD81-LEL and mutagenesis to
non-permissive CD81-LEL sequences abrogated viral entry.
In this section, we present evidence for the role of our hCD81-LEL in specific,
dlose-dependent inhibition of HCV entry. Our purified, recombinant hCD81-LEL protein
, and not the CD9-LEL, inhibits envelope-null human immunodeficiency virus (HIV)
pseudotyped with HepC H and Conl glycoproteins (Figure A. 1). Neither protein
inhibited the entry of envelope-null HIV particle pseudotyped with vesicle stomatitis
virus (VSV) envelope, which mediates ubiquitous cellular entry. The inhibitory effect
was dose dependent with an IC,, in the high ng/ml range, exhibiting approximately an
order of magnitude greater potency than previously observed with GST-CD8 1-LEL
fusions.
To further test both the specificity and potency of inhibition, we constructed and
purified mouse and rat hCD81-LEL. Rat CD81-LEL did not inhibit binding, similar to
negative controls. As expected, none of the recombinant CD8 1-LEL proteins inhibited
virions pseudotyped with Murine Moloney Leukemia virus. Mouse CD81-LEL inhibited
virions pseudotyped with HepC envelope strain H77, but not HepC envelope strain JFH
(Figure A.2).
Recently, Brett Lindenbach and colleagues were able to produce infectious non-
pseudotyped HepC virions (Lindenbach, Evans et al. in press). Infection of these virions
were inhibited both with a antibody against the HepC glycoprotein known to inhibit entry
(clone C1) and also with our hCD81-LEL protein (Figure A.3). These inbition
experiments suggest that the HepC viral particle, called HCVcc, is similar to native HepC
virions. To further study the mechanism of hCD81-LEL mediated inhibition, Jane
McKeating will screen for HCVcc escape mutations. Lastly, the greater potency of our
reagents will allow us to test inhibition of HepC virions in a SCID mouse model system
transplanted with human hepatocytes in collaboration with both Jane McKeating and the
Leroux-Roels laboratory (Meuleman, Libbrecht et al. 2005). If these in vivo inhibition
experiments are successful, I expect that the CD8 1-LEL protein may be commercialized.
200
HIV-HCV H
250000
U CD81
200000- 0 CD9
150000 -T
100000-
50000 T
[n
HIV-HCV Con1
250000
200000
150000
100000
50000
0
T
T III I II Ii
d
!- !
d r
% neutralization
HIV-HCV H
96%
89%
34%
CD81 pg.ml
10.0
1.0
0.1
CD9 pglml
10.0
1.0
0.1
of pseudotype infectivity
HIV-HCV Con 1
99%
97%
55%
Figure A.1 Plasmids carrying Hepatitis C virus strain H or Conl E1E2 glycoproteins were
cotransfected with a luciferase plasmid containing an env-defective human immunodeficiency
virus (HIV) proviral genome into 293T cells. Supernatants were collected after 48h post-
transfection, HIV p24 antigen was assessed, and equal volumes of p24-antigen normalized viral
supernatants were added with the indicated concentration of tetraspanin-LELs to target cells.
After 4 hours, media was changed and 72 hours post-infection, cells were washed, lysed, and
assayed for luciferase activity. Dose dependence of both the hCD81-LEL and hCD9-LEL is
graphed at top and tabulated below.
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Figure A.2 Pseudotyped Hepatitis C virions were produced as described in A. 1. Instead,
glycoproteins from either Hepatitis C virus strain H77 or JFH were used as experimentals with
the Murine Moloney Leukemia virus envelope as a negative control. All tetraspanin-LELs were
tested at 5pg/ml. Data with the CD9-LEL protein, which had no effect on infectivity, is not
shown. Dose dependence curves are in progress.
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Figure A.3 Entry of the non-pseudotyped Hepatitis C virion, HCVcc, is indicated by
immunohistochemical staining for epitope-tagged NS5A protein with monoclonal antibody
9E10 (brown). Huh-7 cells were treated with A) clarified, filtered culture sup containing
HCVcc virions or B) untreated. To test for inhibition, HCVcc supernatants were pretreated for
lhr at 370 C with either C) inhibitor anti-E2 human monoclonal antibody Cl or D) lpg/ml of
hCD81-LEL. Cell nuclei are stained with hematoxylin (blue).
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SUMMARY
Gamete fusion is the fundamental first step initiating
development of a new organism. Female mice with a gene
knockout for the tetraspanin CD9 (CD9 KO mice) produce
mature eggs that cannot fuse with sperm. However, nothing
is known about how egg surface CD9 functions in the
membrane fusion process. We found that constructs
including CD9's large extracellular loop significantly
inhibited gamete fusion when incubated with eggs but not
when incubated with sperm, suggesting that CD9 acts by
interaction with other proteins in the egg membrane. We
also found that injecting developing CD9 KO oocytes with
CD9 mRNA restored fusion competence to the resulting
CD9 KO eggs. Injecting mRNA for either mouse CD9 or
human CD9, whose large extracellular loops differ in 18
residues, rescued fusion ability of the injected CD9 KO
eggs. However, when the injected mouse CD9 mRNA
contained a point mutation (F174 to A) the gamete fusion
level was reduced fourfold, and a change of three residues
(173-175, SFQ to AAA) abolished CD9's activity in gamete
fusion. These results suggest that SFQ in the CD9 large
extracellular loop may be an active site which associates
with and regulates the egg fusion machinery.
Key words: Gamete fusion, CD9, Tetraspanin, mRNA injection,
Mutation, Mouse
INTRODUCTION
Sperm-egg binding and fusion initiate the development of a new
organism, but the molecular mechanisms of gamete adhesion,
gamete membrane fusion and associated signaling are still poorly
understood. Recently, one egg surface protein, CD9, was shown
to be essential for gamete fusion. The fertility of CD9-deficient
female mice is severely reduced because membrane fusion
ability is lost in CD9-deficient eggs (Kaji et al., 2000; Le Naour
et al., 2000; Miyado et al., 2000). CD9 belongs to a family of
proteins called tetraspanins, which contain four transmembrane
domains, one small extracellular loop (EC1) and one large
exlracellular loop (EC2), and cytoplasmic amino and carboxyl
termini (Boucheix and Rubinstein, 2001). Tetraspanins are
reported to function in a variety of cell activities including cell
adhesion., motility, proliferation, differentiation and signaling
(Maecker et al., 1997; Lagaudriere-Gesbert et al., 1997).
Immunoprecipitation and other studies suggest that tetraspanins
in the plasma membrane are associated with each other and with
several other cell surface molecules, including a subset of 1
integrins and Ig superfanmily members, to form a tetraspanin web
(Nakamura et al., 1995; Berditchevski et al., 1996; Rubinstein et
al., 1996:, Serru et al., 1999; Charrin et al., 2001; Stipp et al.,
2001; Maecker et al., 1997; Boucheix and Rubinstein, 2001).
Tetraspanins may organize specific cell surface molecules to
form functional macromolecular complexes on the surface of the
cell that express the tetraspanin (Maecker et al., 1997; Boucheix
and Rubinstein, 2001). Additionally, it is possible that
tetraspanins are ligands for receptors on other cells, as reported
for the tetraspanin CD81 (Kelic et al., 2001).
Another egg surface protein, the integrin ic6pl, was
previously proposed as the receptor for sperm on mouse eggs
(Almeida et al., 1995). It was thought that a631 binds to the
disintegrin domain of fertilin 3 on the sperm surface (Chen and
Sampson, 1999; Chen et al., 1999; Evans, 2001). Because it was
found that xa631 and CD9 could be coimmunoprecipitated from
mouse eggs, it was suggested that CD9 plays its crucial role in
gamete fusion through involvement in a fertilin 3-a6t61/CD9
intergamete complex (Miyado et al., 2000). This view, however,
is challenged by two other reports. One shows that fertilin 3-
deficient sperm fuse with eggs at 50% of the wild-type level
(Cho et al., 1998). The other shows that a63 1-deficient eggs fuse
with sperm at the same level as the wild-type eggs (Miller et al.,
2000). These two reports indicate that there must be other
molecules on the cell surface of gametes that can act in sperm-
egg fusion.
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Thus, how CD9 functions in gamete fusion is still unknown.
In the present study, we addressed two questions. Does CD9
work by binding to sperm or to other egg surface proteins? What
is the binding site on CD9? Our data suggest that CD9 interacts
through its large extracellular loop (EC2) domain with other egg
surface proteins (i.e. in cis), and that the three residues SFQ (173-
17'5) in EC2 are required for CD9's function in gamete fusion.
These findings add to our understanding of the mechanism of the
gamete fusion process and emphasize the importance of
identifying the egg protein(s) that interact with the SFQ site in
CD9.
MATERIALS AND METHODS
Plasmid construction
The plasmid pmCD9 was constructed by inserting the full-length mouse
CD9 cDNA (GenBank accession number NM007657) into the EcoRI
site of the pBluescript vector (Stratagene). The plasmid phCD9 was
constructed by inserting the full-length human CD9 cDNA (GenBank
accession number NM001769) into the EcoRI site of pcDNA3.1
(Invitrogen). pmCD9 was used as the parental plasmid to construct the
three-amino-acid-mutant plasmid pmCD9-SFQ(173-175)AAA by PCR.
Two overlapping mutated fragments were generated by two sets of
primers (forward 5'-GCAGGAATTCCGGCCCTTCTGT-3' and reverse
5'-AACCgcGgccgcTTCCAAAAGCTGTTTCTTGGG-3', forward 5'-
GG&AgcggcCgcGGTTAAGCCCTGCCCTGAAGC-3' and reverse 5'-
ATCGATAAGCTTGATATCGAATTC-3', the mutated sequence in
lowercase)., digested with NotI and ligated together to form a single
fragment. This fragment was digested with EcoRI and ligated back into
the parental EcoRI-digested pBluescript vector.
The green fluorescent protein (GFP)-tagged chimeric plasmids were
constructed as follows. The forward primer 5'-ACGTagatctAGTCACG-
AC(GTTGTAAAACGACGGCC-3' (BglII site in lower case) and the
reverse primer 5'-ACGTaagcttGACCATTTCTCGGCTCCTGCGGAT-
3' (HindlII site in lower case) were used in PCR to make a construct
including the T7 promoter and the open reading frame (ORF) of the
mouse CD9 cDNA from the plasmid pmCD9. After digestion with BglII
and HindII, the PCR product was ligated into the vector pEGFP-N1
(Clontech) to obtain the GFP chimeric plasmid pmCD9-eGFP. This
plasmid was used as the parental vector to construct the single-amino-
acid-mutant plasmid pmCD9-F174A-eGFP, according to the instruction
of the Quick-ChangeTM mutagenesis kit (Stratagene). The primers used
in the mutagenesis were forward 5'-CCAAGAAACAGCTTflTG-
GAAAGT(GCCCAGGTTAAGCCCTGCCCTGAAGCC-3' and reverse
5'-GGCTTCAGGGCAGGGCTTAACCTGGGCACTTTCCAAAAG-
CTGC;ITTCI'ITGG-3'.
All constructs were sequenced to show that undesired mutations had
not been introduced during the PCR and cloning steps.
In vitro synthesis of mRNA
The plasmids pmCD9, phCD9, pmCD9-SFQ(173-175)AAA, pmCD9-
eGFP and pmCD9-F174A-eGFP were linearized by digestion with
appropriate restriction enzymes whose recognition sites are downstream
of the ORErs of the corresponding cDNAs. The linearized plasmids
were used as templates to synthesize mRNA using the mMessage
mMachine 'M capped RNA transcription kit with T7 RNA polymerase
(Ambion), according to the manufacturer's protocol. The mRNAs were
dissolved in RNase/DNase-free water.
Antibodies
Antibodies used include the anti-mouse CD9 monoclonal antibodies:
KMC8 (Pharmningen), 4.1F12, 1.2C4, 1.1F2 and 1.4G1, isolated and
characterized in one of our laboratories (C. B. and E. R., unpublished
results). The anti-human CD9 monoclonal antibody, ALB-6, has been
described (Rendu et al., 1981).
Media for oocyte culture and in vitro fertilization assay
Medium 1: (M199; Gibco BRL), 3.5 mM sodium pyruvate, 1,000 i.u.
penicillin-streptomycin, 0.1% polyvinyl alcohol, 2 mM L-glutamine,
0.2 mM 3-isobutyl-1 -methylxanthine (IBMX, Calbiochem); Medium 2:
10 mM Hepes (N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic
acid] in Medium 1; Medium 3: 5% fetal calf serum in Medium 1;
Medium 4: Medium 3 without IBMX; Medium 5: Medium 2 without
IBMX; Medium 6: 0.3% bovine serum album (BSA) in Medium 1
without IBMX; Medium 7: 3.0% BSA in Mediuml without IBMX.
Oocyte culture and microinjection
Wild-type or CD9-deficient C57BL6 female mice (Le Naour et al.,
2000) (6-8 weeks old) were primed with 10 i.u. of pregnant mare serum
gonadotropin 48 hours prior to ovary isolation. Isolated ovaries were
placed in Medium 1 to collect germinal vesicle (GV)-stage oocytes.
After the removal of granulosa cells, the GV-stage oocytes were allowed
to recover in Medium 1 at 37C, 5% CO2 for 2-3 hours and then loaded
into a 25 1tl drop of Medium 2 in a 35 mm tissue culture dish (Corning).
A 0.5 gl drop of mRNA solution was placed approximately 2 mm away
from the drop containing oocytes in Medium 2. Both drops were
overlaid with dimethylpolysiloxane (DMPS, 20 centistokes; Sigma) to
prevent evaporation. Each oocyte was injected with approximately 30
pg of mRNA. Injections were carried out on a Zeiss Axiovert 135
equipped with a bipolar temperature controller set at 37°C (Medical
Systems Co.) Injected oocytes were transferred to Medium 3 for a period
of approximately 12 hours at 37°C, 5% CO2. After incubation, oocytes
were allowed to incubate for approximately 16 hours in Medium 4. The
metaphase II eggs among the cultured oocytes were selected for use in
experiments.
In vitro fertilization assay (IVF)
Eggs, prepared as described above, were treated with acid Tyrodes
solution for about 30 seconds to remove the zona pellucida and then
allowed to incubate in Medium 6 at 37°C, 5% CO2 for 3 hours. Sperm
for the in vitro adhesion and fusion assay were isolated from the cauda
epididymis and the vas deferens of C57BL6 male mice (10-12 weeks
old) into Medium 7, and capacitated for 3 hours in Medium 7 at 37°C,
5% CO2, resulting in a population of 60-70% acrosome-reacted sperm
(Moller et al., 1990). The other steps for in vitro fertilization were
carried out as previously described (Miller et al., 2000).
Indirect immunofluorescence of eggs expressing human
or mouse CD9
After in vitro fertilization, the eggs were fixed in 4% paraformaldehyde
and 0.1% PVA in phosphate-buffered saline (PBS, pH 7.4) for 10
minutes at room temperature. After fixation, eggs were incubated with
either 10 gg/ml anti-mouse CD9 antibody KMC8 (BD Pharmingen) or
10 gg/ml anti-human CD9 antibody ALB-6 for 1 hour at 37°C, 5% CO2
in Medium 6, followed by a 30-minute incubation with an appropriate
secondary antibody conjugated to Oregon GreenTM or Alexa FluorTM
488 fluorophore (Molecular Probes Inc.). The fluorescence images were
acquired with a laser scanning confocal microscope (model LSM 410;
Carl Zeiss).
Visualization of CD9-eGFP fusion protein expression
using confocal microscopy
For eggs injected with CD9-eGFP or CD9-F174A-eGFP mRNAs, the
expression of the eGFP fusion protein on the eggs was observed with a
laser scanning confocal microscope (model LSM 410; Carl Zeiss) after
the eggs were incubated in Medium 4 for 16 hours and then coincubated
with sperm for in vitro fertilization assay.
Preparation of glutathione S-transferase (GST)-mouse
CD9 extracellular large loop (EC2) fusion protein and EC2-
histidine (HT) fusion protein
The DNA fragment encoding the extracellular loop of mouse CD9
(EC2) was inserted into EcoRI and BamHI restriction sites of the PGEX-
Functional site of CD9 in gamete fusion 1997
3X vector (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The
GST-EC2 fusion protein and GST alone were expressed in E. coli BL21
cells (Amersham Pharmacia Biotech). The cells were lysed by mild
sonication, and GST-EC2 or GST was allowed to bind to a glutathione
affinity matrix (Amersham Pharmacia Biotech). The GST-EC2 fusion
protein or GST was eluted from the affinity matrix using 10 mM reduced
glutathione in 50 mM Tris-HCI (pH 8.0). The eluted proteins were used
fresh in the in vitro fertilization assay.
The EC2 DNA fragment was also inserted into the NheI and XhoI
restriction sites of the carboxy-terminal hexa-histidine expression vector
pET24a (Novagen, Madison, WI, USA). The resulting plasmid, denoted
pET24a-CD9EC2/HT, was transformed into E. coli BL21/pLysS cells
for protein expression. The cells were lysed in a French press and
separated into soluble and insoluble fractions by centrifugation. The
insoluble portion was resuspended in 6 M guanidine-HC1, and
subsequently clarified by both centrifugation and filtration. The fusion
protein EC2/HT was purified by nickel-nitrilotriacetic acid metal-
affinity chromatography (Qiagen, Chatsworth, CA, USA), followed by
reverse-phase HPLC (Waters, Milford, MA, USA) using a Vydac C18
preparative column (Vydac, Hesperia, CA, USA) with a
water/acetonitrile gradient of 0.05%/minute in the presence of 0.1%
trifluoroacetic acid. Protein peaks were collected, centrifuged under
vacuum to remove the acetonitrile, and lyophilized. A single oxidized
species was recognized by the monoclonal antibody KMC8. Circular
dichroism analysis revealed that this species had significant helical
structure and was thermally stable (C. C. L. et al., unpublished results).
This fraction of the EC2/HT was resuspended in PBS just before use in
the in vitro fertilization assay.
Western blot analysis
Western blot analysis was performed according to the standard method
for ECL western blotting detection reagent (Amersham Pharmacia
Biotech). Protein samples were analyzed by non-reducing SDS-PAGE.
Gels were transferred onto Hybond-C membranes (Amersham
Pharmacia Biotech) by electroblotting. Monoclonal antibody KMC8
(BD Pharmingen) against CD9 was used as the primary antibody at a
final concentration of 0.5 gtg/ml. The blotting signals were developed
using the ECL system (Amersham Pharmacia Biotech), using film
development times that gave a signal in the linear range of blot
intensities.
RESULTS
The fusion proteins GST-EC2 and EC2/HT inhibit
mouse sperm-egg fusion
We first asked which region(s) of the CD9 protein is important
1 2
- 45
- 31
Fig. 1. Western blot of GST-EC2 and
EC2/HT. Western blotting was carried out
as described in Materials and Methods.
Lane 1, 50 ng GST-EC2; lane 2, 10 ng
EC2/HT. The molecular mass (kDa) of
protein standards is indicated.
- 21.5 for its function in gamete fusion. The
monoclonal antibody KMC8 to mouse
S14 CD9 has been reported to inhibit
sperm-egg fusion but not binding
(Miller et al., 2000), but the KMC8
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large extracellular loop (EC2) of mouse CD9 as a GST fusion
protein (GST-EC2) and this fusion protein bound KMC8 in
western blotting (Fig. 1, lane 1), suggesting that a functional
site of CD9 may be in EC2. Freshly purified GST-EC2 fusion
protein was tested for its effect on gamete fusion. Three
parameters were measured: (1) fertilization rate FR = the
percentage of eggs that fuse with at least one sperm; (2)
fertilization index FI = total number of fused sperm/total
number of eggs; (3) the mean number of sperm bound at the
equator of the egg. When zona-free eggs were incubated with
GST-EC2 for 3 hours before insemination, gamete fusion was
inhibited (Table 1). The fertilization rate was reduced from
100% to 60%, and the fertilization index was reduced from 1.5
to 0.6. The average number of sperm bound to the egg plasma
membrane was unaffected. When sperm were incubated with
GST-EC2 for 3 hours before insemination, no significant
inhibitory effect was seen (Table 1).
To test the effect of EC2 in another kind of construct, EC2
was fused with a histidine tag (HT) and purified by HPLC.
EC2/HT binds KMC8 in western blots (Fig. 1, lane 2) and folds
properly by biophysical criteria, e.g. it shows expected
amounts of helical structure by circular dichroism and has a
conformation related to the native form of CD9 on the mouse
egg (C. C. L. et al., unpublished results). When zona-free eggs
were incubated with the EC2/HT polypeptide for 3 hours
before insemination, gamete fusion was inhibited (Table 1).
The fertilization rate was reduced from 83% to 43%, and the
fertilization index from 0.83 to 0.42. The average number of
sperm bound to the egg plasma membrane was not affected
(Table 1). When sperm were incubated with EC2/HT for 3
Table 1. The effect of GST-EC2 and EC2/HT on in vitro fertilization
Incubation Pre-incubated Number of Fertilization Fertilization Sperm bound
protein gamete eggs tested rate (%) index per equator
GST
GST-EC2
GST-EC2
Buffer (PBS)
EC2/HT
EC2/HT
Egg
Egg
Sperm
Egg
Egg
Sperm
100±0
60±5.1
97±3.0
83±3.5
43±2.6
75±5.2
1.5±0.15
0.6±0.05
1.1±0.11
0.83±0.04
0.42±t0.02
0.75±0.05
6.2±0.5
5.7±0.5
7.1±1.6
4.6±0.3
4.8±0.4
4.5±0.3
Values are meants.e.m.
300 gtg/ml of GST-EC2 or 250 gg/ml of EC2/HT were pre-incubated with sperm or with eggs for 3 hours. Then the EC2 construct remained present
(undiluted) during a 40 minute insemination period beginning when the other gamete was added. After the 40 minute insemination, fertilization rate, fertilization
index and sperm bound per equator were scored (see text).
For eggs pre-incubated with GST-EC2, significant inhibition was seen for both fertilization rate and fertilization index (P<0.02).
For sperm pre-incubated with GST-EC2, fertilization rate was unaltered and fertilization index showed a slight, statistically non-significant reduction (P>0.1).
For eggs pre-incubated with EC2/HT, significant inhibition was seen for both fertilization rate and fertilization index (P<0.002).
For sperm pre-incubated with EC2/HT, fertilization rate and fertilization index showed statistically non-significant reduction (P>0.2).
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Fig. 2. Immunofluorescent staining of
CD9 on the surface of CD9 - /- eggs
injected with either mouse or human
CD9 mRNAs. (A) Immunofluorescent
staining using the anti-mouse CD9
antibody KMC8 on wild-type eggs.
(B) Immunofluorescent staining using
the anti-mouse CD9 antibody KMC8
on CD9 - /- oocytes injected with
mouse CD9 mRNA.
(C) Immunofluorescent staining using
the anti-human CD9 antibody ALB6
on CD9 - /- oocytes injected with
human CD9 mRNA.
hours before insemination, no
significant inhibition was observed
(Table 1).
In the protocol used in these
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1), the CD9 EC2 construct is
preincubated with sperm or with
eggs for 3 hours. Then the EC2
construct remains present
(undiluted) during the 40 minute
insemination period beginning
when the other gamete is added.
Inhibition occurs when the eggs
are ncuoatea wltn vLi9 tv2z or
the initial 3 hours plus 40 minutes insemination but not when
they are incubated with CD9 EC2 for only the final 40 minute
insemination. This indicates that the preincubation time of the
CD'9 EC2 with the eggs is required for inhibition of gamete
fusion. Overall, the results suggest that EC2 is a functional
region of the CD9 molecule in gamete fusion, that sperm may
lack a counter-receptor for egg CD9, and that the constructs
GST-EC2 and EC2/HT may displace endogenous egg CD9
from a complex with other egg molecules, thereby inhibiting
sperm-egg fusion.
Injection of CD9 mRNA into CD9-deficient oocytes
restores their fusion ability
Given that the CD9 EC2 loop has a role in sperm-egg fusion,
we asked what is the functional site within EC2? To address
this question, we applied a mouse oocyte expression system
(detailed below) using oocytes from CD9 null female mice,
along with CD9 mutagenesis and IVF techniques, to
investigate the key amino acid residues in EC2 required for
CD9's function in sperm-egg fusion.
It has been well demonstrated that mouse oocytes can
express functional proteins from injected mRNAs (Paynton et
al., 1983; Kola and Sumarsono, 1996; Williams et al., 1998).
The mRNAs encoding mouse or human CD9 were synthesized
and injected into CD9-deficient oocytes. The injected oocytes
were cultured in vitro to the metaphase II stage (see Materials
and Methods). After the in vitro culture period, the mean
percentages of wild-type (WT) oocytes, KO (CD9-/ -) oocytes,
or injected KO oocytes that produced first polar bodies were
in the range 61-78% and were not significantly different among
the different groups (data not shown). This result indicates that
CD9-deficient GV-stage oocytes, after injection with mRNA,
can develop normally to metaphase II.
As expected, KO eggs, injected with CD9 mRNA, express
CD9 on the egg surface as seen by immunofluorescent staining
using the anti-mouse CD9 monoclonal antibody KMC8 or the
anti-human CD9 monoclonal antibody ALB6 (Fig. 2B,C). The
localization of staining is similar to that of WT eggs, with CD9
over the microvillar region and absent over the metaphase plate
(Fig. 2A). CD9 KO eggs without mRNA injection show no
surface staining (data not shown). The absence of CD9 in
uninjected CD9 KO eggs and the expression of CD9 in KO
eggs injected with CD9 mRNA was also confirmed by western
blot (Fig. 6, lanes 1,2).
To test whether or not in ovum expression of the CD9 protein
on the egg surface was capable of restoring fusion ability, GV-
stage KO oocytes were injected with CD9 mRNAs, allowed to
mature to metaphase II, and promptly used for in vitro
fertilization assays (see Materials and Methods). The
Table 2. In vitro fertilization assay with CD9-/ - oocytes injected with different CD9 mRNAs
Oocyte Injected Number of Fertilization Fertilization Sperm bound
genotype mRNA eggs tested rate (%) index per equator
_ _.
None
Mouse CD9 (mCD9)
Human CD9 (hCD9)
None
None
mCD9-eGFP
mCD9-F174A-eGFP
None
None
mCD9
mCD9-SFQ(173-1 75)AAA
None
131
76
64
140
166
92
73
131
122
54
68
78
83±4.3
46±4.2
48±3.3
0±0
66±7.4
55±13.0
13±4.0
1±1.2
80±3.3
48±3.1
1±1.1
0±0
0.89±0.07
0.46±0.04
0.58±0.08
0±0
0.83±0.04
0.85±0.09
0.20±0.07
0.02±0.01
0.81±0.04
0.48±0.03
0.01±0.01
0±0
10.0±1.3
10.1±2.2
12.1±1.0
10.2±1.2
14.4±1.7
12.3±1.2
12.0±2.1
14.0±1.7
8.3±0.8
8.4±1.2
8.3±1.2
8.6±0.5
Values are mean±s.e.m.
(A.) 'The mean fertilization rate and index for CD9- /- oocytes injected with mouse CD9 mRNA are not significantly different from the values of CD9- /- oocytes
injected with human CD9 mRNA (P>0.2).
(B) The mean fertilization rate and index are reduced about fourfold after injection of mCD9-F I 174A-eGFP mRNA compared to mCD9-eGFP mRNA.(C) Fertilization is almost abolished after injection of mCD9-SFQ(173-175)AAA mRNA compared to mCD9 mRNA.
(A)
CD9+/+
CD9-/-
CD9-/-
CD9-/-
(B)
CD9+/+
CD9-/-
CD9-/-
CD9-/-
(C)
CD9+ /+
CD9-/-
CD9-/-
CD9-/-
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Fig. 4. Western blot assay of CD9-eGFP expression in CD9-/- eggs
injected with either wild-type or F174A mutant mouse CD9-eGFP
mRNA. The injected eggs were allowed to develop to the M-II phase,
then were lysed in non-reducing SDS-sample buffer. Western blots
were carried out as described in Materials and Methods. Each lane
contains 20 eggs. Lane 1, CD9-/- eggs; lane 2, CD9- - eggs injected
with wild-type CD9-eGFP mRNA; lane 3, CD9-/- eggs injected with
mutant CD9- F174A-eGFP mRNA. The molecular mass (kDa) of
protein standards is indicated.
Fig. 3. CD9-eGFP fluorescence observed for CD9-/ - oocytes injected
with either wild-type or F174A mutant mouse CD9-eGFP mRNA.
(A) Fluorescence observed in CD9 -'- eggs injected with wild-type
CD9-eGFP mRNA. (B) Fluorescence observed in CD9- '- eggs
injected with F174A mutant CD9-eGFP mRNA. In A and B, both
intracellular and surface fluorescence are observed. (C) Fluorescence
observed in uninjected CD9-/ - eggs. (D-F) Phase contrast images of
A-C, respectively. Fluorescence levels were somewhat variable
within each group of eggs injected with the identical amount and
type of mRNA.
expression of mouse or human CD9 on the surface of KO eggs
rescued sperm-egg fusion (Table 2A). The mean fertilization
rate for WT eggs is 83±4.3%; for KO eggs expressing mouse
CD9, 46±4.2%, and for KO eggs expressing human CD9,
48±3.3%. No fusion was observed in the KO eggs without
mRNA injection. The fertilization index mirrors the
fertilization rate (Table 2). Sperm-egg binding is not
significantly different in the four groups tested (Table 2).
Reduced fusion ability of CD9-deficient oocytes
injected with the CD9-F174A-eGFP mutant mRNA
To hypothesise about which CD9 EC2 residues might be
critical for gamete fusion, we considered the structure of the
related human tetraspanin CD81 EC2, which has been solved
by X-ray crystallographic methods (Kitakodora et al., 2001).
The CD81 EC2 structure reveals a 'head domain', delineated
Fig. 5. Immunofluorescent staining of CD9 on the surface of CD9-/-
eggs injected with either wild-type or SFQ(173-175)AAA mutant
mouse CD9 mRNA. After in vitro fertilization, eggs were fixed and
washed as described in Materials and Methods. The fixed eggs were
incubated with anti-mouse CD9 antibody KMC8 as the primary
antibody, followed by a goat anti-rat IgG (H+L) conjugated with Alexa
FluorTM 488 as the secondary antibody. Immunofluorescent staining
was obtained with a laser scanning confocal microscope (Carl Zeiss,
LSM 410). (A) Immunofluorescent staining on CD9-/- eggs injected
with wild-type mouse CD9 mRNA. (B) Immunofluorescent staining
on CD94- - eggs injected with SFQ-to-AAA mutated mouse CD9
mRNA. (C,D) Phase contrast images of A and B, respectively.
Fluorescence levels were somewhat variable within each group of eggs
injected with the identical amount and type of mRNA.
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blot are very similar for CD9 and CD9-SFQ(173-175)AAA
(Fig. 5A,B, Fig. 6, lanes 2,3). The SFQ (173-175) to AAA
mutation essentially abolished the ability of CD9 to rescue the
fusion competence of KO eggs (Table 2). While the mean
fertilization rate is 48±3.1% for KO eggs injected with wild-
type CD9 mRNA, it is only 1±1.1% for KO eggs injected with
mutant CD9-SFQ(173-175)AAA mRNA (Table 2C). Similarly,
the mean fertilization index is 0.48+0.03 for KO eggs injected
with wild-type CD9 mRNA, but 0.01+0.01 for KO eggs
injected with mutant CD9-SFQ(173-175)AAA mRNA (Table
2). Sperm binding, as measured by the number of sperm
bound/egg equator, is statistically equivalent for all
experimental groups (Table 2).
DISCUSSION
Fig. 6. Western blot assay of CD9 expression in CD9-4- eggs injected
with either wild-type or mutant CD9-SFQ(173-175)AAA mRNA.
The injected eggs were allowed to develop to the M-II phase, then
were lysed in non-reducing SDS-sample buffer. Western blots were
carried out as described in Materials and Methods. Each lane
contains 20 eggs. Lane 1, CD9-/- eggs; lane 2, CD9-/- eggs injected
with wild-type CD9 mRNA; lane 3, CD9-4- eggs injected with
mutant CD9-SFQ(173-175)AAA mRNA. The molecular mass (kDa)
of protein standards is indicated.
by disulfide bond patterning conserved in all tetraspanin family
members. This head domain contains regions of the tetraspanin
molecule that can associate with other surface proteins. In its
head domain CD81 EC2 has a phenylalanine residue F186 in
a solvent-exposed, low polarity patch. F186 is required for
CD81 binding with hepatitis C virus (Higginbottom et al.,
2000). CD9 F174 is present in a corresponding head domain
region and we mutated CD9 F174 to alanine to determine if
there would be an effect on sperm-egg fusion.
To allow direct observation of CD9 protein expression,
eGFP was fused at the carboxyl terminus of the F174A mutant
or wild-type CD9. The wild-type CD9-eGFP or mutant CD9-
F174A-eGFP mRNAs were synthesized and injected into
CD9-deficient oocytes (see Materials and Methods). In
CD9-deficient oocytes, levels of expression detected by
immunofluorescence and by western blot are very similar for
CD9-eGFP and CD9-F174A-eGFP (Fig. 3A,B, Fig. 4, lanes
2,3). However, the F174A mutant is crippled in its ability to
rescue sperm-egg fusion. The mean fertilization rate and
fertilization index are reduced about fourfold after injection of
mutant mRNA compared to wild-type mRNA (Table 2B).
Sperm binding, measured by the number of sperm bound/egg
equator, is not significantly different in any of the experimental
groups (Table 2).
Lack of fusion ability of CD9-deficient oocytes
Injected with the CD9-SFQ(173-175)AAA mRNA
The above result indicates that residue F174 may be part of a
required site necessary for CD9 function in sperm-egg fusion.
To test this, we further mutated the three CD9 amino acid
residues SFQ (173-175) to AAA, and determined the effect of
injecting this mutant mRNA on the fusion ability of CD9-
deficient oocytes. In CD9-deficient oocytes, levels of
expression detected by immunofluorescence and by western
Previous work demonstrated that egg surface CD9 is essential
for sperm-egg fusion (Kaji et al., 2000; Le Naour et al., 2000;
Miyado et al., 2000), but nothing is known about how CD9 acts
in this system. Egg CD9 could bind in trans to a counter-
receptor on sperm as suggested for CD81 on astrocytes
interacting with neurons (Kelic et al., 2001). Alternatively,
CD9 may function by cis interactions on the egg surface with
other egg surface molecules. One egg protein suggested to
interact in a physiologically significant way with CD9 is the
integrin a631 (Chen et al., 1999; Miyado et al., 2000).
However, eggs lacking a6j31 fuse normally with sperm, so a
role for this integrin in gamete fusion is in doubt (Miller et al.,
2000).
The anti-CD9 monoclonal antibody KMC8 blocks sperm-
egg fusion (Chen et al., 1999; Miller et al., 2000), and we found
that KMC8 binds to constructs containing CD9 EC2,
suggesting a role for EC2 in the fusion process. The EC2
constructs, preincubated with sperm, had no significant effect
on fertilization rate or index, suggesting that either the
constructs lack biological activity or that sperm do not have a
receptor for CD9. The EC2 constructs when preincubated with
eggs reduce fertilization rate and index, showing that the
constructs do have biological activity. The data therefore
suggest that CD9 acts in cis at the egg surface and that sperm
lack a receptor acting as a trans partner for CD9.
Why do the EC2 constructs inhibit sperm-egg fusion when
preincubated with eggs? The simplest interpretation is that the
exogenously added EC2 can compete with endogenous CD9
for association with some key egg surface molecule(s). But the
exogenous EC2, having associated and displaced endogenous
CD9, cannot function to promote gamete fusion. The inability
of the exogenous EC2 to exercise all CD9 functions may reflect
the need for other CD9 regions for full function.
To allow further dissection of the basis of CD9 function, we
tested if the fusion ability of CD9 KO oocytes could be
restored after the injection of CD9 message. We found a high
level of rescue of fusion ability by CD9 message injection. In
the current experiments uninjected KO eggs usually did not
fuse, and their fertilization rate was 0% (Table 2), though in
one test uninjected KO eggs had a fertilization rate of 2%. KO
eggs injected with wild-type CD9 mRNA fused at rates of 46-
55%, far above the rate for uninjected KO eggs, but usually a
little lower than the rate for uninjected wild-type eggs (66-
83%).
25 --
19 -
We found that injection of KO eggs with wild-type mouse
CD9 mRNA and wild-type human CD9 mRNA gave
equivalent levels of rescue of fusion. Sequence comparison
of EC2 of mouse and human CD9 shows they differ by 18
residues, including nine non-conservative substitutions,
indicating that certain alterations of amino acids in the
mouse EC2 structure are compatible with retention of full
function. This result reveals the position of various EC2
residues where specific amino acid substitutions are not
deleterious and serves as a control for mutations that do
reduce function.
We found that the fertilization index obtained with CD9 null
oocytes injected with mutant CD9-F174A-eGFP mRNA was
reduced fourfold compared to wild-type CD9-eGFP mRNA.
This result indicates that F174 plays a significant role in CD9
function in sperm-egg fusion. It also suggests that F174 might
be part of a required site necessary for CD9 function. Further
experiments showed that a change of three residues SFQ (173-
175) to AAA essentially abolished the ability of CD9 message
to restore fusion competence to CD9 KO eggs. This loss of
activity is probably not due to misfolding of the mutant protein,
and this conclusion is supported by three types of evidence (our
unpublished data). (1) Several anti-mouse CD9 monoclonal
antibodies including K.MC8, 4.1F12, 1.2C4, 1.1F2 and 1.4G1
bind to the SFQ-to-AAA mutant as well as to wild-type CD9;
(2) after expression in tissue culture cells, CD9 with the SFQ-
to-AAA mutation associates as well as does wild-type CD9
with CD9 P-1, the major cis partner of CD9 in various cell
types (Charrin et al., 2001; Stipp et al., 2001); (3) EC2
containing the SFQ-to-AAA mutation folds properly by
biophysical criteria, e.g. it shows amounts of helical structure
equivalent to wild-type by circular dichroism. Therefore, the
absence of fusion activity in the SFQ-to-AAA mutant suggests
that SFQ in the CD9 EC2 loop comprises a functional site,
which may associate with and regulate the egg fusion
machinery.
One reason to posit a close interaction of CD9 with an egg
protein(s) acting in fusion is that in the in vitro fusion assay
with CD9-null eggs, the number of sperm bound to the egg
plasma membrane is the same as wild type (Kaji et al., 2000;
Le Naour et al., 2000; Miyado et al., 2000). In all the
experiments here, addition of EC2 constructs and the mutations
in CD9 did not affect the number of sperm bound. These results
suggest that CD9 may interact with the egg fusion machinery
downstream of sperm adhesion.
A possible model to explain our findings is that CD9 is
associated with an egg fusion protein. The process of sperm
binding to the egg plasma membrane triggers and promotes the
formation and stability of an association between the SFQ site
of CD9 and the egg fusion protein. The egg fusion protein,
upon associating with CD9, changes conformation and
specifically interacts with a sperm fusion protein. Thus, relying
on a portion of CD9's association repertoire, an inter-gamete
functional fusion machinery composed of CD9, the egg fusion
protein and the sperm fusion protein, is established and
promotes membrane fusion.
This work was supported by NIH grants U54-29125 and HD 16580
(to P. P. and D. G. M.) and CA17007 (to R. O. H). We thank Lisa
Mehlmann and Richard Schultz for advice on the oocyte injection
procedure.
Functional site of CD9 in gamete fusion 2001
REFERENCES
Almeida, E. A., Huovila, A. P., Sutherland, A. E., Stephens, L. E., Calarco,
P. G., Shaw, L. M., Mercurio, A. M., Sonnenberg, A., Primakoff, P.,
Myles, D. G. and White, J. M. (1995). Mouse egg integrin alpha 6 beta 1
functions as a sperm receptor. Cell 81, 1095-1104.
Berditchevski, F., Zutter, M. M. and Hemler, M. E. (1996). Characterization
of novel complexes on the cell surface between integrins and proteins with
4 transmembrane domains (TM4 proteins). Mol. Biol. Cell 7, 193-207.
Boucheix, C. and Rubinstein, E. (2001). Tetraspanins. Cell Mol. Life Sci. 58,
1189-1205.
Charrin, S., Le Naour, F., Oualid, M., Billard, M., Faure, G., Hanash, S.
M., Boucheix, C. and Rubinstein, E. (2001). The major CD9 and CD81
molecular partner. Identification and characterization of the complexes. J.
Biol. Chem. 276, 14329-14337.
Chen, H. and Sampson, N. S. (1999). Mediation of sperm-egg fusion:
evidence that mouse egg alpha6betal integrin is the receptor for sperm
fertilin beta. Chem. Biol. 6, 1-10.
Chen, M. S., Tung, K. S., Coonrod, S. A., Takahashi, Y., Bigler, D., Chang,
A., Yamashita, Y., Kincade, P. W., Herr, J. C. and White, J. M. (1999).
Role of the integrin-associated protein CD9 in binding between sperm
ADAM 2 and the egg integrin alpha6betal: implications for murine
fertilization. Proc. Natl. Acad. Sci. USA 96, 11830-11835.
Cho, C., Bunch, D. O., Faure, J. E., Goulding, E. H., Eddy, E. M.,
Primakoff, P. and Myles, D. G. (1998). Fertilization defects in sperm from
mice lacking fertilin beta. Science 281, 1857-1859.
Evans, J. P. (2001). Fertilin beta and other ADAMs as integrin ligands:
insights into cell adhesion and fertilization. BioEssays 23, 628-639.
Higginbottom, A., Quinn, E. R., Kuo, C. C., Flint, M., Wilson, L. H.,
Bianchi, E., Nicosia, A., Monk, P. N., McKeating, J. A. and Levy, S.
(2000). Identification of amino acid residues in CD81 critical for interaction
with hepatitis C virus envelope glycoprotein E2. J. Virol. 74, 3642-3649.
Kaji, K., Oda, S., Shikano, T., Ohnuki, T., Uematsu, Y., Sakagami,
J., Tada, N., Miyazaki, S. and Kudo, A. (2000). The gamete fusion
process is defective in eggs of Cd9-deficient mice. Nat. Genet. 24, 279-
282.
Kelic, S., Levy, S., Suarez, C. and Weinstein, D. E. (2001). CD81 regulates
neuron-induced astrocyte cell-cycle exit. Mol. Cell Neurosci. 17, 551-560.
Kitadokoro, K., Bordo, D., Galli, G., Petracca, R., Falugi, E, Abrignani,
S., Grandi, G. and Bolognesi, M. (2001). CD81 extracellular domain 3D
structure: insight into the tetraspanin superfamily structural motifs. EMBO
J. 20, 12-18.
Kola, I. and Sumarsono, S. H. (1996). Microinjection of in vitro transcribed
RNA and antisense oligonucleotides in mouse oocytes and early embryos
to study the gain- and loss-of-function of genes. Mol. Biotechnol. 6, 191-
199.
Lagaudriere-Gesbert, C., Le Naour, E, Lebel-Binay, S., Billard, M.,
Lemichez, E., Boquet, P., Boucheix, C., Conjeaud, H. and Rubinstein,
E. (1997). Functional analysis of four tetraspans, CD9, CD53, CD81, and
CD82, suggests a common role in costimulation, cell adhesion, and
migration: only CD9 upregulates HB-EGF activity. Cell Immunol. 182, 105-
112.
Le Naour, F., Rubinstein, E., Jasmin, C., Prenant, M. and Boucheix, C.
(2000). Severely reduced female fertility in CD9-deficient mice. Science
287, 319-321.
Maecker, H. T., Todd, S. C. and Levy, S. (1997). The tetraspanin superfamily:
molecular facilitators. FASEB J. 11, 428-442.
Miller, B. J., Georges-Labouesse, E., Primakoff, P. and Myles, D. G. (2000).
Normal fertilization occurs with eggs lacking the integrin alpha6betal and
is CD9-dependent. J. Cell Biol. 149, 1289-1296.
Miyado, K., Yamada, G., Yamada, S., Hasuwa, H., Nakamura, Y., Ryu,
F., Suzuki, K., Kosai, K., Inoue, K., Ogura, A., Okabe, M. and Mekada,
E. (2000). Requirement of CD9 on the egg plasma membrane for
fertilization. Science 287, 321-324.
Moller, C. C., Bleil, J. D., Kinloch, R. A. and Wassarman, P. M. (1990).
Structural and functional relationships between mouse and hamster zona
pellucida glycoproteins. Dev. Biol. 137, 276-286.
Nakamura, K., Iwamoto, R. and Mekada, E. (1995). Membrane-anchored
heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin
receptor-associated protein (DRAP27)/CD9 form a complex with integrin
alpha 3 beta 1 at cell-cell contact sites. J. Cell Biol. 129, 1691-1705.
Paynton, B. V., Ebert, K. M. and Brinster, R. L. (1983). Synthesis and
secretion of ovalbumin by mouse-growing oocytes following microinjection
of chick ovalbumin mRNA. Exp. Cell Res. 144, 214-218.
2002 G.-Z. Zhu and others
Rendu, F., Boucheix, C., Lebret, M., Bourdeau, N., Benoit, P., Maclouf, J.,
Soria, C. and Levy-Toledano, S. (1987). Mechanisms of the mAb
ALB6(CD9) induced human platelet activation: comparison with thrombin.
Biochem. Biophys. Res. Commun. 146, 1397-1404.
Rubinstein, E., Le Naour, F., Lagaudriere-Gesbert, C., Billard, M.,
Conjeaud, H. and Boucheix, C. (1996). CD9, CD63, CD81, and CD82 are
components of a surface tetraspan network connected to HLA-DR and VLA
integrins. Eur. J Immunol. 26, 2657-2665.
Serru, V., Le Naour, F., Billard, M., Azorsa, D. O., Lanza, F., Boucheix, C.
and Rubinstein, E. (1999). Selective tetraspan-integrin complexes
(CD81/alpha4betal, CD151/alpha3betal, CD151/alpha6betal) under
conditions disrupting tetraspan interactions. Biochem. J. 340, 103-111.
Stipp, C. S., Orlicky, D. and Hemler, M. E. (2001). FPRP, a major, highly
stoichiometric, highly specific CD81- and CD9-associated protein. J. Biol.
Chem. 276, 4853-4862.
Williams, C. J., Mehlmann, L. M., Jaffe, L. A., Kopf, G. S. and Schultz,
R. M. (1998). Evidence that Gq family G proteins do not function in mouse
egg activation at fertilization. Dev. Biol. 198, 116-127.
erval:ion of both types of information in the
hippocampal output may form the basis of its
key role in episodic memory (2, 34).
References and Notes
1. J. O'Keefe, L. Nadel, The Hippocampus as a Cognitive
Map (Clarendon, Oxford, 1978).
2. H. Eichenbaum, P. Dudchenko, E. Wood, M. Shapiro,
H. Tanila, Neuron 23, 209 (1999).
3. B. L. McNaughton, R. G. M. Morris, Trends Neurosci.
10, 408 (1987).
4. J. O'Keefe, J. Dostrovsky, Brain Res. 34, 171 (1971).
5. R. LU. Muller, J. L. Kubie, J. B. Ranck, J. Neurosci. 7,
1935 (1987).
6. B. L. McNaughton, C. A. Barnes, J. O'Keefe, Exp. Brain
Res. 52, 41 (1983).
7. J. J. Knierim, H. S. Kudrimoti, B. L. McNaughton, J.
Neurosci. 15, 1648 (1995).
8. J. O'Keefe, D. H. Conway, Exp. Brain Res. 31, 573
(1978).
9. K. M. Gothard, W. E. Skaggs, B. L. McNaughton, J.
Neurosci. 16, 8027 (1996).
10. M. L. Shapiro, H. Tanila, H. Eichenbaum, Hippocam-
pus 7, 624 (1997).
11. E. R. Wood, P. A. Dudchenko, H. Eichenbaum, Nature
397, 613 (1999).
12. E. J. Markus et al., J. Neurosci. 15, 7079 (1995).
13. M. A. Moita, S. Rosis, Y. Zhou, J. E. LeDoux, H. T. Blair,
J. Neurosci. 24, 7015 (2004).
14. E. R. Wood, P. A. Dudchenko, R. J. Robitsek, H.
Eichenbaum, Neuron 27, 623 (2000).
15. J. Ferbinteanu, M. L Shapiro, Neuron 40, 1227 (2003).
16. M. R. Bower, D. R. Euston, B. L. McNaughton, J.
Neurosci. 25, 1313 (2005).
17. S. A. Hollup, S. Molden, J. G. Donnett, M.-B. Moser, E. I.
Moser,J. Neurosci. 21, 1635 (2001).
18. E. Bostock, R. U. Muller, J. L. Kubie, Hippocampus 1,
193 (1991).
19. C. Kentros et al., Science 280, 2121 (1998).
20. A. Cressant, R. U. Muller, B. Poucet, Exp. Brain Res.
143, 470 (2002).
21. D. Marr, J. Physiol. 202, 437 (1969).
22. S. Leutgeb, J. K. Leutgeb, A. Treves, M.-B. Moser, E. I.
Moser, Science 305, 1295 (2004); published online
22 July 2004 (10.1126/science.1100265).
23. Materials and methods are available as supporting
material on Science Online.
24. The mean number of pretraining days in the test
environment was 17 (square-circle), 14 (two rooms),
and 4 (black-white).
25. The rate threshold was 0.27 Hz. Similar results were
obtained with rate thresholds of 0.10 Hz and 0.50 Hz
(tables S1 and S2) (23).
26. K. M. Gothard, W. E. Skaggs, K. M. Moore, B. L.
McNaughton, J. Neurosci. 16, 823 (1996).
27. W. E. Skaggs, B. L. McNaughton, J. Neurosci. 18,
8455 (1998).
28. H. Tanila, Hippocampus 9, 235 (1999).
29. If the external spatial input is strong enough, it is
theoretically possible for large changes to occur in
the firing rates of some cells, whereas intrinsic
attractor dynamics of the network maintain the
relative relations between the place fields of the
ensemble (35).
REPORTS
30. S. A. Hollup, S. Molden, J. G. Donnett, M.-B. Moser, E. I.
Moser, Eur. J. Neurosci. 13, 1197 (2001).
31. In these studies, which all focused on CA1, much of
the residual activity in the less active condition
appeared inside the cell's place field in the more
active condition [e.g., figure 8 in (30), figures 3 to 5
in (14), figures 2 to 6 in (15), figure 6 in (16), figures
6B and 9 in (12), and figure 4 in (73)], as expected if
the remapping was primarily rate-based. In (30),
70% of the cells exhibited peak activity in the same
quadrant in the two directions.
32. T. J. Wills, C. Lever, F. Cacucci, N. Burgess, J. O'Keefe,
Science 308, 873 (2005).
33. H. Markram, M. Tsodyks, Nature 382, 807 (1996).
34. E. Tulving, Annu. Rev. Psychol. 53, 1 (2002).
35. A. Samsonovich, B. L. McNaughton, J. Neurosci. 17,
5900 (1997).
36. We thank R. G. M. Morris and M. P. Witter for
discussion and A. M. Amundsgard, I. M. F. Hammer,
K. Haugen, K. Jenssen, R. Skjerpeng, E. Sjulstad, B. H.
Solem, and H. Waade for technical assistance. The
work was supported by a Centre of Excellence grant
from the Norwegian Research Council.
Supporting Online Material
www.sciencemag.org/cgi/content/full/309/5734/619/
DC1
Materials and Methods
Figs. S1 to S5
Tables S1 and S2
25 April 2005; accepted 10 June 2005
10.1126/science.1 1 4037
Complete Replication of Hepatitis
C Virus in Cell Culture
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Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced
in cell culture, which has slowed research progress on this important human
pathogen. Here, we describe a full-length HCV genome that replicates and
produces virus particles that are infectious in cell culture (HCVcc). Replication of
HCVcc was robust, producing nearly 105 infectious units per milliliter within 48
hours. Virus particles were filterable and neutralized with a monoclonal anti-
body against the viral glycoprotein E2. Viral entry was dependent on cellular
expression of a putative HCV receptor, CD81. HCVcc replication was inhibited
by interferon-a and by several HCV-specific antiviral compounds, suggesting
that this in vitro system will aid in the search for improved antivirals.
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liver disease frequently progresses to cirrhosis,
which can lead to liver failure and hepato-
cellular carcinoma. Current drug therapies are
often poorly tolerated and effective in only a
fraction of patients; there is no vaccine for
HCV. A major obstacle to understanding the
virus life cycle and to developing improved
therapeutics is the inability to efficiently grow
HCV in cell culture.
HCV is an enveloped, positive-sense RNA
virus of the family Flaviviridae. Naturally
occurring variants of HCV are classified into
six major genotypes. The 9.6-kb genome
encodes one large polyprotein that is processed
by viral and cellular proteinases to produce the
virion structural proteins (core and glycopro-
teins El and E2) as well as nonstructural (NS)
proteins (p7 through NS5B) (Fig. 1A). Sub-
genomic RNA replicons have been adapted for
efficient RNA replication in the human hepa-
toma line Huh-7 and other cultured cells (2-5).
However, full-length genomes containing cell
culture-adaptive mutations do not produce
infectious virus particles in culture and are
severely attenuated in vivo (6-8). This led us
to hypothesize that mutations that enhance
RNA replication may have deleterious effects
on virion production. To test this idea, we used
a genotype 2a subgenomic replicon, SGR-
JFH1, that efficiently replicates in cell culture
without adaptive mutations (4). Full-length
chimeric genomes were constructed with the
use of the core-NS2 gene regions from the
infectious J6 (genotype 2a) and H77 (genotype
la) virus strains (Fig. 1A). Both full-length
chimeras and the subgenomic RNA were
competent for RNA replication, as seen by
the accumulation of NS5A protein and viral
RNA 48 hours after RNA transfection into the
Huh-7.5 cell line (Fig. B). As expected, mu-
tation of the NS5B RNA polymerase active
site [GlyAspAsp to GlyAsnAsp (GND)]
destroyed the ability of FL-J6/JFH to replicate
(Fig. B). Within transfected cells, both full-
length genomes expressed core, E2, and NS5A
(Fig. 1C). As expected, SGR-JFH1 expressed
NS5A but not core or E2. While z30% of
cells were productively transfected with FL-
J6/JFH, FL-H77/JFH, or SGR-JFH1 RNA
(Fig. lB), >95% of FL-J6/JFH-transfected cells
were positive for NS5A by 96 hours (fig.
Si). This suggested that FL-J6/JFH spread
within the transfected cell cultures.
To test whether infectivity could be trans-
ferred to naive cells, we clarified conditioned
www.sciencemag.org SCIENCE VOL 309 22 JULY 2005 623
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media from these cultures by centrifugation
(9), filtered the supernatants (0.2 pm), and
incubated them with naive Huh-7.5 cells.
NS5A expression could be transferred by
the FL-J6/JFH-transfected culture media
but not by media from cells transfected
with FL-H77/JFH or SGR-JFHI (Fig. IB).
Interestingly, the amount of FL-J6/JFH RNA
released into the transfected cell culture media
exceeded that of the other RNAs by a factor of
>200, and only FL-J6/JFH produced an
extracellular form of core (Fig. IC, lower
panel). Given that the infectivity of the
genotype 2a chimera is filterable and is
associated with the release of HCV RNA and
core protein, we refer to this cell culture-
produced virus as HCVcc. The ability of the
genotype la/2a chimera to replicate but not
spread suggests that interactions between the
structural and nonstructural gene products may
be important for HCVcc formation, as has
been observed for other members of this virus
family (10, 11).
Limiting dilution assays for NS5A expres-
sion in electroporated cells showed that 30.3 +
9.5% (n = 6) of cells were productively
transfected with FL-J6/JFH, and of these,
55% produced infectivity that was detectable
upon transfer to naive cells. Thus, FL-J6/JFH
RNA transcripts were highly infectious and
formation of HCVcc did not depend on the
emergence of rare variants. Limiting dilution
assays were also used to quantitate the amount
of HCVcc infectivity between samples as
median tissue culture infectious units per
milliliter (TCIDso/ml). The TCIDso is the
dilution that infects 50% of replicate cell
cultures (9). After an eclipse phase (29 hours),
FL-J6/JFH infectivity could be detected in the
media by 18 hours posttransfection, and it
continued to accumulate until 48 hours (Fig.
ID). Interestingly, FL-J6/JFH (H2476L),
which contained a weakly adaptive mutation
in NS5B (4), showed slightly delayed growth
kinetics but also peaked to similar levels by 48
hours. Viruses could be serially passaged,
infecting 50 to 90% of cells within 5 days
after two rounds of passage at a low multi-
plicity of infection (MOI) of 0.1 to 1.0 (Fig.
lE). The expression and subcellular localiza-
tion of core, E2, and NS5A within FL-J6/JFH-
infected cells was consistent with what was
previously seen in full-length and subgenomic
replicon-bearing cells [supporting online ma-
terial (SOM) text]. Taken together, these
measurements show that HCVcc replication
is robust and occurs with kinetics similar to
those of other Flaviviridae.
A classic method in virus identification is
to neutralize the suspected virus with specific
antisera. As shown in Fig. 2A, an E2-specific
human monoclonal antibody neutralized
HCVcc infectivity in a dose-dependent man-
ner, whereas an isotype-matched control anti-
body had no effect on HCVcc titer. These
data affirm the viral nature of HCVcc infec-
tivity and show that E2 is essential for virus
entry.
HCV E2 has been shown to bind to the
cellular surface protein CD81 (12), which is
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an essential coreceptor for the entry of HCV
glycoprotein-pseudotyped retroviruses (13-15).
We found that HCVcc infectivity could be
blocked with a soluble recombinant form of
the CD81 large extracellular loop (Fig. 2B).
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Fig. 1. Production of infectious HCV in cell culture. (A) The structures of the HCV RNA genome,
the SGR-JFH1 replicon, and full-length chimeric genomes FL-J6/JFH and FL-H77/JFH. NCR,
noncoding region; C, core; yellow, J6; cyan, H77. (B) Huh-7.5 cells were electroporated with RNA
transcripts of the indicated genomes [or the RNA-polymerase defective mutant FL-J6/JFH(GND)]
48 hours before immunostaining for NS5A (brown, upper panel). Nuclei were counterstained with
hematoxylin (blue). Below is the relative amount of HCV RNA detected in each transfected cell
population at 48 hours by quantitative reverse transcription polymerase chain reaction (RT-PCR).
Naive Huh-7.5 cells were incubated for 48 hours with filtered, conditioned media from the
transfected cells and immunostained for NSSA expression (lower panel). (C) Western blot for HCV
core, E2, NSSA, or actin protein expression at 48 hours in RNA transfected Huh-7.5 cells. Below
each lane is the relative amount of HCV RNA and core detected in cell culture media by
quantitative RT-PCR and Western blot, respectively. ND, not determined. (D) The accumulation of
HCVcc infectivity after electroporation of FL-J6/JFH (blue) or FL-J6/JFH (H2476L) (purple) into 6 x
10s cells/timepoint, assessed by a limiting dilution assay (mean ± SEM; n = 4). Dotted line, assay
sensitivity. (E) Cells were immunostained for NS5A 5 days after infection with serially passaged
virus. Scale bars, 100 gm.
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To further examine the role of CD81 in virus
entry we used HepG2 cells, which lack CD81
expression but are capable of supporting HCV
RNA replication (3). As seen in Fig. 2C,
normal HepG2 cells were not infected by
FL-J6/JFH, whereas CD81-expressing HepG2
cells were infected under the same conditions,
albeit with reduced efficiency (=850 times less
than Huh-7.5 cells). These data confirm that
interactions between E2 and CD81 are impor-
tant for HCV entry.
The physical nature of HCV particles has
been difficult to study in the absence of an
infectious culture system. In density gradients,
clinical isolates of HCV exhibit a broad
distribution and unusually low buoyant den-
sities [reviewed in (16)]. These properties have
been partly explained by the interaction of
HCV with serum components such as immuno-
globulins and 3-lipoproteins. We examined
the profiles of RNA and infectivity associated
with HCVcc particles by equilibrium centrifu-
gation in 10 to 40% iodixanol, an iso-osmotic
gradient material. A series of controls con-
firmed that this method accurately measured
the buoyant density of HCVcc (SOM text).
HCV RNA was broadly distributed through
the top of the gradient, with a peak in fractions
16 and 17 (1.13 to 1.14 g/ml), and was not
found beyond fraction 20 (1.18 g/ml) (Fig.
3A). HCVcc infectivity was also broadly
distributed among fractions I to 15 (1.01 to
1.12 g/ml), and infectivity was not seen
beyond fraction 18 (1.17 g/ml). Surprisingly,
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fractions 16 and 17, which contained the
highest levels of HCV RNA, had little
infectivity associated with them. The specific
infectivity of a virus preparation relates the
amount of infectivity to the total number of
virus particles or genomes in the preparation.
Interestingly, a plot of HCVcc-specific infec-
tivity versus buoyant density indicates that the
most infectious material is at 1.09 to 1.10 g/ml
(Fig. 3B), which is similar to the peak of
infectivity (1.09 to 1.11 g/ml) previously seen
in chimpanzees (17). In contrast, RNA-
containing material with a buoyant density of
1.14 g/ml (fraction 17) had a low specific
infectivity, with =300,000 RNA molecules per
infectious unit. Many groups have reported an
HCV RNA peak near this density (18-20),
although infectivity could not be assessed.
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Fig. 3. Characterization of HCVcc particles. (A) The profiles of FL-J6/JFH (H2476L) RNA (open circles)
and infectivity (solid gray) are shown after isopycnic centrifugation in a 10 to 40% iodixanot
gradient. Closed circles indicate the buoyant density of each fraction. (B) The specific infectivity of
each fraction in panel (A) was calculated as the infectivity per RNA copy and plotted against the
buoyant density.
0.1 1 10 100
hCD81-LEL concentration (Itglml)
HepG2 H1p G2 CD1
Fig. 2. HCVcc infection is dependent on HCV
glycoprotein functions. (A) FL-J6/JFH (H2476L)
was pre-incubated for 1 hour at 370C with the
indicated concentrations of recombinant hu-
man anti-E2 C1 (circles) or anti-dengue virus
NS1 (square) immunoglobulin G1 monoclonal
antibodies (mAb), then titered by limiting
dilution assay (mean ± SEM; n = 3). Assays
for both antibodies were conducted in parallel.
The dotted line indicates the titer of untreated
virus. (B) FL-J6/JFH (H2476L) was preincubated
with 12 glg/ml of a recombinant form of the
large extracellular loop (LEL) of CD81 and used
to infect naive cells. The levels of HCV RNA,
relative to an untreated control, were deter-
mined at 48 hours postinfection by quantita-
tive RT-PCR (mean ± SEM; n = 4). (C) HepG2 or
HepG2/CD81 cells were infected with FL-J6/JFH
for 48 hours before immunostaining for NS5A
expression. Scale bar, 100 pm.
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Fig. 4. Antiviral inhibi-
tion of HCVcc. (A)
Huh-7.5 cells were
incubated for 18 hours
with the indicated
doses of IFN before in-
fection with FL-J6/JFH
(H2476L) (MOI of 1.0).
The fraction of inhibi-
5 tion was calculated
from the levels of HCV
RNA at 48 hours post-
infection. The mean +
SEM (n = 3), best-fit
curve (black), and 95%
confidence interval (gray
curves) are shown. (B to
E) After 8 hours inoc-
ulation with FL-J6/JFH
(H2476L) (MOI of 0.1),
5 Huh-7.5 cells were
washed and incubated
in media containing
0.1% dimethylsulfoxide, as a carrier control, with or
without the indicated doses of each anti-HCV compound.
The inhibition of RNA accumulation at 48 hours was
calculated as above. 2'C-MeAd, 2'C-methyladenosine.
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Thus, HCVcc exhibits physical properties
similar to those that have been previously
described for natural isolates of HCV.
There is an urgent need for improved HCV
drug therapies. The current standard treatment,
pegylated interferon-a (IFNa) and ribavirin,
leads to a sustained response in only =50% of
genotype l-infected patients. We examined
the ability of HCVcc replication to be inhibited
by IFNa and other antiviral compounds. Dose-
response experiments showed that IFNa in-
hibited HCVcc RNA accumulation in infected
cells with a median effective concentration
(EC,,o) of 1 international unit (IU)/ml (Fig.
4A). We also tested three HCV-specific in-
hibitors of the NS3 serine protease for their
effects on HCVcc infection. As seen in Fig.
4, El to D, BILN 2061 (21), SCH6 (22), and
PI-i (23) all inhibited HC'Vcc RNA accumu-
lation in the submicromolar range. In addition,
a nucleoside analog inhibitor of the NS5B
RNA polymerase, 2'C-methyladenosine (24),
was found to inhibit HCVcc replication in the
low nanomolar range (Fig. 4E). Thus, HCVcc
infection can be inhibited by IFNa and sev-
eral HICV-specific antiviral compounds. The
specificity of these latter compounds further
shows that HCVcc infection leads to au-
thentic replication in target cells and dem-
onstrates that this infectious system may be
useful for testing current and future anti-
viral compounds.
We describe a full-length genotype 2a
HC'V genome that replicates and produces
virus particles that are infectious in cell culture.
This system lays a foundation for future in
vitro studies to examine new aspects of the
virus life cycle and to develop new drugs for
combating HCV.
Note added in proof: Full-length JFH-I
has also been recently reported to produce
infectious virus in cell culture (25-27), as has
a genotype lb Coml/JFH-1 chimera (28),
albeit with lower efficiency and slower
growth kinetics than the system reported here.
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Genome-Scale Identification
of Nucleosome Positions
in S. cerevisiae
Guo-Cheng Yuan, Yuen-Jong Liu,* Michael F. Dion,
Michael D. Slack, t Lani F. Wu, Steven J. Altschuler, Oliver J. Rando}
The positioning of nucleosomes along chromatin has been implicated in the
regulation of gene expression in eukaryotic cells, because packaging DNA into
nucleosomes affects sequence accessibility. We developed a tiled microarray
approach to identify at high resolution the translational positions of 2278
nucleosomes over 482 kilobases of Saccharomyces cerevisiae DNA, including
almost all of chromosome III and 223 additional regulatory regions. The majority
of the nucleosomes identified were well-positioned. We found a stereotyped
chromatin organization at Pol II promoters consisting of a nucleosome-free
region -200 base pairs upstream of the start codon flanked on both sides by
positioned nucleosomes. The nucleosome-free sequences were evolutionarily
conserved and were enriched in poly-deoxyadenosine or poly-deoxythymidine
sequences. Most occupied transcription factor binding motifs were devoid of
nucleosomes, strongly suggesting that nucleosome positioning is a global
determinant of transcription factor access.
Nucleosomes prevent many DNA binding
proteins from approaching their sites (1-3),
whereas appropriately positioned nucleosomes
can bring distant DNA sequences into close
proximity to promote transcription (4). Current
understanding of the primary structure of chro-
matin and its effects on gene expression comes
from a handful of well-characterized loci (see
examples below). High-resolution measurements
of nucleosome positions over chromosome-scale
distances would enhance our understanding of
chromatin structure and function.
To measure nucleosome positions on a
genomic scale, we developed a DNA micro-
array method (5) to identify nucleosomal and
linker DNA sequences on the basis of suscep-
tibility of linker DNA to micrococcal nuclease
(fig. S1). Nucleosomal DNA was isolated,
labeled with Cy3 fluorescent dye (green), and
mixed with Cy5-labeled total genomic DNA
(red). This mixture was hybridized to micro-
arrays printed with overlapping 50-mer oligo-
nucleotide probes tiled every 20 base pairs
across chromosomal regions of interest (fig.
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